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During pregnancy, the maternal hemodynamic system undergoes major changes in order to adapt to the 
pregnant condition. Blood volume and cardiac output increase, while the systemic vascular resistance 
decreases. This decrease in systemic vascular resistance is facilitated through changes in endothelial 
function and in activity of the renin-angiotensin aldosterone system (RAAS), and is clinically apparent 
from a slight decrease in blood pressure, mainly during the first and second trimester of pregnancy. In the 
kidney, vascular resistance also decreases substantially, with consequently a marked rise in renal blood flow 
and glomerular filtration rate (GFR).  
 The importance of these pregnancy-specific adaptations for a healthy course of pregnancy is 
highlighted by our current knowledge that maladaptation of the maternal hemodynamics to pregnancy 
is associated with pregnancy complications such as preeclampsia. Preeclampsia is characterized by 
hypertension and proteinuria in the second half of pregnancy, and has major impact on maternal and 
fetal health. To date, there is no real treatment option for preeclampsia apart from delivery, which usually 
results in resolution of the maternal signs and symptoms of preeclampsia within days. 
 In the last decade, it has become apparent that these women may not be completely cured from 
preeclampsia after delivery, as cohort studies report an increased risk for cardiovascular and renal disease 
later in life in these women. Whether the increased risk is a consequence of preeclampsia itself, or whether, 
alternatively, common (pre-pregnancy) risk factors contribute both to the development of preeclampsia 
and the increased long-term risk is still matter of debate. Also, the mechanisms behind this increased risk 
for cardiovascular and renal disease remain unknown. Since preeclampsia is characterized by vascular 
and hemodynamic maladaptation during pregnancy, it can be hypothesized that the maladaptive profile 
is not completely restored postpartum, thereby increasing the susceptibility to cardiovascular and renal 
disease in women with a history of preeclampsia. Elucidating the mechanisms involved in the increased 
cardiovascular and renal risk later in life in formerly preeclamptic women is important to understand why 
these women are more susceptible to cardiovascular and renal disease, and will guide the development of 
preventive strategies.  In this thesis, therefore, we will study long-term renal function, RAAS, and endothelial 
function in women with a history of preeclampsia and in rats following experimental preeclampsia. 
Preeclampsia
Preeclampsia, a pregnancy specific syndrome, complicates up to 6-8% of all pregnancies worldwide 
and is the leading cause of fetal and maternal morbidity and mortality 1, 2. Preeclampsia is clinically 
characterized by de novo hypertension and proteinuria in the second half of pregnancy 3. Preeclampsia 
can also occur superimposed upon chronic hypertension or pre-existing proteinuria. Preeclampsia 
can be classified by the gestational age at onset of the disease or by severity of the disease. Early-
onset preeclampsia is defined as onset of preeclampsia before 34 weeks of gestation and severe 
preeclampsia is defined by blood pressure values >160mmHg systolic or >110mmHg diastolic 4, 5. 
 Preeclampsia is a systemic disorder that affects multiple maternal organs including the 
vascular bed, leading to generalized endothelial dysfunction, and the kidneys. Specific glomerular 




be considered the most common glomerular disease worldwide 6. Moreover, preeclampsia can affect 
the liver as part of the HELLP syndrome (Haemolysis Elevated Liver enzymes and Low Platelets) 3, or 
the brain, resulting in eclampsia. Eclampsia is the convulsive form of preeclampsia and affects 0.1% 
of all pregnancies (reviewed by Brezan, E et al. 2). Although the pathophysiology of preeclampsia 
has been studied widely, the exact mechanism underlying the development of preeclampsia remains 
unclear. The prevailing hypothesis states that preeclampsia can be considered a multifactorial 
two-stage condition, involving the immune system, angiogenic factors, and the endothelium, 
with the placenta being the origin, that triggers the multi-system abnormalities that characterize 
preeclampsia  7-9.
 Unfortunately, there is no treatment option to cure a woman from preeclampsia apart from 
termination of pregnancy; and thereby delivery of the placenta 10. This often results in premature 
birth. Several options have been studied as potential preventive treatment for preeclampsia, 
including anti-oxidants 11, fish oil 11, and low sodium diet 12, with however disappointing results. 
Current studies focus on restoring the anti-angiogenic balance and deficiency in nitric oxide, and 
treatment with L-arginine, statins, relaxin, and other therapies to restore angiogenic factors are 
under investigation 2, 13, 14. Aspirin and calcium supplementation (in populations where there is 
inadequate intake) have small beneficial effects in preventing preeclampsia in high-risk populations 
and may be effective when started early in gestation 10, 15. 
Pathophysiology of preeclampsia
Current understanding of the syndrome describes preeclampsia as a two-stage syndrome with the 
placenta as the organ of origin 7, 16. Although in both early and late-onset preeclampsia, placental 
dysfunction is involved, the mechanisms of placental dysfunction, and its role in the pathophysiology 
of preeclampsia seems to be different 8. During early-onset preeclampsia impaired placentation 
plays a key role in the pathogenesis of preeclampsia, where in late-onset preeclampsia placental 
dysfunction is not due to impaired placentation, but may be related to its functional limit at the 
end of pregnancy. The placental dysfunction (stage 1) is then followed by the release of factors 
by the diseased placenta into the maternal circulation (stage 2), inducing widespread endothelial 
dysfunction 17 and inflammation 18 resulting in the classic manifestation of the syndrome. In late-
onset preeclampsia, pre-pregnancy maternal endothelial health may also play an important role 19. 
 During normal development of the placenta, trophoblasts migrate through the decidua 
and part of the myometrium to invade the spiral arteries and play a role in the remodelling of the 
wall of the spiral artery such that the vascular wall is broken-down 20. Due to the process of spiral 
artery remodelling, the spiral arteries transform into large capacitance vessels of low resistance 
and sufficient blood supply to the placenta and growing foetus is thereby guaranteed 20, 21. During 
the first stage of early-onset preeclampsia, the invasion of the trophoblasts is limited, mainly in 
the myometrium, resulting in incomplete remodelled spiral arteries, leading to small muscular 
spiral arteries 22-24. Due to this incomplete spiral artery remodelling, maternal blood will enter the 
intervillous space intermittently and with increased velocity, resulting in villous damage, ischaemia 
reperfusion injury, and oxidative stress of the chorionic villi 25. 
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 The maternal reaction to this poor placentation is the so-called second stage of preeclampsia. 
Over the past years, several studies report that in the preeclamptic placenta, the syncytiotrophoblast 
produces and secretes several factors, mainly pro-inflammatory and anti-angiogenic factors 26-28. 
These factors are then via the intervillous space spread into the maternal circulation 26, 29 and lead to 
a generalized activation of the inflammatory system, endothelial dysfunction and culminate into the 
symptoms of preeclampsia.
 Late-onset preeclampsia is suggested to be a maternal syndrome with no evidence of 
decreased spiral artery remodelling 3, 30, 31. However, it has been hypothesized recently, that late-onset 
preeclampsia can be considered as a process of restricted intervillous perfusion near term. Near 
term, placental growth reaches its functional limit restricting intervillous perfusion. This leads to 
disturbed placental perfusion and thereby oxidative stress in e.g. (syncytio)trophoblast cells 8. As 
in early-onset preeclampsia, these stressed syncytiotrophoblast cells then release several factors 
into the maternal circulation inducing the clinical stage (stage 2) of preeclampsia. However, several 
pre-existing maternal disorders, i.e. hypertension, obesity, and diabetes mellitus, have also been 
associated with the occurrence of late-onset preeclampsia (reviewed by Ness, R.B. et al. 30). In these 
women, endothelial dysfunction is present pre-pregnancy, and it is thought that together with the 
increased systemic inflammatory status seen in healthy pregnancy, this contributes to the clinical 
symptoms of preeclampsia 19.
Development of clinical signs of preeclampsia
Role of the inflammatory response 
During healthy pregnancy, circulating inflammatory cells, i.e. granulocytes and monocytes, 
become activated 32. During pregnancy, circulating leukocytes come into direct contact with the 
syncytiotrophoblasts in the intervillous space. This may result in activation of inflammatory cells 
33. Moreover, the healthy placenta sheds syncytiotrophoblast micro- and nanoparticles and other 
factors into the maternal circulation 34-37 and these particles and factors are thought to interact 
with the maternal immune system thereby stimulating the inflammatory response in pregnancy 
38-40. This activation of maternal inflammatory cells is even more pronounced during preeclampsia 
40, 41. Various factors, partly corresponding to those found in normal pregnancy, produced by the 
oxidatively stressed placenta, such as syncytiotrophoblast micro- and nanoparticles 35, 41, pro-
inflammatory cytokines 42, chemokines 43, and ATP 44 are held responsible for the marked activation 
of the inflammatory cells in preeclampsia. Activation of these inflammatory cells together with 
endothelial dysfunction have widespread consequences that are characteristic for preeclampsia 7, 45.
Role of angiogenic factors
In normal pregnancy, pro-angiogenic factors (vascular endothelial growth factor (VEGF) and 
placental growth factor (PlGF)) are balanced with anti-angiogenic factors (soluble Fms-like tyrokinase 
1 (sFlt-1), soluble endoglin (sEng), and reactive oxygen species (ROS)) 46, 47. During preeclampsia, 
this balance is disrupted; high levels of sFlt1 and sEng were found 27, 48, together with low levels of 




contribute to the stage 2 manifestation of preeclampsia. sFlt1 induces endothelial dysfunction by 
inhibiting VEGF signalling 49. This is particularly true in endothelial cells that are fenestrated and 
have constitutive expression of VEGF, such as those that reside in the glomerulus of the kidney 50. 
Inhibition of VEGF not only impairs angiogenesis, but might also impair endothelium-dependent 
vasodilation, contributing to a rise in blood pressure 51. 
Role of maternal hemodynamics
To secure a healthy pregnancy, the maternal hemodynamic system has to adjust to the pregnant 
condition 52. Changes in the endocrine environment of pregnant women lead to a decrease in 
systemic vascular resistance 53, 54 accompanied by a decrease in arterial stiffness 55, 56. This decrease 
in systemic vascular resistance 57 enlarges the vascular capacity mimicking a state of under filling 58, 
59. Subsequently, plasma volume increases about 40%, thereby ensuring sufficient blood supply and 
oxygen and nutrition supply to the placenta and fetus 52. In contrast, preeclampsia is characterized 
by a relative increased vascular resistance and arterial stiffness as compared to healthy pregnant 
women 60-63 and in concordance with this increase, the rise in plasma volume is diminished in 
preeclampsia 64, 65. Adaptations of the RAAS 66, of the endothelial cells 67, and of the stiffness of 
the vascular wall 55 are all suggested to be involved in the maternal hemodynamic adaptations to 
pregnancy, while impairments in these adaptive mechanisms are assumed to contribute to the 
development of the maternal syndrome of preeclampsia. In the next paragraphs, the respective 
roles of the RAAS, endothelial function, and of arterial stiffness in the regulation of vascular tone are 
described in more detail.
Renin-angiotensin aldosterone system
Figure 1 represents a schematic and simplified overview of the RAAS. Activation of the RAAS 
occurs mainly by sympathetic activation, volume depletion, and hypotension. Renin stimulates the 
conversion from angiotensinogen (produced by the liver) to angiotensin I (ang I), which is not 
biologically active. Ang I is converted to angiotensin II (ang II) by angiotensin-converting enzyme 
(ACE). Ang II is the main effector hormone of the RAAS and induces vasoconstriction in the systemic 
and renal vascular bed 68 by binding to the ang II type I receptor (AT1-R) 69. In addition, binding of 
ang II to the ang II type 2 receptor (AT2-R) leads to vasodilation 70 thereby opposing the effect of 
the AT1-R. Furthermore, ang II stimulates aldosterone release from the adrenal cortex 53. Next to 
the classical ACE/ang II/AT1-R axis, a counterbalancing arm has been identified within the RAAS, 
consisting of angiotensin converting enzyme 2 (ACE2), angiotensin 1-7 and its receptors (Mas 
receptor and AT2-R) 53, 70. 
 The RAAS becomes activated during healthy pregnancy as response to the decrease in 
systemic vascular resistance 53, 71 and increased oestrogen levels 72. Although activation of the RAAS 
leads to increased levels of renin and angiotensinogen, and thereby increased ang II levels 73, 74, 
healthy pregnant women are less sensitive to the vasoconstrictor actions of ang II compared to non-
pregnant women 75. Counteracting effects of other vasodilators and/or a decrease in AT1-R density 
are suggested mechanisms involved in this decreased sensitivity 53, 76, 77. This decreased vascular 
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responsiveness to ang II contributes to the pregnancy-induced decrease in systemic vascular 
resistance.   
 During preeclampsia, plasma volume expansion and the decrease in systemic vascular 
resistance are less pronounced. In response, most circulating components of the RAAS, such as 
ang II, are lower during preeclampsia as compared to a healthy pregnancy 78. However, importantly, 
the diminished ang II sensitivity seen in healthy pregnancy is blunted in preeclampsia 79-81. Since 
ang II is an important vasoconstrictor agent, this non-adaptation of ang II sensitivity might play an 
important role in hypertension during preeclampsia 82. The exact mechanisms behind the increased 
ang II sensitivity are unknown but possibly altered placental and vascular AT1-R expression are 
involved 83-85. Other mechanisms like decreased angiotensin 1-7 expression 86, the presence of AT1-R 
autoantibodies 83, 87, 88, and decreased hemopexin activity 89 could also be involved.
Figure 1. Simplified overview of the renin-angiotensin aldosterone system. 
ACE: angiotensin converting enzyme, AT1-R: angiotensin II type 1 receptor, AT2-R: angiotensin II type 2 receptor. 





The endothelium, by production of vasoactive factors, is important in the regulation of the vascular 
tone 90, 91. Important vasoactive factors are nitric oxide (NO), the prostanoids, and unidentified 
endothelium-derived hyperpolarizing factor(s) (EDHF) 92. NO is a potent vasodilator 93 and is formed 
by the conversion of L-arginine by three different NO synthase (NOS) isoforms; endothelial NOS, 
inducible NOS, and neuronal NOS 93. Prostanoids derive from arachidonic acid and via conversion 
by cyclooxygenase, prostaglandins (mainly prostacyclin and PGE
2
) and thromboxane 94 are produced. 
In vascular tone regulation, prostacyclin and PGE
2
 induce vasodilation and thromboxane induces 
vasoconstriction 95-97. Next to NO and prostanoids, there is a third group of endothelial-derived 
factors, which are able to induce vasodilation, collectively named EDHF 98, 99. EDHF is associated 
with hyperpolarisation of the smooth muscle cells via influencing the influx of potassium ions 
100. One member of the EDHF group is hydrogen sulfide (H
2
S) 101 which is suggested to enhance 
vasodilation 102. 
 Changes in the production of these endothelium-derived vasoactive factors may 
account for the pregnancy-related decrease in systemic vascular resistance. During pregnancy, 
NO production and NO bioactivity are increased as compared to non-pregnant women 103, 104. In 
addition, eNOS protein expression is increased in human uterine arteries during pregnancy 105. 
Also, the prostaglandin pathway may be important in the regulation of the vascular tone during 
pregnancy 106, since  increased production of prostacyclin has been found during pregnancy  107-109. 
The contribution of EDHF in endothelium-dependent vasodilation has also been suggested to be 
increased during healthy pregnancy  110-112. H
2
S has recently been linked with pregnancy, since in the 
placenta 113, the enzymes involved in H
2
S production are active and able to produce H
2
S 114.
 Preeclampsia is characterized by endothelial dysfunction whereby impaired regulation 
and secretion of the endothelium-derived vasoactive factors occurs, thereby increasing the systemic 
vascular resistance 115. NO bioavailability is decreased during preeclampsia 93 and the balance 
between the prostanoids, prostacyclin and thromboxane, is towards increased thromboxane levels, 
leading to increased vasoconstriction 96, 109, 116-123. The contribution of EDHF is suggested to be 
reduced in preeclampsia 110, 124 and down regulation of the enzymes involved in H
2
S production has 
been shown in the placenta 113, 125, 126.
Arterial stiffness
Arterial stiffness, defined as a reduced capacity of an artery to dilate or contract in response to 
pressure changes 127, is another important modulator of vascular tone. It can be assessed non-
invasively by analysing the peripheral arterial pulse waveform using indirect measures such as pulse 
wave analysis (PWA) 128 or pulse wave velocity (PWV) 129.  Arterial stiffness increases with aging and 
in several disease conditions, such as diabetes mellitus, atherosclerosis, hypertension, and chronic 
kidney disease 130-133. Moreover, an increased arterial stiffness is an independent risk factor for 
cardiovascular diseases 134. Although arterial stiffness is highly associated with structural changes of 
the arterial wall 135, it is also known that vascular tone can reversibly affect arterial stiffness (reviewed 
by Wilkinson, I.B. et al. 136). Therefore, mechanisms that regulate vascular tone, i.e. endothelial 
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function, can also affect arterial stiffness in the short term 131, 137.  
 During pregnancy, starting around 5 weeks, arterial stiffness is decreased 55, 138-140. In 
contrast, in women who develop preeclampsia, an increase in arterial stiffness as compared to 
control pregnant women is shown already in the first trimester of pregnancy 60-63. The mechanism 
behind these changes in arterial stiffness during pregnancy and preeclampsia remains to be 
elucidated. In healthy pregnancy, the increased oestrogen level causing relaxation of the muscular 
layer of the vessel wall is suggested to play a role in the decrease in arterial stiffness 141. In addition, 
the vascular filling state, the decreased blood pressure, and the rise in heart rate may be involved in 
the pregnancy-induced decrease in vascular stiffness 142. Also the mechanism of increased arterial 
stiffness before and during preeclampsia remains to be established. It may however be suggested 
that endothelial dysfunction, which is prominent in preeclampsia 17, may result in impaired release 
of endothelial-derived vasoactive factors, thereby enhancing arterial stiffness 137. 
Animal models of preeclampsia
Preeclampsia occurs only in humans and, rarely, in higher apes 143. Therefore, much effort has 
been put into the development of animal models, which ideally are pregnancy specific and mimic 
a majority of the spectrum of the biochemical and clinical features of human preeclampsia. Widely 
used models, mainly in mice and rats, include inflammatory models with low-dose endotoxin 
(lipopolysaccharides; LPS) 144, ATP 145 or IL-6 146. Also non-inflammatory models are widely used, i.e. 
overexpressing sFlt-1 27, decreased uteroplacental perfusion by clipping the aorta or uterine arteries 
147, 148, chronic NOS inhibition 149, 150, and RAAS overactivity 151 or genetic adjustments 152-154.  
 Over the years, our research group has gained experience in working with the low-dose 
endotoxin rat model for preeclampsia. This model will be used in the current thesis and has the 
following characteristics. It is based on infusion of a low-dose endotoxin on day 14 of pregnancy 144. In 
response to this infusion, a generalized low-grade inflammatory response, including endothelial cell 
activation, develops 155. This response is considered the underlying mechanism of the development 
of hypertension and proteinuria in pregnant rats infused with endotoxin 156-160.
As pointed out earlier, both the RAAS, via ang II sensitivity, and endothelial dysfunction via impairing 
the endothelium-dependent relaxation, are thought to play an important role in preeclampsia, but so 
far, these have not yet been well characterized in this model. 
Renal function in pregnancy and preeclampsia
During healthy pregnancy glomerular hyperfiltration up to 40-60% above the habitual level of renal 
function occurs in the second half of pregnancy 161 accompanied by an increased effective renal 
plasma flow (ERPF) 162. The relationship between the GFR and ERPF changes throughout pregnancy 
leading to alterations in filtration fraction (FF=GFR/ERPF) as pregnancy advances, i.e. lower FF 
during first trimester to higher FF in third trimester as compared to non-pregnant women 163. At 
term, GFR is still 40% higher than in non-pregnant women and then declines to normal, non-





 These functional changes in renal hemodynamics are different during preeclampsia. In 
women with preeclampsia, GFR is significantly lower than in healthy pregnant women 166, without 
differences in ERPF, resulting in a decreased FF during preeclampsia 167. The mechanism of the 
decreased GFR during preeclampsia has not been elucidated. Changes can be functional, due to 
altered hemodynamics, or due to secondary effects of structural renal changes, i.e. high blood 
pressure and albuminuria 6, 166, 168, or due to primary renal changes, such as podocyte alterations 
169. Histologically, glomerular endotheliosis is seen 6, characterized by fibrin deposition, endothelial 
swelling and detachment, reduced density and size of endothelial fenestrae, thickening of the 
glomerular basement membrane, and loss of capillary space 6, 167, 170. The finding that women with 
chronic kidney disease experience an increased risk for developing preeclampsia when pregnant 171, 
highlights the importance of accurate renal hemodynamic adaptations to pregnancy. 
Long-term consequences of preeclampsia – cardiovascular and renal perspective
For a long time, preeclampsia was thought to be a reversible syndrome, with full recovery after 
pregnancy. However, over the past years epidemiologic studies have shown consistently that 
preeclampsia carries an increased risk for premature cardiovascular and renal disease in later 
life. Women with a history of preeclampsia experience a 3-4 fold increased risk for long-term 
cardiovascular disease 172 and approximately a 5-12 fold increased risk for end stage renal disease 
173-175. 
 Whether renal function is affected in formerly preeclamptic women is debated. Current 
small studies (mostly up-to 10 years post-partum) report no difference or just subtle differences in 
renal function and renal hemodynamics after preeclampsia. A high normal estimated GFR (eGFR) 
has been reported but other studies showed no differences in renal function 176-178. However, in 
studies that found altered renal parameters in formerly preeclamptic women, co-morbidity, i.e. 
hypertension, was present. This may well have caused these alterations 179, 180. The persistence of 
proteinuria postpartum is subject of debate as well. Proteinuria has been reported to persist in the 
postpartum period in a considerable number of formerly preeclamptic women. A meta-analysis 
showed that the occurrence of micro-albuminuria is as high as 31% in formerly preeclamptic women 
versus 7% in controls 177. However, individual retrospective studies, report lower incidences of 
proteinuria in formerly preeclamptic women 176, 181, 182. Both persistent renal hemodynamic alterations 
and persistent proteinuria following preeclampsia can potentially be involved as pathophysiological 
mechanisms underlying the increased susceptibility to cardiovascular and renal disease later in life. 
 The underlying pathways leading to cardiovascular and renal disease in women with a 
history of preeclampsia remain to be fully elucidated. It is generally assumed that the increased risk 
results from the presence of pre-existing cardiovascular risk factors in combination with preeclampsia 
induced disturbances that persist postpartum or develop after a preeclamptic pregnancy 183-186. To 
differentiate between pre-pregnancy cardiovascular (risk) factors and the effect of preeclampsia 
itself on the future cardiovascular and renal health, ideally long-term follow-up studies starting pre-
pregnancy need to be performed. However, with the relatively low incidence of preeclampsia, these 
studies are almost impossible to perform. Therefore, to discriminate between pre-pregnancy risk 
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factors and preeclampsia-induced impairments, studies focussing on the long-term consequences 
of preeclampsia, which only include currently healthy women following preeclampsia are needed. 
Also, animal models are needed, in which the animals can be studied before, throughout, and after 
an experimental preeclamptic pregnancy. The advantage of studying animal models, is that all 
animals have the same pre-pregnancy health. 
 As described above, plasma levels of ang II are decreased while the sensitivity for ang II is 
increased during preeclampsia. Persistent post-partum increased ang II sensitivity might potentially 
play a role in the increased cardiovascular and renal risk after preeclampsia 187, 188. Moreover, arterial 
stiffness is suggested to be increased during preeclampsia and arterial stiffness has been identified 
as an independent risk factor for cardiovascular diseases 189-191. It can be hypothesized that persistent 
post-partum increased ang II sensitivity and arterial stiffness may also be involved in the mechanism 
behind the increased cardiovascular and renal risk following preeclampsia 192, 193. 
This thesis presents studies performed in women, without comorbidities, after preeclampsia and in 
an animal model for experimental preeclampsia, to investigate the possible role of renal function, 
the RAAS, endothelial function, and arterial stiffness as mechanisms in the increased susceptibility 




Aim of this thesis
The aim of this thesis is to gain more insight into the mechanisms behind the increased late risk 
for cardiovascular and renal diseases in women with a history of preeclampsia. We hypothesized 
that changes in the RAAS and maternal (renal) hemodynamics (including endothelial function) are 
involved. These changes could be pre-existing, and hence contribute to the development of both 
preeclampsia and cardiovascular and renal disease, and/or could be induced by preeclampsia itself. 
To differentiate between the contribution of comorbid conditions and of preeclampsia itself, women 
with a history of preeclampsia without comorbid conditions were studied, in parallel with studies in 
an animal model of experimental preeclampsia (i.e. the low-dose endotoxin infused pregnant rat). 
To this purpose, first the changes in the RAAS and endothelium during experimental preeclampsia 
in this animal model were characterized. This was done in Chapter 2 of this thesis. Thereafter, from 
Chapter 3 to Chapter 7, we focussed on the long-term renal risk after preeclampsia in humans and in 
the animal model, and studied potential mechanisms involved in the susceptibility of the increased 
cardiovascular and renal risk following (experimental) preeclampsia. 
 Animal models for preeclampsia are essential to study the pathophysiology of this 
syndrome. Ideally, the phenotype of experimental preeclampsia closely resembles the human 
situation. Since we aim to study the role of the RAAS and endothelial function in the increased risk 
for cardiovascular and renal diseases in later life, we aimed to select an animal model that closely 
resembles preeclampsia in these respects. However, whether or not these features were present in 
the low-dose endotoxin infused pregnant rat was unknown. Therefore, we first characterized the 
changes in the RAAS and endothelial function in this model. 
• In Chapter 2, we studied whether the endotoxin rat model for preeclampsia is characterized 
by increased ang II sensitivity and endothelial dysfunction
 Then, from Chapter 3 to Chapter 7 of this thesis, we focus on the renal risk and mechanisms 
involved in this renal risk in women after preeclampsia. To rule out effects of common pre-pregnancy 
cardiovascular risk factors, we included healthy, normotensive women, selected for absence of 
comorbidity and without signs of underlying cardiovascular diseases. In addition, since sodium 
status is a well-known modulator of RAAS activity and affects endothelial function, the prospective 
studies were performed with a standardized sodium intake. We also studied healthy pregnant rats in 
which experimental preeclampsia was induced by low-dose endotoxin infusion during pregnancy. 
• In Chapter 3, we review the proposed mechanisms behind the increased risk for renal 
disease in formerly preeclamptic women
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• In Chapter 4, long-term follow-up of renal function data collected in the Prevention of REnal 
and Vascular ENd-stage Disease (PREVEND) study were used to study the long-term course 
of post-partum renal function in a large cohort of women with self-reported hypertensive 
disorders of pregnancy and in women with a history of pregnancy induced hypertension, 
HELLP or preeclampsia 10-years postpartum
• In Chapter 5, we studied renal hemodynamics in healthy formerly preeclamptic women as a 
potential mechanism behind the increased risk for renal disease later in life in these women
• In Chapter 6, we studied the ang II sensitivity in healthy formerly preeclamptic women and 
in formerly experimental preeclamptic rats as a potential mechanism behind the increased 
risk for cardiovascular and renal disease later in life in these women
• In Chapter 7, we studied arterial stiffness and markers for endothelial dysfunction in healthy 
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We investigated endothelial dysfunction and the role of angiotensin (Ang)-II type I (AT1-R) and type 
II (AT2-R) receptor in the changes in the Ang-II sensitivity in experimental preeclampsia in the rat.
Methods 
Aortic rings were isolated from low dose lipopolysaccharide (LPS) infused pregnant rats 
(experimental preeclampsia; n=9), saline-infused pregnant rats (n=8), and saline (n=8) and LPS 
(n=8) infused non-pregnant rats. Endothelium-dependent acetylcholine-mediated relaxation was 
studied in phenylephrine-preconstricted aortic rings in the presence of vehicle, NG-nitro-L-arginine 
methyl ester and/or indomethacin. To evaluate the role for AT1-R and AT2-R in Ang-II sensitivity, full 
concentration response curves were obtained for Ang-II in the presence of losartan or PD-123319. 
mRNA expression of the AT1-R and AT2-R, eNOS and iNOS, COX1 and COX2 in aorta were evaluated 
using real-time RT-PCR. 
Results 
The role of vasodilator prostaglandins in the aorta was increased and the role of endothelium-
derived hyperpolarizing factor and response of the AT1-R and AT2-R to Ang-II was decreased in 
pregnant saline infused rats as compared with non-pregnant rats. These changes were not observed 
during preeclampsia. 
Conclusion 
Pregnancy induced adaptations in endothelial function, which were not observed in the rat model for 
preeclampsia. This role of lack of pregnancy induced endothelial adaptation in the pathophysiology 
of experimental preeclampsia needs further investigation.
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INTRODUCTION
Preeclampsia is a pregnancy specific syndrome, clinically characterized by the presence of 
hypertension, associated with proteinuria in the second half of pregnancy 1. Preeclampsia 
complicates about 5% of pregnancies and is a leading cause of maternal and perinatal mortality 
1. The etiology of preeclampsia remains unknown, but appears to be related to the presence of 
the placenta 2. In preeclamptic patients physiological remodelling of the uterine spiral arteries is 
diminished, resulting in decreased placental perfusion 3. Several mechanisms have been implicated 
in the pathophysiology of preeclampsia, including activation of inflammatory cells 4, endothelial 
cell activation and vascular dysfunction 5, as well as changes in the renin-angiotensin-aldosterone 
system (RAAS) 6. 
 During normal pregnancy, vascular function changes dramatically; increased endothelium 
dependent vascular relaxation as well as increased flow mediated dilation can be observed 7. 
Together this may result in a decrease in blood pressure (mainly in the second trimester) and a 
decrease in peripheral vascular resistance 8. By production of vasoactive factors, endothelial cells are 
important mediators of vascular tone 9. Changes in the production of these vasoactive factors may 
therefore account for the pregnancy-related changes in vascular relaxation. Indeed, the production 
of endothelial prostacyclin, nitric oxide (NO) as well as the unidentified endothelium-derived 
hyperpolarizing factor (EDHF) has been shown to be increased during pregnancy 10–13. In contrast to 
normal pregnancy, vascular relaxation is reduced in preeclampsia 8. The endothelial cell dysfunction 
in preeclampsia appears to be associated with an impaired regulation and secretion of vasodilating 
factors, such as NO, prostacyclin production or EDHF 12,14,15. 
 In addition, the RAAS may also be involved in the changes in vascular dysfunction 
in preeclampsia. While normal pregnancy is associated with a decreased sensitivity to the 
vasoconstrictor angiotensin II (Ang-II) 16, preeclampsia is associated with an increased response to 
Ang-II as compared to normal pregnancy 17. During preeclampsia, the increased Ang-II sensitivity 
may even develop before the clinical manifestation of the disease 18,19. Ang-II exerts its effects via two 
receptors. Binding of Ang-II to the Ang-II Type I receptor (AT1-R) causes contraction 17. The other 
Ang-II receptor is the Type II receptor (AT2-R). The function of this receptor is less well understood. 
There is however, increasing evidence that the AT2-R may exert an inhibitory influence on AT1-R 
mediated stimulation 20. It is largely unknown if and how these receptors are involved in the changes 
in Ang-II sensitivity during normal pregnancy and preeclampsia. However, it seems likely that the 
AT1-R is involved in the pathophysiology of preeclampsia, since in both rat and mice it has been 
demonstrated that treatment with AT1-R blockers inhibited the development of clinical signs in 
models of preeclampsia 21,22. Unfortunately, treatment with AT1-R blockers is contraindicated during 
pregnancy 23.
 In the present study, we evaluated endothelial function during pregnancy and experimental 
preeclampsia in the rat, by studying the role of the vasoactive factors in endothelial function as well 
as the role of the AT1-R and AT2-R in the Ang-II sensitivity. We used the well-established model 
for preeclampsia, i.e. the low-dose lipopolysaccharide (LPS) infused pregnant rat 24. This model is 
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characterized by hypertension and proteinuria  and has been used as a model for preeclampsia for 
many years and was used in many studies 21,25–27, including a recent study by Wang et al. 28.
MATERIALS AND METHODS
Animals
Experiments were conducted in accordance with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals and approved by the Committee for Animal Ethical Experiments of 
the University of Groningen (application number: DEC-5516A).
 Female Wistar outbred rats (Harlan Inc, Horst, the Netherlands) were kept in a 12 hour 
light-dark cycle and constant room temperature, with food and water available ad lib in the home 
cages. Until selection for experiments vaginal smears were taken daily. Rats were rendered pregnant 
by housing them on pro-oestrus with fertile males for one night.  Day 0 of pregnancy was documented 
by the presence of spermatozoa in the vaginal smear. In cyclic and pregnant rats, the latter ones 
on day 0 of pregnancy, a cannula was inserted into the right jugular vein under isoflurane/oxygen 
anesthesia according to standard methods 29. The jugular vein cannula allows stress free infusion. 
On day 14 of pregnancy or 14 days after cannula placement, infusion of either saline or LPS took 
place. Day 14 of pregnancy was chosen since in the rat trophoblast invasion into the mesometrial 
triangle, i.e. the equivalent of the placental bed, and the spiral arteries starts around this day of 
pregnancy. 
 The low-dose LPS treated pregnant rat is an established model of preeclampsia, 
characterized by hypertension, proteinuria, disseminated intravascular coagulation, generalized 
activation of the inflammatory response and endothelial cell activation 24,28,30. LPS is infused at day 14 
during 1 hour. The final concentration of LPS immediately after the infusion is found to be very low or 
even undetectable in some rats and from fifteen minutes onward undetectable in all rats (unpublished 
results). The development of the preeclamptic-like syndrome in this model is considered to result 
from a systemic inflammatory response induced by LPS 25,26,30. In addition to studies focussing on 
the pathophysiology of preeclampsia, studies concerning therapeutic options for preeclampsia have 
also been performed in this model 27,28,31. The rats were randomly divided into four groups as follows: 
non-pregnant (NP) saline infused (2 ml in 1 hour); pregnant (P) saline infused (2 ml in 1 hour); P 
LPS (E-Coli, 0.55: B5, Whittaker MA Bioproducts, Walkerville, Md.) infused (1µg/kg bw in 2 ml saline 
in 1 hour); NP LPS infused (1µg/kg bw in 2 ml saline in 1 hour). P-saline infused rats served as 
healthy pregnant controls whereas the LPS infused pregnant rats served as the preeclampsia group 
24. Six days after infusion (on day 20 of pregnancy), the animals were anesthetized with isoflurane/
oxygen and decapitated. The aorta was isolated and placed in cold oxygenated Krebs solution. The 
number of pups was counted and their length as well as maternal weight measured.
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Drugs and chemicals
Krebs buffer (pH 7.4) was freshly made before the start of each experiment and contained in mmol/L: 













. All Krebs ingredients were purchased from E. Merck (Darmstadt, Germany). The 
stock solutions for phenylephrine (Sigma, St. Louis, MO, USA), acetylcholine (Sigma, St. Louis, 
MO, USA), Ang-II (Bachem AG, Bubendorf, Switzerland), PD-123319 (Park-Davis), Losartan (Merck 
Research laboratories, Rahway, USA), and NG-nitro-L-arginine methyl ester (L-NMMA; Calbiochem 
Brand of EMD Biosciences, Inc., La Jolla) were prepared in saline (0.9%NaCl in distilled water). 




The endothelium-dependent relaxation and sensitivity to Ang-II in aortic tissue was studied by 
standard isotonic contraction experiments with thoracic aorta rings of the rat as previously described 
32,33. Aortic rings (2mm) from the rats were kept in Krebs solution (at 37°C) and gassed with 95% 
CO
2
 and 5% O
2
. Prior to priming the aortic rings were equilibrated for 30 minutes and subsequently 
checked for viability by evoking a contraction with KCl (60mM) for 10 minutes. Excess aortic tissue 
was snap frozen and kept in -80°C.
Endothelium-dependent relaxation
Eight aortic rings of each rat were used to study the endothelium-dependent relaxation. The rings 
were studied in duplo in the continuous presence of either vehicle, NO synthase inhibitor L-NMMA 
(10-4M), cyclooxygenase (COX) inhibitor indomethacin (10-5M) or with L-NMMA plus indomethacin, 
to study the resultant role of EDHF. After 20 minutes of pre-incubation, aortic rings were pre-
contracted with 10-6M phenylephrine. Then, increasing concentrations of acetylcholine (10-8M-
10-4M) were added to the medium to investigate endothelium-dependent dilation after stabilization. 
Subsequently, the NO donor sodium nitroprusside (SNP; 10-5M) was added as a control for 
endothelium-independent relaxation. The mean acetylcholine-mediated relaxation of the two rings 
in each condition was calculated as a percentage of the phenylephrine mediated pre-contraction. 
Response of the aortic rings to Ang-II
Functional response of the AT1-R to Ang-II
To determine the Ang-II induced contractile response via the AT1-R, two aortic rings of each rat 
were pre-incubated for 20 minutes with 10-6M PD-123319, an AT2-R antagonist 34 and the selective 
NO synthase inhibitor L-NMMA (10-4M) to prevent any confounding effects by the basal release 
of NO 35. Both compounds were present during the entire experiment. Then, a cumulative Ang-II 
concentration-response curve (10-10M-10-6M) was obtained according to standard methods 36,37. A 
subsequent amount of Ang-II was added after renewed stabilization. Following the response curve, 
a reference contraction response was evoked by stimulation with 10-5M phenylephrine and after 
stabilization of the phenylephrine response KCl (60mM) was added, to produce maximal contraction. 
The mean Ang-II-mediated contraction of the duplo rings in each condition was calculated as a 
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percentage of the maximal KCl induced response. 
Functional response of the AT2-R to Ang-II
To determine the functional response of the AT2-R to Ang-II, two aortic rings of each rat were pre-
incubated for 20 minutes with 10-5M losartan, an AT1-R antagonist 38. This antagonist was present 
during the entire experiment. Following the pre-incubation period, the aortic rings were pre-
contracted with 10-6M phenylephrine. After pre-contraction reached a stable contraction, cumulative 
Ang-II concentration-response curve (10-10M-10-6M) was obtained according to standard methods 
36,37. Thereafter, the NO donor SNP (10-5M) was added to the aortic rings, as a control for maximal 
endothelium-independent relaxation. For each rat, and for each dose of Ang-II, the mean Ang-II 
mediated vasodilatory response for the two rings was calculated as a percentage of the maximal 
pre-contraction with phenylephrine.
Gene-expression analysis
Total aortic RNA was isolated with TriReagent (Sigma-Aldrich, St. Louis, MO) following the 
manufacturer’s instructions. Total RNA was quantified using a NanoDrop ND1000 spectrophotometer 
(NanoDrop Technologies Inc., Wilmington, DE). cDNA synthesis was performed as described before 39. 
Real time quantitative PCR was performed using an Applied Biosystems 7900 FAST sequence detector 
(Foster City, California, USA) and Applied Biosystems reagents according to the manufacturer’s 
instructions. Expression levels were normalized to those of 18S ribosomal RNA which was analyzed 
in separate runs. Primers and probes for the AT1-R and AT2-R were obtained from Applied Biosystems 
(TaqMan Gene Expression Assays, AT1-R: Rn00578456_m1 and AT2-R: Rn00560677_m1).  Primers 
and probes for iNOS, eNOS, COX1, COX2 and 18S ribosomal RNA were obtained from Invitrogen 
(Breda, Invitrogen). The sequences were (sense primer, antisense primer, and probe, respectively; 
all from 5’ to 3’): 18S (M11188), CGGCTACCACATCCAAGGA, CCAATTACAGGGCCTCGAAA, 
CGCGCAAATTACCCACTCCCGA. Cox1 (XM_579388.1), CCCAGAGTCATGAGTCGAAGG, 
AACAACAGGGATTGACTGGTGA, TTTCCCCTGCTGCTGCTCCTGC. Cox2 (NM_017232.2), 
TTGTTGAGTCATTCACCAGACAGAT, GCCTTTGCCACTGCTTGTACA, CCCCAGCAACCCGGCCAGC. 
Enos (NM_021838.2), AGGAAGTAGCCAATGCAGTGAA, AGCCATACAGGATAGTCGCCTT, 
CGCTTCGCCATCACCGTGCC. Inos (NM_012611), CTATCTCCATTCTACTACTACCAGATCGA, 
CCTGGGCCTCAGCTTCTCAT, CCCTGGAAGACCCACATCTGGCAG.  
The expression levels of AT1-R, AT2-R, iNOS, eNOS, COX1 and COX2 were normalized to those of 
18S ribosomal RNA. 
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Statistics





calculated using GraphPad Prism 5, on a standard computer. The independent sample T-test was 
used to analyze differences between the number and length of the rat pups. Two-way analysis of 
variance (Two-way ANOVA) was used to analyze differences in bodyweight of the rats. We show the 
dose response curves of all four groups after vehicle incubation. Whether there was a significant 
difference between the four groups of rats was tested using General Linear Model for repeated 
measures. To calculate whether NO, PG or EDHF played a significant role in the acetylcholine 
mediated relaxation the E
max
 of the different curves was analyzed and compared with the E
max
 of 
the vehicle curve (i.e. total relaxation) using Student t-test. To test differences in contribution of a 
certain factor between the four groups of rats, Two-way ANOVA was used. If the Two-way ANOVA 
detected significant differences, we tested whether P-saline infused rats differed from NP-saline 
infused rats and whether LPS infused rats differed from saline infused rats in both pregnant and 
non-pregnant groups, using independent student T-test with Bonferroni corrections.  For the Ang-II 




 were calculated to represent individual responses. Differences 
in the E
max
  and EC
50
 of the Ang-II response curves between the four groups were analyzed using 
Two-way ANOVA to detect an effect of pregnancy or LPS infusion. If the Two-way ANOVA detected 
significant differences, we tested whether P-saline infused rats differed from NP-saline infused rats 
and whether LPS infused rats differed from saline infused rats in both pregnant and non-pregnant 
groups, using independent student T-tests with Bonferroni corrections. To test whether correlations 
existed between Ang-II mediated relaxation through the AT2-R and the vasoactive role of NO, PG or 
EDHF in acetylcholine-mediated relaxation Pearson Correlation test were performed. PCR data are 
presented as relative gene expression to 18S ribosomalRNA and analyzed using Two-way ANOVA 
with log transformed data. We tested whether P-saline infused rats differed from NP-saline infused 
rats and whether LPS infused rats differed from saline infused rats in both pregnant and non-
pregnant rats, using independent student T-test with Bonferroni corrections. In all cases, differences 
were considered significant if p≤0.05. Data are presented as mean ± SEM.
RESULTS
The body weight was significantly increased in pregnant rats compared to non-pregnant rats 
(p<0.001). No significant effect of treatment (saline or LPS infusion) was found (p=0.093). The 
number of pups was not significantly different between the two pregnant groups (p=0.329). However, 
the length of the pups in the P-LPS infused rats was significantly lower compared to the P-saline rats 
(p=0.01). The number of resorptions did not differ between these groups, one animal of each group 
showed one resorption. Table 1 presents these rat characteristics.
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Table 1. Rat characteristics
Group (n) NP-saline (8) P-saline (8) P-LPS (9) NP-LPS (8)
Maternal weight (g) 242.12 (7.4) 325.50* (6.9) 344.22* (8.5) 249.75 (6.9)
Number of pups - 12.0 (1.0) 13.44 (1.0) -
Length pups (mm) - 32.36† (0.22) 31.57 (0.21) -
P= pregnant; NP=non-pregnant; LPS= Lipopolysaccharide. 
Data are presented as mean ±SEM. n=number of rats in group. *: p<0.05 vs NP; †: p<0.05 vs P-LPS.
Endothelium-dependent relaxation in aortic rings
To study endothelial function in pregnancy and experimental preeclampsia in the rat, we used 
aortic rings, precontracted with phenylephrine and dilated with acetylcholine in the presence of 
vehicle, L-NMMA, to identify the role of NO, indomethacin, to identify the role of PG or L-NMMA 
and indomethacin, to identify the role of other factors then NO or PG, mainly EDHF. There was 
no effect of pregnancy or treatment (LPS or saline infusion), nor of the various inhibitors on the 
contraction with KCl prior to the start of the experiment (results not shown). Also, precontraction 
with phenylephrine following the incubation with the various inhibitors did not differ between the 
four groups, apart from the increased precontraction in P-saline rats vs the other three groups after 
indomethacin incubation (results not shown). Moreover, SNP evoked endothelial independent 
relaxation was decreased in P-saline rats vs NP-saline rats following incubation with all inhibitors 
(results not shown).
 After vehicle incubation, all routes for relaxation are available and by adding acetylcholine 
in a cumulative fashion after precontraction with phenylephrine, relaxation appeared equal in all 
four groups (Figure 1). No significant difference in total acetylcholine mediated relaxation was seen 
between the four groups. Moreover, no significant differences in -logEC50 or Emax were found between 
the four groups (Table 2; acetylcholine relaxation and Figure 2B).
 The contribution of the different factors to the acetylcholine mediated relaxation is presented 
in Figure 2. Figure 2A shows the curves after vehicle, L-NMMA, indomethacin, and L-NMMA plus 
indomethacin incubation in NP-saline infused rats as an example. This figure shows that when 
aortic rings were relaxated in the presence of L-NMMA, which inhibits NO production, we observed 
a significantly decreased relaxation. This curve represents the resultant relaxation in the absence of 
NO. The curve after incubation with indomethacin, which inhibits the production of PG, represents 
the resultant relaxation in the absence of PG. In the presence of indomethacin, we observed a 
significant increase in relaxation as compared with the curve after vehicle incubation. This increase 
in relaxation following indomethacin indicates that the aorta produced mainly contractile PG (Figure 
2A). When aortic rings were incubated with both L-NMMA and indomethacin, production of both 
NO and PG are inhibited, the curve therefore represents the resultant relaxation, which is due to 
other factors, i.e. EDHF. After incubation of aortic rings with L-NMMA and indomethacin, relaxation 
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was significantly decreased as compared with the relaxation after vehicle incubation (Figure 2A). 
Table 2. -logEC
50
 dose response curves
Group NP-saline P-saline P-LPS NP-LPS
Acetylcholine relaxation 
(total relaxation)
6.82 ± 0.21 6.87 ±0.28 6.86 ± 0.06 6.63 ±  0.56
Acetylcholine relaxation in presence 
of L-NMMA 
6.74 ± 0.29 6.58 ± 0.10 6.23 ± 0.52 6.79 ± 0.28
Acetylcholine relaxation in presence 
of Indomethacin
7.25 ± 0.13 6.98 ± 0.12 7.00 ± 0.16 7.24 ± 0.08
Acetylcholine relaxation in presence 
of L-NMMA + indomethacin
6.65 ± 0.14 6.69 ± 0.25 6.89 ± 0.17 6.45 ± 0.17
Ang-II contraction 7.92 ±  0.10* 7.56 ±  0.38 8.12 ±  0.11* 7.75 ± 0.10 
Ang-II relaxation 8.33±  0.52 10.21 ±  3.74 9.45 ±  0.80 9.48 ±  0.40
P= pregnant; NP=non-pregnant; LPS= Lipopolysaccharide. Two-way ANOVA showed no effect of pregnancy or 
treatment (saline or LPS infusion) for acetylcholine mediated relaxation, for L-NMMA, indomethacin and L-NMMA 
plus indomethacin, and for Ang-II induced relaxation. Two-way ANOVA did shown an interaction between pregnancy 
and treatment for Ang-II mediated contraction (p=0.0122). Therefore, Student T-tests were performed with Bonferroni 
corrections. Data are presented as mean ± SEM. *: p<0.001 vs P-saline.
Figure 2B shows the E
max
 of the acetylcholine induced relaxation after incubation with vehicle, 
L-NMMA, indomethacin or L-NMMA and indomethacin of aortic rings of the four groups of rats. 
Since the E
max
 for NO and PG was calculated after incubation with their blockers (L-NMMA and 
indomethacin respectively), a higher E
max
 represents a lower NO or PG production. Since the curve 
after L-NMMA plus indomethacin incubation represents the relaxation due to EDHF, a higher E
max
 
for this curve, represents a higher EDHF production. 
 The total relaxation, i.e. relaxation after vehicle incubation, did not differ between the groups 
(Figure 2B, first graph). Also no difference in -logEC
50
 for total relaxation was observed between 
the groups (Table 2). After incubation of the aortic rings with L-NMMA, when NO production is 
inhibited, the E
max
 is very low and significantly decreased from the E
max
 after vehicle incubation in all 
groups, with no differences between the groups. This indicates that the resultant relaxation in the 
absence of NO is very small. NO thus play a large role in the relaxation of the aorta in all groups 
(Figure 2B, second graph). Also no difference in -logEC
50
 after L-NMMA incubation was observed 
between the groups (Table 2). After incubation with indomethacin, when PG production is inhibited, 
the E
max
 is significantly increased compared to the E
max
 of the vehicle curve, in NP-saline and LPS 
infused rats and in P-LPS infused rats (Figure 2B, third graph and Table 2). 
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Figure 1. Endothelium dependent relaxation.
The mean ± SEM acetylcholine-mediated endothelium dependent relaxation in the thoracic aorta of non-pregnant 
saline (NP-saline; circle), pregnant saline (P-saline; square), pregnant-LPS (P-LPS; triangle upward), and non-
pregnant-LPS (NP-LPS; triangle downward) infused rats after incubation with vehicle.
The percentage relaxation  was calculated as percentage of the pre-contraction with phenylephrine (PE). Analyzing the 
data with General Linear Model of repeated measures showed no significant differences between the curves in the four 
groups.
 Thus in the absence of PG, the aorta’s showed an increased relaxation, indicating that in these aorta’s 
mainly contractile PG are produce. In P-saline infused rats, however, the E
max
 after indomethacin 
incubation was not different from the E
max
 following vehicle incubation, suggesting that PG are 
not produced by aorta of these pregnant rats. The E
max
 from P-saline infused rats is significantly 
lower than the E
max
 of the other three groups. However, no difference in -logEC
50 
after indomethacin 
incubation was observed between the groups (Table 2).
 The last graph of Figure 2B shows the E
max
 after incubation with L-NMMA and indomethacin, 
i.e. when both NO and PG are inhibited. This E
max
 represents the relaxation due to other factors than 
NO and PG, i.e. EDHF. The resultant relaxation due to EDHF is low, indication a minor role for EDHF 
in the contraction of the aorta after acetylcholine and significantly decreased from the E
max
 after 
vehicle incubation in all groups except in the NP-LPS infused rats. However, the E
max
 after L-NMMA 
and indomethacin incubation was significantly increased in P-LPS infused rats as compared to the 
E
max
 of the P-saline infused rats, suggesting a more important role for EDHF in acetylcholine-induced 
aortic relaxation in P-LPS as compared to P-saline infused rats. However, no difference in -logEC
50
 
after L-NMMA and indomethacin incubation was observed between the groups (Table 2).
These data thus show that pregnancy induced a shift in components inducing relaxation compared 
to NP rats, which is annihilated in preeclampsia.
45
Endothelium-dependent relaxation and angiotensin II sensitivity in experimental preeclampsia
2
Figure 2. Endothelium dependent relaxation – contribution of the different factors.
(A) The mean ± SEM acetylcholine-mediated endothelium dependent relaxation in the thoracic aorta of the non-
pregnant saline infused rats after vehicle incubation (total relaxation; circle), after L-NMMA incubation (nitric oxide; 
square), after indomethacin incubation (prostaglandin; pyramid upward), and after L-NMMA and indomethacin 




 of the endothelium dependent relaxation under the different conditions in the thoracic aorta from pregnant 
rats (P; left set of bars) and non-pregnant rats (NP; right set of bars) infused with saline (white bars) or lipopolysaccharide 
(LPS; black bars). Data are presented as mean ± SEM. *: p<0.05 vs E
max
 of the total relaxation within the same group 
of rats (Student T-test). α: p<0.05 vs P-saline; σ: p<0.1 vs P-saline (Two-way ANOVA). A trend towards a significant 
interaction between pregnancy and treatment (saline or LPS) was found for prostaglandin (p=0.09).
Endothelium mRNA expression
Four types of enzymes related to the production of NO and PG were analyzed for expression of their 
mRNA level in thoracic aortas. mRNA expression of endothelial and inducible nitric oxide synthase 
(eNOS and iNOS respectively) was not different between the four groups. Also, mRNA expression of 




Figure 3. mRNA expression of eNOS, iNOS, COX-1 and COX-2 in aortic tissue.
The mRNA expression of eNOS (A), iNOS (B), COX-1 (C) and COX-2 (D) in aortic tissue from pregnant-saline (left 
set of bars) and non-pregnant (right set of bars) infused with saline (open bars) or LPS (black bars). Two-way ANOVA 
showed no effect of pregnancy or treatment (saline or LPS infusion).
Response of aortic rings to Ang-II
Ang-II mediated contraction
Figure 4 represents the cumulative Ang-II contraction curves (E
max
 shown in inset). In the presence 
of the AT2-R blocker PD-123319, when Ang-II can only bind to the AT1-R, contraction was observed 
in all groups. However, Ang-II mediated contraction was significantly blunted in P-saline infused 
rats (significantly decreased E
max
) compared to NP-saline infused rats (p=0.007). Moreover, after 
LPS infusion in P-rats a significant increase in Ang-II mediated contraction was seen as compared 
to the P-saline infused rats (p=0.017). There was, however, no effect of LPS treatment compared to 
saline infusion pertaining to the response of the AT1-R to Ang-II in NP-rats (p=0.713). Table 2 shows 
the -logEC
50
 of the Ang-II mediated contraction dose response curves. The -logEC
50
 was significantly 
increased in P-LPS infused rats as compared P-saline infused rats (p<0.001). Moreover, the -logEC
50 
was significantly increased in NP-saline infused rats as compared to P-saline infused rats (p<0.01). 
Thus, the pregnancy related decrease in Ang-II mediated contraction is absent in preeclampsia.
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Figure 4. Cumulative Ang-II contraction response curves. 
The mean ± SEM cumulative Ang-II contraction curves in the thoracic aorta from the female rat in the non-pregnant-
saline (NP-saline; circle; n=8), the pregnant-saline (P-saline; square; n=9), the pregnant-LPS (P-LPS; pyramid upward; 
n=9), and the non-pregnant-LPS (NP-LPS; pyramid downward; n=8) group. Percentages are calculated as percentage 
of the maximum contraction reached after adding 10-5M phenylephrine  and 60mM KCl, at the end of the concentration 
response curves. Inset: Mean ± SEM E
max
 of the cumulative contraction curves. Two-way ANOVA showed a significant 
effect of pregnancy(p=0.05) and a trend for treatment (p=0.1), with no interaction effect between pregnancy and 
treatment (p=0.315). The effect of pregnancy and treatment was further analyzed with Student T-test using Bonferroni 
corrections.*: p<0.05; ^: p<0.1.
Ang-II mediated relaxation through the AT2-R
Figure 5 represents the cumulative Ang-II dilation response curves (E
max
 shown in inset). In the 
presence of the AT1-R blocker losartan, when Ang-II can only bind to the AT2-R, relaxation was 
observed in all but the P-saline infused rats. The response upon Ang-II (i.e. the E
max
) was significantly 
blunted in P-saline compared to NP-saline infused rats (p<0.001). Infusion of LPS in pregnant rats 
increased the Ang-II mediated dilation compared to P-saline infused rats (p=0.05). There was no 
effect of LPS on the Ang-II sensitivity in non-pregnant rats (p=0.06). No significant differences were 
found between the four groups in the -logEC
50
 of the Ang-II mediated relaxation through the AT2-R 
dose response curves (Table 2).
Thus, preeclampsia seems to reverse the decrease in Ang-II mediated relaxation through the AT2-R 
seen in healthy pregnancy compared to the non-pregnant situation.
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Figure 5. Cumulative Ang-II dilation response curves.
The mean ± SEM cumulative Ang-II dilation curves of the in the thoracic aorta of non-pregnant saline (NP-saline; 
circle), pregnant saline (P-saline; square), pregnant-LPS (P-LPS; triangle upward), and non-pregnant-LPS (NP-LPS; 
triangle downward) infused rats.  Percentages are calculated as percentage contraction upon Ang-II of the maximum 
contraction reached after adding 10-6M phenylephrine. Inset: Mean ± SEM E
max
 of the cumulative Ang-II dilation curves. 
Two-way ANOVA showed a significant effect of pregnancy (p=0.001), with an interaction effect between pregnancy and 
treatment (p=0.006). The effect of pregnancy and treatment was further analyzed with Student T-test using Bonferroni 
corrections. *: p<0.05; **: p<0.01.
Ang-II receptor expression
There was no effect of pregnancy or treatment (LPS or saline infusion) on AT1-R or AT2-R mRNA 
expression in aortic tissue. However, the ratio between the AT1-R and the AT2-R mRNA in aortic 
tissue showed a significant effect of treatment. The LPS-infused rats showed a significant higher 
ratio (Figure 6) compared to the saline-infused rats, regardless of pregnancy (p=0.03).
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Figure 6. mRNA expression of AT1-R and AT2-R in aortic tissue.
The mRNA expression of the AT1-R (A) and the AT2-R (B) in aortic tissue from pregnant-saline (left set of bars) and 
non-pregnant (right set of bars) infused with saline (open bars) or LPS (black bars). Values for AT1-R and AT2-R mRNA 
were normalized to those of 18S ribosomal RNA. Two-way ANOVA was used to analyze the data. No significant 
differences were found between either LP and NP, saline infusion and LPS infusion or the interaction effect between 
pregnancy and treatment, in aortic tissue.
(C.) The ratio of the AT1-R and AT2-R mRNA expression in aortic tissue from pregnant-saline (left set of bars) and 
non-pregnant (right set of bars) infused with saline (open bars) or LPS (black bars). Values for AT1-R and AT2-R mRNA 
were normalized to those of 18S ribosomal RNA. The ratio was calculated by dividing AT2-R to AT1-R. Using two-way 
ANOVA a significant effect of treatment (p=0.03) was found in aortic tissue, independent of pregnancy.
*:p<0.05, LPS versus saline.
Correlation endothelium-dependent relaxation and response to Ang-II
The Ang-II relaxation mediated through the AT2-R significantly correlated with the contribution of 
EDHF (r=0.535, p=0.018)  (Figure 7). No significant correlation was found between Ang-II mediated 
relaxation through the AT2-R and the contribution of NO (r=0.020, p=0.934; data not shown) and 
between Ang-II mediated relaxation through the AT2-R and the contribution of PG (r=0.411, p=0.081; 
data not shown).
Figure 7. Correlation contribution of EDHF and Ang-II mediated relaxation through the AT2-R.
The correlation between contribution of EDHF (AUC) and the Ang-II mediated relaxation through the AT2-R (relaxation 
(%)) in all groups. 1=non-pregnant-saline group; 2=pregnant-saline group; 3=pregnant-LPS group; 4=non-pregnant-




In this study, we investigated endothelial function by studying the endothelium-dependent relaxation 
and the role of the AT1-R and AT2-R in the Ang-II sensitivity of healthy control pregnant and 
preeclamptic rats 24 using aortic rings in an organ bath setup for isotonic displacement 40. The model 
used for experimental preeclampsia, i.e. the low dose LPS-infused pregnant rat is an established 
model for preeclampsia, which has been used for many years 25,26. It is not only characterized 
by hypertension and proteinuria in the last week of pregnancy 24,28, but also with endothelial cell 
activation and generalized inflammation 25. Unfortunately, due to the experimental setup we were 
not able to measure blood pressure in this study. However, as stated above, the model used is an 
established model for studying preeclampsia and all studies performed, including recent studies in 
our lab, showed increase in blood pressure in this preeclampsia rat model.
 We found that during pregnancy, there appeared to be a decreased role for contractile 
PG and a decreased role for EDHF in acetylcholine-induced relaxation of the aorta as compared 
to the non-pregnant state. We also found that the Ang-II sensitivity was blunted during pregnancy: 
we demonstrated a decreased response upon binding of Ang-II to the AT1-R (vasoconstriction) 
as well as upon binding to the AT2-R (vasorelaxing) in P-saline infused rats compared with NP-
saline infused rats. Interestingly, similar to human preeclampsia, the pregnancy-induced changes in 
endothelium-dependent relaxation as well as in the decrease in contraction and relaxation response 
upon Ang-II were not observed in experimental preeclampsia in the present study. In fact, the 
endothelium-dependent relaxation and the responses upon Ang-II in experimental preeclamptic rats 
were comparable to those in the non-pregnant rats. 
 Incubation of aortic rings with vehicle showed no differences in relaxation between the 
four groups, suggesting that the total vascular vasoactive capacity of the aorta is not altered during 
normal pregnancy or during preeclampsia in the rat. This does not corroborate with some other 
studies 41–43, but it is in line with the study of Ballejo et al., who also showed that endothelium 
dependent relaxation in response to acetylcholine is not altered in late pregnancy 44. It also agrees with 
various other studies showing that acetylcholine induced relaxation does not differ in non-pregnant 
vs late pregnant rats 45–47. Differences in results may be due to strain differences 48 or to differences 
in timing of termination of pregnant or non-pregnant animals, differences in vascular bed used 
or differences in experimental methods. However, SNP treatment at the end of the experiments, 
showed a significantly attenuated relaxation in pregnant rats compared to non-pregnant rats (results 
not shown). This may indicate that during pregnancy, relaxation in the aorta is more dependent on 
endothelium-derived factors than in the non-pregnant state. Other models for preeclampsia, TNF 
infusion 49 or IL-6 infusion 50 in pregnant Sprague-Dawley rats did show decreased total vascular 
reactivity in the aorta as compared with control rats. These are, however, other models, in another 
rat strain, which may explain the differences.  
 In our study, also the role of NO in the vasodilatory capacity of the aorta did not differ 
between pregnant and non-pregnant rats. Although this suggestion is not in line with some previous 
studies 51,52, it agrees with others 44,46. This lack of differences in role of NO between the groups in 
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our study  is in accordance with the lack of differences in aortic iNOS or eNOS expression between 
the groups. Various studies have suggested a role for NO in the relaxation in pregnancy and the 
contraction in preeclampsia. Indeed, some studies showed that endogenous production of NO and 
eNOS mRNA are increased in pregnant rats 38,53. Also in-vivo treatment of rats with L-NMMA induced 
a higher increase in blood pressure in pregnant as compared to non-pregnant rats suggesting 
an increased role for NO in vascular vasoactive responses in pregnant versus non-pregnant rats 
54. It may be suggested that our lack of difference in the role of NO in the aorta may be due to 
the fact that endothelial NO production during pregnancy may be enhanced spontaneously or in 
response to vasoconstricting agents, but not in response to vasorelaxing agents 44. As suggested 
above, differences in responses may also be due to strain differences, since vascular responses to 
pregnancy are generally lower in Wistar rats as compared to Sprague-Dawley rats 48. Also differences 
in vascular beds used may account for differences between studies, since the aorta, which is a 
conduit vessel, and largely depends on NO, may respond differently than a mesenteric vessel, which 
is a resistance vessel and depends to a much lesser extend on NO 55. However, methodological 
differences or differences in timing of pregnancy may also play a role. 
 In contrast to NO, the involvement of vasoactive PG in acetylcholine-induced relaxation 
responses appeared to change during pregnancy in the present study. Changes in PG in pregnancy 
have also been found by Bobadilla et al. 56, but not by others studies (including another study of 
Bobadilla et al.  52,57. As described above, differences might be due to difference in strain used and 
methodological differences since Aloamaka et al. studied responses upon vasocontractile agents. In 
NP rats, inhibition of PG with indomethacin enhanced acetylcholine-induced relaxation, indicating 
the involvement of contractile PG in rats. However, this effect was absent in P-saline infused rats, 
suggesting that pregnancy was associated with a larger role of vasorelaxing PG, such as prostacyclin, 
in endothelium dependent relaxation. Alternatively, a decrease in contractile PG or receptor down 
regulation of the prostaglandin route during pregnancy may also be suggested. This observation 
is strengthened by the observation that precontraction with phenylephrine after incubation with 
indomethacin is enhanced in P-saline infused rats as compared with the other 3 groups of rats. These 
data are in line with the suggestion that vasodilatory PG may oppose the action of vasoconstrictors 
in pregnancy 58. As incubation with indomethacin caused an increase in relaxation in P-LPS infused 
rats, this putative role of prostacyclin during pregnancy is blunted in experimental preeclampsia. 
With these results, our findings seem to be in line with results in human preeclampsia 59–63, which 
showed decreased prostacyclin production in preeclampsia versus normal pregnancy 64, as well as 
with other models of preeclampsia 65,66. The altered involvement of vasoactive PG in acetylcholine-
induced relaxation responses found in our study, appeared independent of regulation of COXs 
expression, since we found no differences in mRNA expression of COX-1 or COX-2. However, we take 
into account that mRNA expression is not a surrogate for protein expression or post-translational 
effects in target cells. 
 The role of EDHF in endothelium-dependent relaxation was studied using concomitant 
incubation of the aortic rings with L-NMMA and indomethacin. This results in inhibition of NO 
and PG, therefore the resultant relaxation response is due to EDHF, or other unknown factors, 
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such as hydrogen sulfide 67 by means of exclusion. EDHF is an endothelium-derived relaxing factor 
that causes vasorelaxation in association with vascular smooth muscle hyperpolarization 68. The 
chemical identity of EDHF is uncertain 13. In our study in aortic rings, EDHF or these other factors 
significantly contributed to acetylcholine-induced relaxation in all groups, but was of significantly of 
less importance in P-saline infused rats. Other studies comparing the role of EDHF during pregnancy 
found an increased role for EDHF in pregnancy 52,69. However, these studies were performed in 
mesenteric arteries. Results may be different in humans, since EDHF was found to play a significant 
role in myometrial and subcutaneous arteries of pregnancy compared to preeclampsia 15,70. This 
inconsistency in our rat model may also be explained by the fact that different arteries were used, 
since it is well known that EDHF has different vasoactive properties depending on the arteries 
studied 55,71. Indeed, in rat mesenteric arteries the role of EDHF in relaxation appears to be increased 
during pregnancy 69. 
 To study the role of the AT1-R and AT2-R in the blunted responsiveness to Ang-II during 
pregnancy 16,  we studied the in-vitro responsiveness of the AT1-R and AT2-R to Ang-II in the rat. 
The contractile response to Ang-II was dramatically decreased in P-saline infused rats as compared 
to the NP rats, which is in line with a decreased blood flow reducing effect of Ang-II during human 
pregnancy 16. Our data also confirm previous studies in the rat 72,73. Also, the increased contraction 
response to Ang-II in aortic rings of experimental preeclamptic rats as compared to P-saline infused 
rats appears to be in line with the well-known increased Ang-II sensitivity during human preeclampsia 
19 and with studies in other models of experimental preeclampsia 74. This increase in response to 
Ang-II may be caused by an increased AT1-R expression in LPS infused pregnant animals, although 
we only found a trend towards increase in AT1-R mRNA expression. Whether this increased response 
to Ang-II in the aorta of rats with experimental preeclampsia contributes to the hypertension seen 
in these animals, remains speculative, since the aorta is a conductance vessel and not a resistance 
vessel. Further studies into the response to Ang-II in other vessels on the preeclamptic rats are in 
progress. However, a role for Ang-II and the AT1-R in this model for experimental preeclampsia has 
been shown by Doering et al. who observed that hypertension was decreased in this model after 
treatment with the AT1-R antagonist losartan. 
 Interestingly, we found that the vasorelaxing response to Ang-II mediated through the 
AT2-R was absent during late pregnancy in the P-saline infused rat and increased in the P-LPS 
infused rats, suggesting that also the AT2-R does play a role in the adaptations of the sensitivity 
to Ang-II during normal pregnancy and preeclampsia. In contrast to the present study, however, 
Stennett et al. observed an increased responsiveness of the AT2-R to Ang-II during normal pregnancy 
38. The difference between our study and the study by Stennett et al. may be explained by strain 
differences, since Stennett  et al. used Sprague-Dawley rats rather than Wistar rats. A recent review 
of van Drongelen et al., showed large differences in pregnancy induced vascular responses between 
Wistar and Sprague-Dawley rats 48 or concomitant long-term use of AT1-R blockers as shown in 
another study 75. Apart from placental and uterine tissue 76–78, data on function and expression of the 
AT1-R and AT2-R in tissues of humans during pregnancy are largely lacking. Therefore, the role of 
the AT2-R versus the AT1-R during human pregnancy and preeclampsia is relatively unclear. Since 
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both the vasocontractory response (via the AT1-R) as well as relaxation response (via the AT2-R) to 
Ang-II were blunted at the end of pregnancy, but not in experimental preeclampsia, the RAAS may 
be of relative low importance in blood pressure control at the end of normal rat pregnancy, while in 
preeclamptic rats, the contribution of the RAAS may be enhanced. 
 Finally, our results show that the decreased involvement of EDHF in acetylcholine-induced 
relaxation during pregnancy correlates with a decreased relaxation responsiveness of the AT2-R 
to Ang-II in these conditions. This correlation may be in line with the suggestion that bradykinin 
and the B
2
-receptor are involved in relaxation induced by Ang-II 79 and the notion that bradykinin-
induced relaxation is typically mediated by multiple EDHF’s 80. Although NO and PG-F
2
 are also 
suggested to play a role in the relaxation after binding of Ang-II to the AT2-R, we did not find a 
significant correlation between the role of NO or PG in the vasoactive capacity of the aorta and the 
AT2-R induced relaxation. This may suggest that the contribution of NO to relaxation was relatively 
constant and that differences in responses of the AT2-R to Ang-II  during pregnancy and experimental 
preeclampsia may result from differences in the role of EDHF. The lack of correlation between the 
role of PG and the vasorelaxing effect of Ang-II may result from the fact that we did not specifically 
study PG-F
2
, but PG in total. 
 Our observations were obtained with aorta which is a conductance vessel rather than a 
resistance vessel typically involved in blood pressure regulation. Our present observations in the 
aorta provide evidence of altered involvement of different endothelial mediators in acetylcholine-
induced relaxation and responsiveness to Ang-II in pregnancy and preeclampsia. They need to be 
confirmed in future studies employing preparations of other vessels – such as small resistance 
arteries, for example – to more directly link changes in vascular function to hypertension in pregnancy. 
However, it may be speculated that such changes may play a role in the regulation of blood pressure 
by influencing vascular smooth muscle tone and therefore aortic stiffness and thus central blood 
pressure 81,82.It may be of additional interest in future studies to include the role of Ang 1-7 when 
aiming to unravel the RAAS pathways involved in the development of preeclampsia. Ang 1-7 is a 
metabolite of Ang-II which is able to counteract the vasoconstriction effect of Ang-II by binding to 
the MAS-receptor and subsequently causing vasodilation via NO through eNOS activation 83.
 From this study, the pathway of how LPS induced the endothelial dysfunction and increased 
Ang-II seen in this experimental rat model for preeclampsia is still unknown. It is interesting to note 
that although the infusion of LPS took place on day 14 of pregnancy, endothelial dysfunction was 
observed on day 20 of pregnancy. This implies that LPS, which is infused during 1 hour on day 14, and 
cannot be traced in the circulation 15 minutes after infusion (unpublished data from previous work), 
induced a long-lasting effect in pregnant rats. This might be a direct effect of LPS on the endothelial 
cells, since LPS was shown to directly affect endothelial cells in-vitro 84. However, it might also be 
an indirect effect, since it has been shown that LPS induced long-lasting activation of inflammatory 
cells in pregnant rats 26,30. These activated inflammatory cells, for instance by producing oxygen free 
radicals, may then induce the endothelial cell dysfunction 85. Future studies will be performed to test 




 In conclusion, pregnancy in the rat was associated with a change in the involvement of 
different mediators of thoracic aortic endothelial relaxation function and the response to Ang-II. The 
contribution of vasodilatory PG to acetylcholine-induced relaxation was increased while that of EDHF 
was decreased in pregnant rats, as compared to that in non-pregnant rats. Moreover, we observed 
a decreased sensitivity to Ang-II (both contraction and relaxation) in the aorta during pregnancy 
in the rat. Interestingly, the pregnancy-induced changes appeared to be absent in experimental 
preeclampsia in the rat. The present findings may imply that the LPS-induced pregnant rat is a 
suitable model for future studies aiming to unravel the etiology of preeclampsia and test treatment 
options directed to Ang-II receptors and endothelial cells in preeclampsia.
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Complicating up to 8% of pregnancies, preeclampsia is the most common glomerular disease 
worldwide and remains a leading cause of infant and maternal morbidity and mortality. Although, the 
exact pathogenesis of this syndrome of hypertension and proteinuria is still incomplete, a consistent 
line of evidence has identified an imbalance of proangiogenic and antiangiogenic proteins as a key 
factor in the development of preeclampsia 1–3. Furthermore, recently, more attention has turned to 
the renin-angiotensin aldosterone system (RAAS) to provide understanding for the hypertension of 
preeclampsia 4. The imbalance of the RAAS and imbalance between angiogenic and anti-angiogenic 
factors, which may be both common to preeclampsia and chronic kidney disease (CKD), might 
explain why a history of preeclampsia predisposes women to develop CKD. 
 In this review, we briefly describe the characteristics of preeclampsia with a focus on 
the mechanisms of angiogenesis and the RAAS and its role in the pathogenesis of preeclampsia. 
Our main focus will be on the intriguing association between preeclampsia and the subsequent 
increased risk of developing CKD and on the potential mechanisms by which the risk of CKD is 
elevated in women with a history of preeclampsia.
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PREECLAMPSIA
The diagnosis of preeclampsia is clinical. As defined by the International Society of Studies of 
Hypertension in Pregnancy, the diagnosis requires blood pressures of 140/90 mmHg or higher on 
two occasions combined with urinary protein excretion of ≥300mg/day 5. Laboratory tests, such 
as liver function tests, quantification of urinary protein, or serum creatinine may be helpful in 
characterizing the degree of end-organ damage, but none is specific for preeclampsia 6.
 In the pathogenesis of preeclampsia, the placenta is the central organ since removal 
of the placenta abolishes the disease 7. Pathological examination reveals several abnormalities 
including infarcts, atherosis, thrombosis, and chronic inflammation 8. During normal placentation, 
the embryo-derived cytotrophoblast cells invade the maternal spiral arteries. As part of this process, 
the cytotrophoblasts adopt an endothelial phenotype 7,9. In preeclampsia, the invasion of the 
cytotrophoblasts into the spiral arteries is incomplete; they are only present in the superficial layers 
of the decidua. The abnormal placentation is thought to lead to release of secreted factors that 
enter the mother’s circulation, culminating in the clinical signs and symptoms of preeclampsia.
Kidney 
Renal function undergoes physiological adaptations in pregnancy. Healthy pregnant women 
show marked glomerular hyperfiltration by 40 to 60% in the second half of pregnancy 10. This 
hyperfiltration appears to result primarily from depression of the oncotic pressure 10. Furthermore, 
an increased rate of effective renal plasma flow (ERPF) is found during pregnancy, (approximately 
80% by 12 weeks’ gestation) 10. In contrast, during preeclampsia these functional changes in 
renal hemodynamics are different. The GFR in women with preeclampsia is significantly lower as 
compared with healthy gravid control subjects (91 ml/min per 1.73 m2 vs 149 ml/min per 1.73 m2). 
Of interest, no differences were found in ERPF between women with preeclampsia and healthy 
controls 11. 
 This depression in GFR during preeclampsia coincides with typical histopathological 
changes in the kidney, called glomerular endotheliosis, which is characterized by fibrin deposition, 
endothelial swelling and loss of capillary space 12. Although these renal histological changes have 
been considered pathognomonic for preeclampsia, this may not be the case. Several groups 
have performed antenatal renal biopsies in normal pregnant women and women with gestational 
hypertension. For instance, Strevenset al. demonstrated that five of twelve normal pregnant women 
had, albeit very mild, evidence of glomerular endotheliosis 3. These endotheliosis lesions resolve 
at variable rates postpartum, but it has been proposed that the characteristic renal changes of 
preeclampsia can be more long-standing 13. The mechanism for hypofiltration during preeclampsia 
is not elucidated; both (renal) hemodynamic mechanisms and secondary changes to structural 
renal changes are proposed 4. Lately, podocyte alterations and podocyturia have been described 
during preeclampsia 14. Proteinuria in patients with preeclampsia might not only be mediated by 
endothelial alterations described classically, but also by disturbances of podocyte biology including 
impaired survival, enhanced apoptosis and down-regulation of nephrin and other key proteins of 
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the slit diaphragm 15.
Angiogenic factors
Recent observations support the hypothesis that altered expression of placental anti-angiogenic 
factors are partially responsible for the clinical manifestations of preeclampsia. Soluble Fms-like 
tyrosine kinase-1 (sFlt1, the soluble form of vascular endothelial growth factor (VEGF) receptor 
1) and placenta-derived soluble TGF-B co-receptor endoglin (sEng), secreted by the placenta, are 
increased in the maternal circulation weeks before the onset of preeclampsia 3. These elevated 
factors might lead to endothelial dysfunction and therefore decreased endothelium dependent 
vasodilation and proteinuria. Several days after delivery, sFlt1 levels normalize coinciding with 
decrease in proteinuria and blood pressure. The fact that increasing circulating sFlt1 levels in 
gravid mice and rats, either by direct infusion of the protein or by injecting adenovirus expressing 
the sFlt1 mRNA, produces a syndrome resembling human preeclampsia, including hypertension, 
proteinuria and glomerular endotheliosis, suggests that sFlt1 plays a role in the pathogenesis of 
preeclampsia 1,16. 
 The exact mechanism by which (anti)-angiogenic factors are involved in the development 
of the typical renal phenotype during preeclampsia is unknown. However, recent evidence shows that 
VEGF and its type 2 receptor have a clear role in the podocyte and slit diaphragm 17. Overexpression 
of VEGF-A induces glomerular diseases 18. VEGF produced by the podocyte regulates the structure 
and function of the adjacent endothelial cell. 
Renin-angiotensin aldosterone system
In normal pregnancy there are marked changes in the RAAS including considerably elevated 
angiotensin II (ang II) levels 16. However, vascular resistance decreases markedly during normal 
pregnancy, suggesting that pregnant individuals are less sensitive to ang II than non-pregnant 
individuals 19,20. In contrast, during preeclampsia decreased circulating components of the RAAS 
with enhanced sensitivity to ang II infusion have been reported 5,20,21.
 There are several possible explanations for this enhanced sensitivity of ang II infusion. 
Firstly, it may be mediated through increased placental ang II type 1 receptor (AT1-R) expression, 
which has been specifically observed to be upregulated on the decidual or maternal side of the 
placenta 22. Secondly, angiotensin 1-7 (ang 1-7), a counterregulator of ang II, is decreased during 
preeclampsia compared with normal pregnancy. Therefore, this decreased ang 1-7 in these 
women may play a role in the hypertension seen in these patients 23. A third explanation is that 
circulating ang II type 1 receptor autoantibodies (AT1-AA) levels are elevated, which may explain 
the hypersensitivity to the effects of ang II 24. After injecting AT1-AA into pregnant mice and rats, 
hypertension, proteinuria, glomerular endothelial damage, and elevated levels of anti-angiogenic 
factors can be seen, suggesting that AT1-AA contribute to the pathogenesis of preeclampsia 25,26.
 However, in humans, increases in AT1-AA are not specifically related to preeclampsia, as 
this autoantibody is also elevated during intra-uterine growth restriction without preeclampsia 27. 
Therefore, the AT1-AA could be more related to impairment in placental development (placental 
ischemia) rather than mediating the preeclamptic phenotype. This is enforced by the fact that the 
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disappearance of clinical symptoms do not require the loss of the autoantibody 28. 
Interaction between sFlt1 and RAAS 
So far, most studies on preeclampsia have focused on angiogenic factors or on the RAAS, and not 
on the combination of both and the interaction between the two. Below, we will point out some 
evidence of interaction between sFlt1 and the RAAS. 
 A link between AT1-AA and angiogenic factors has been made by Zhou et al. 29; circulating 
AT1-AA and ang II are capable of inducing sFlt1 production via AT1-R activation and downstream 
calcineurin/nuclear factor of activated T-cells signaling. Therefore, both may be responsible for 
placental sFlt1 up-regulation in preeclampsia. These observations extend a previous finding from 
the same group that ang II stimulates sFlt1 production in placental explants 30. Moreover, Kim et 
al. have shown that in human proximal tubule cells, ang II induces an increased sFlt1 production 
cells, which is significantly blocked by losartan 31. 
 Furthermore, in pregnant mice, injection of serum from preeclamptic women with AT1-
AA increases the sFlt1 concentrations via the AT1-R significantly as compared to pregnant mice 
injected with serum from normotensive pregnant women 29. Moreover, another study in mice 
shows that the AT1-AA induced hypertension, proteinuria and renal abnormalities is reduced by co-
injection with losartan or infusion of VEGF121 32. In contrast, in the transgenic renin overexpression 
preeclampsia rat model, in which AT1-AA is elevated, no increase in sFlt1 concentration was 
found 33. 
 Whether a similar relation between AT1-AA and sFlt1 also exist in human pregnancy is 
unclear. In preeclamptic patients, some studies show no correlation between sFlt1 and AT1-AAs 
34,35, while another study shows the titer of AT1-AA, is significantly correlated with sFlt1 level in 
severe preeclamptic women 36.
 In conclusion, although the exact interaction between the RAAS and sFlt is still unknown 
(especially in humans), the studies described above suggest that during preeclampsia the 
impairment in the RAAS may influence the sFlt1 production. 
AFTER PREECLAMPSIA
Long-term vascular risk after preeclampsia 
Long term vascular risk following a preeclamptic pregnancy has been recognized for many years. 
Already in the 1960s 36 it was shown that a history of preeclampsia increases the risk of future 
hypertension. A meta-analysis showed that 1885 of 3658 formerly preeclamptic women developed 
chronic hypertension in a follow-up time of 5-32 years. Therefore, the relative risk of a later diagnosis 
of hypertension in formerly preeclamptic women is 3.7 37. Not only the risk for hypertension is 
increased in formerly preeclamptic women, they also have a higher risk for hypertension related 
diseases, i.e. ischaemic heart disease, in the next 15-19 years 38. Furthermore, another meta-analysis 
concluded that formerly preeclamptic women have an approximately double risk of early cardiac, 
cerebrovascular, and peripheral arterial disease, and cardiovascular mortality 39.
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Kidney disease after preeclampsia
Preeclampsia is more common in women with an underlying kidney disease. On the other hand, it 
has been suggested that preeclampsia itself increases the risk of kidney disease later in life. From 
the early 1960s till 1980s, several renal biopsy studies discussed the appearance of renal damage 
in women who had a pregnancy affected by preeclampsia. Zech et al. have studied the appearance 
of renal injury in biopsies three months to four years after pregnancy in a series of sixty formerly 
preeclamptic women. In many cases, typical glomerular lesions disappeared rapidly within six 
months. However, vascular lesions remained the same or changed only very slowly. Furthermore, 
these vascular lesions were directly related with an increased blood pressure 40. 
 Although nowadays, postpartum renal biopsy studies in formerly preeclamptic women 
are uncommon, a recent large cohort study has shown that a history of preeclampsia is a risk factor 
for undergoing a kidney biopsy later in life 41 . In a cohort of 756,420 women, the relative risk of 
undergoing a kidney biopsy was significantly higher in women with a history of preeclampsia (RR of 
12 (95% CI 6.3 to 23)). Subsequently, in another large cohort of 570,433 women, Vikse et al. studied 
the risk of developing end stage renal disease (ESRD) after preeclampsia 42 Preeclampsia during 
the first pregnancy was associated with a relative risk of ESRD of 4.7 (95% CI 3.6 to 6.1). Moreover, 
if women also had preeclampsia during subsequent pregnancies the relative risk of ESRD was 
even higher (15.5 95% CI 7.8 to 30.8). According to the authors, the association was stronger in 
preeclamptic women who had given birth to preterm infant or child with low birth weight, which 
might suggest that women with severe, early-onset preeclampsia have a higher risk for developing 
ESRD. 
Microalbuminuria after preeclampsia
A recent meta-analysis concluded that 31% of formerly preeclamptic women had microalbuminuria 
compared with 7% of women with uncomplicated pregnancies on average 7.1 years postpartum. 
This prevalence is similar to that found in patients with type 1 diabetes mellitus (28% at 14 
years after diagnosis) 43. Furthermore, women have a 4-fold increased risk of microalbuminuria 
after mild preeclampsia, and a 8-fold increased risk after severe preeclampsia, suggesting a 
graded relationship according to severity of the preeclamptic episode 43. The high incidence of 
microalbuminuria in formerly preeclamptic women found in the meta-analysis might partly be 
caused by the inclusion of a study that examined women with diabetes mellitus type 1 44. Especially 
since diabetic nephropathy, which is present in 41.9% of the formerly preeclamptic women with 
diabetes, is associated with elevated blood pressure and endothelial dysfunction. Still, the finding 
that almost one-third of formerly preeclamptic women have microalbuminuria is important 
given the associated risks of ESRD and cardiovascular disease. Several factors may explain the 
increased risk of microalbuminuria in formerly preeclamptic women: undetected hypertension and 
microalbuminaria before pregnancy, shared risk factors for preeclampsia and kidney disease and 
the fact that preeclampsia itself may damage the kidneys with scarring or incomplete healing from 
the endotheliosis. A potential mechanism of long-term renal damage might be that renal damage 
during preeclampsia results in epigenetic changes, and therefore leading to permanent kidney 
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damage. It would be interesting to unravel the role of epigenetic changes in the development of 
kidney damage after preeclampsia.
Renal function parameters after preeclampsia
Although several studies, as described above, have found persistent microalbuminuria in formerly 
preeclamptic women several years after pregnancy, no differences were found in serum renal function 
parameters in formerly preeclamptic women 43. None of these studies have shown a significant 
difference in serum creatinine values or creatinine clearance between formerly preeclamptic 
women and healthy parous controls. However, when looking at particular characteristics of renal 
function and performing renal function measurements in a more accurate way, abnormalities in 
renal function in formerly preeclamptic women can be seen.
 In 1998, van Beek et al. examined renal hemodynamic values (ERPF and GFR) at least 
four months postpartum in primiparous formerly preeclamptic women and healthy parous 
controls 45. These renal hemodynamic values were derived from the continuous infusion of para-
aminohippurate and inulin. Although, GFR did not differ significantly between the groups, ERPF 
appeared to be significantly lower in formerly preeclamptic women (482 ± 88 vs 553 ± 67 ml/
min/1.73m2). Consequently, filtration fraction (FF) was significantly higher in formerly preeclamptic 
women (0.28% ± 0.04% vs 0.22% ± 0.03%). Likewise, renal vascular resistance (RVR) was also 
higher.
 More recently, Spaan et al. compared in a similar protocol formerly preeclamptic women 
with parous controls at least 20 years after pregnancy 46. They also found a significant difference in 
ERPF (399 ± 61 vs 463 ± 83 mL/min/1.73m2 former preeclamptic women vs controls respectively) 
and RVR (122 ± 28 vs 95 ± 20). Furthermore, creatinine clearance appeared to be significantly lower 
in formerly preeclamptic women (88 ± 15 vs 100 ± 19 mL/min/1.73m2). 
According to these results, we can conclude that women who suffered from preeclampsia have 
abnormalities in renal function later in life. Both after short- and long-term follow-up an increased 
RVR and a reduced ERPF is observed, which supports the idea that renal vasoconstriction might play 
a central role in the development of hypertension and renal impairment in formerly preeclamptic 
women. 
Renin-angiotensin aldosterone system after preeclampsia
During preeclampsia the plasma levels of ang II are decreased, while the sensitivity for ang II is 
increased 5,20–22. In most cases, circulating ang II levels normalize within three months after delivery 
5,20–22. However, in one study, upregulation of ang II was found in hypertensive subgroups of formerly 
preeclamptic women 5,20–22. Although there is no clear difference between formerly preeclamptic 
women and healthy controls in circulating ang II levels, several studies have suggested a difference 
in ang II sensitivity.
 Three studies have examined the ang II sensitivity in formerly preeclamptic women 47–49. 
One study showed no difference in blood pressure response to ang II between formerly preeclamptic 
women and healthy controls 50. However, the two other studies conducted ang II infusion both 
during low and high sodium diet, and showed increased blood pressure responsiveness to 
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ang II during low sodium intake in women with a history of gestational hypertension or preeclampsia 
47,49. Furthermore, Hladunewich et al. have shown that after stimulating the RAAS with lower-body 
negative pressure, a delayed increase in circulating RAAS components was found in formerly 
preeclamptic women 49.
 Differences in results in the studies mentioned above can be explained by the use of 
different doses of ang II, whether or not using a standardized sodium diet and studying patients 
at different periods of the menstrual cycle 51. Sodium intake is of major influence on the RAAS and 
ang II sensitivity, since, low sodium diet is a strong activator of the RAAS. From the above studies 
it seems that there are differences in the function of the RAAS in formerly preeclamptic women as 
compared with women who experienced a normal pregnancy. However, this may only be revealed 
under certain circumstances, such as under low salt diet. In this respect it is of interest to mention 
that after pregnancy complicated by hypertension increased pressor response to a high sodium 
diet, e.g. sodium sensitivity is reported 47. This increased sodium sensitivity could lead to renal 
disease on the long term. 
 As mentioned above, a different expression of AT1-R may be involved in the enhanced 
ang II sensitivity found in formerly preeclamptic women. However, Hladunewich et al. could not 
show differences in AT1-R mRNA expression on tissue level in skin biopsies 49. Another explanation 
for the enhanced ang II sensitivity is elevation of AT1-AA levels in formerly preeclamptic women. 
Although AT1-AA levels decline by 50% at one week after delivery, Hubel et al. concluded that 
significantly more formerly preeclamptic women were characterized by the presence of AT1-AA as 
compared to healthy controls (17.2% vs 2.9%) 52. Because ang II increases sFlt1 production in the 
human proximal tubule cell, the existence of AT1-AA and increased levels of sFlt1 may be linked 53. 
 Concerning other RAAS parameters, no differences in plasma renin concentration and 
plasma aldosterone concentrations were found between former preeclamptic women and control 
pregnancies at least four months postpartum 45,48,54,55. However, in response to ang II infusion, 
aldosterone levels in women with a history of new-onset hypertension during pregnancy are 
significantly increased as compared to normotensive controls 47. Another study could not confirm 
this increased aldosterone response 48. Again, the difference in results might be explained by the 
differences in concentration and duration of ang II infusion and sodium intake.
sFlt1 after preeclampsia
Even though sFlt1 levels rapidly decrease during the first week after delivery, indicating that the large 
fraction of sFlt1 is derived from the placenta, increased levels of sFlt1 have been found in formerly 
preeclamptic women 52,56,57. This persistence of increased levels of sFlt1 in formerly preeclamptic 
women might be due to a richer extra-placental source of sFlt1 in these women, such as endothelial 
cells and monocytes. Indeed, one year postpartum, formerly preeclamptic women showed increased 
expression of sFlt1 in peripheral blood mononuclear cells 58. This increased sFlt1 may lead to 
changes in the vascular endothelium which may increase the risk of reno-vascular diseases in later 
life. Interestingly, patients with CKD and decreased GFR without a history of preeclampsia present 
with increased plasma levels of sFlt1, which correlates positively with proteinuria 59. 
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 However, other studies did not find a significant difference in baseline sFlt1 levels 
between women with a history of new-onset hypertension in pregnancy and women with a history 
of normotensive pregnancies 2,47,60,61. Interestingly, in one of these studies it is shown that during 
low-sodium balance, women with a history of gestational hypertension had greater sFlt1 response 
to ang II compared to women with a history of normotensive pregnancy 47. This not only reinforces 
an interaction between the RAAS and sFlt1, as described above, but also shows that it is important 
to take sodium status into account when studying the interaction between RAAS and angiogenic 
factors. It also shows that sodium intake could be a factor of influence in the discrepancy between 
the human studies on the relationship between AT1-AA and sFlt1 as described above. This 
interaction between sFlt1 and the RAAS after preeclampsia is interesting and should be elucidated 
in future studies.
CONCLUSIVE REMARKS
In summary, preeclampsia is a risk factor for the development of CKD. Why preeclampsia is associated 
with an increased risk for developing kidney disease is still unclear. One possibility could be that 
both preeclampsia and CKD are caused by the same risk factors (such as hypertension, obesity, 
insulin resistance, and endothelial dysfunction). Furthermore, the role of angiogenic factors (sFlt1) 
and the RAAS (AT1-AA and up-regulation of AT1-R) in the pathophysiology of both preeclampsia 
and CKD reinforces the described association. In regards to well-known cardiovascular risk factors, 
Romundstad et al have shown that approximately 50% of the elevated risk for future hypertension 
after preeclampsia can be explained by preexisting risk factors 62. Therefore, as it has been described 
by Sattar et al., pregnancy might be a stress test that can reveal subclinical cardiovascular and renal 
disease 63. 
 Moreover, preeclampsia itself induces deleterious effects to the kidney, revealed by 
persistent microalbuminuria in a subset of formerly preeclamptic women. As described above, 
during preeclampsia and still after preeclampsia, women have a disturbance in their regulation of 
the RAAS (increased sensitivity for angII, possible by up-regulation of the AT1-R and increased AT1-
AA). This might induce persistent increased ang II sensitivity, increased salt sensitivity and altered 
renal hemodynamics. In addition, preeclampsia induced endothelial dysfunction appears to remain 
after preeclampsia in a lot of patients 64 and is an independent risk factor for future cardiovascular 
and renal health. The reason for the remaining endothelial dysfunction is unknown, it may, however, 
be suggested that preeclampsia induces epigenetic changes in endothelial cells. Endothelial cell 
dysfunction may also be enhanced by increased levels of sFlt1 in formerly preeclamptic women. 
Ultimately, these disturbances in formerly preeclamptic women lead to an increased risk for CKD 
(figure 1). Future research should attempt to elucidate the exact mechanisms that underlie the 
complex interaction between preeclampsia and kidney disease.
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Figure 1. Proposed mechanisms.
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Hypertensive disorders of pregnancy (HDP) complicate about 10% of pregnancies. Population 
based studies report an increased risk for developing end stage renal disease after HDP. So far, 
studies have reported on renal function early after HDP. Longitudinal renal function and occurrence 
of chronic kidney disease (CKD) after HDP have not been studied yet.   
Aim
The aim of this study was to longitudinally assess postpartum renal function and occurrence of CKD 
in women with a history of HDP compared to controls.
Materials and Methods
We followed two approaches. First, in the PREVEND study, a general population based prospective 
cohort study, we identified women without and with a history of a self-reported HDP (non-HDP, 
n=1805 and HDP, n=977; respectively). Mean age at start of the study was  50 ± 12 years and median 
follow-up time was 11 years. Second, in a subgroup where hospital records on pregnancy history 
could be retrieved, we created a cohort 10 years postpartum specified by class of hypertensive 
disorder, namely normal pregnancy (control, n=202), pregnancy-induced hypertension (PIH, n=56) 
or preeclampsia (PE) or haemolysis elevated liver enzymes and low platelets (HELLP) syndrome 
(PE/HELLP, n=29). Renal function and the prevalence of CKD (defined as: eGFR <60ml/min per 
1.73m2 and/or 24-hour albuminuria >30mg) were assessed in both approaches.
Results
At baseline and during follow-up eGFR was lower in HDP (98.0 ± 16.2) vs non-HDP (99.4 ± 16.7) 
(p=0.03). In addition, the decline in eGFR was significantly steeper in HDP  (p for interaction=0.04). At 
baseline and during follow-up there was more anti-hypertensive-drug use in the HDP group. 24-hour 
albuminuria was higher in HDP and remained so during follow-up. Hazard ratio (95% confidence 
interval (CI)) for development of CKD during follow-up was 1.13 (0.92-1.38; p=0.24) in HDP. In the 
sub-group analysis, eGFR was significantly lower and 24-hour albuminuria significantly higher in the 
PE/HELLP as compared to controls (p=0.01 and p=0.03; respectively). CKD was present in 7.8% of 
the controls, 10.9% of the PIH group and 19.2% of the PE/HELLP group. The odds-ratio and 95% 
CI for CKD risk for PE/HELLP women with controls as reference group was 1.76 (0.93-3.34; p=0.08).
Conclusion
We report a slightly but significantly lower renal function and a steeper renal function decline over 
time after HDP. Women with severe hypertensive disorders of pregnancy (PE/HELLP) have the 
highest risk of CKD. 
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INTRODUCTION
Hypertensive disorders of pregnancy (HDP) occur in up to 10% of all pregnancies and are a major 
cause of maternal morbidity and mortality worldwide 1. The most severe form of HDP is preeclampsia 
(PE), clinically characterized by the presence of hypertension in combination with proteinuria in the 
second half of pregnancy 2. PE can be accompanied by the HELLP syndrome (haemolysis, elevated 
liver enzymes and low platelets), renal failure, and eclampsia (seizures).
 In the last 5-10 years it was shown that women with a history of HDP have an increased 
risk of end stage renal disease (ESRD). Vikse et al. were the first to show that formerly preeclamptic 
women have a relative risk of 4.7 for developing ESRD 3. This risk triples in case of recurrent PE or 
when complicated by low-birth-weight or premature delivery 3. Later, two Taiwanese cohort studies 
(with overlap) found a HR of 10.6-14 for developing ESRD after PE 4, 5. One of the Taiwanese cohorts 
found that women with a milder form of HDP (pregnancy induced hypertension (PIH)) also have 
an increased risk to develop ESRD with a HR of 5.8 4. The exact risk of chronic kidney disease (CKD) 
in formerly preeclamptic women is unknown, but  Wang et al. estimate the risk for CKD to be 4 to 
10-fold higher in women with a history of HDP 5.
 Long-term accelerated renal function decline might underlie the increased risk for ESRD in 
formerly preeclamptic women. However, studies assessing renal function shortly after HDP reported 
either subtle alterations or no differences in renal function and renal hemodynamics 6-10. Up until 
now, there are no studies reporting long-term renal function, renal function loss over time and CKD 
risk after HDP. 
 In order to evaluate long-term renal function, renal function decline over time, and the 
occurrence of CKD after HDP, we used data from the PREVEND study 11. The PREVEND study is 
a general population based prospective observational cohort study in the city of Groningen with 
longitudinal data on kidney function and albuminuria, which included questionnaires assessing self-
reported HDP. Data on five different time points, over a maximum follow-up of fourteen years are 
presented. In addition, to study the effect of severity of the HDP on renal function we performed 
record linkage with hospital records on pregnancy history in the subgroup of women that gave birth 
in one of the Groningen hospitals. Thus we created a case-control cohort at 10-years postpartum, 
including women with history of a healthy pregnancy, pregnancy induced hypertension (PIH) or 
HELLP/PE. We hypothesize that a history of an HDP increases the risk for accelerated long-term 





The PREVEND study is a prospective investigation of renal function, albuminuria, renal, and 
cardiovascular disease in a large cohort drawn from the general population 12. Details of this study 
are described elsewhere 13, 14. In summary, from 1997 to 1998, all inhabitants of Groningen, the 
Netherlands, aged 28–75 years (n=85,421), were sent a questionnaire and a vial to collect a first-
morning void urine sample. Pregnant women and subjects with type 1 diabetes mellitus were 
excluded. The urinary albumin concentration was assessed in 40,856 responders. Subjects with a 
urinary albumin concentration ≥10mg/L (n=7,768) were invited to participate, of whom 6000 were 
enrolled. In addition, a randomly selected group with a urinary albumin concentration <10 mg/l 
(n=3,394) was invited to participate in the cohort, of whom 2592 were enrolled. From the period 
1997-2012, five screening moments took place (around every 3 years) and detailed measurements 
were performed and blood samples were drawn and 24-hour urine was collected on two consecutive 
days. The PREVEND study has been approved by the medical ethics committee of the University 
Medical Center Groningen. Written informed consent was obtained from all participants. These 
8,592 individuals form the PREVEND cohort.
Selection of subjects
In total, 4,301 women were included in the PREVEND cohort (see Flow chart). Women who ever 
reported a pregnancy and answered the question regarding hypertension during pregnancy at the 
first visit were included in our study (n=2,782). The question on whether the women experienced 
hypertension during their pregnancy could be answered by the following options, ‘no’, ‘I don’t know’, 
‘yes, but allowed to do anything’ and ‘yes, had to keep bed rest’. Women, who had not reported 
hypertension during pregnancy at the first visit, were categorized as ‘women with no self-reported 
hypertensive pregnancy disorder’ (non-HDP; n=1,805). Women who had reported ‘yes, allowed to 
do anything’ or ‘yes, had to keep bed rest’ at the first visit, were categorized as ‘women with a self-
reported hypertensive pregnancy disorder’ (HDP; n=977). 
Data collection
Values for systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure 
(MAP), levels of urine albumin, serum creatinine, and serum cystatin C during the five visits were 
used for current analysis. Measurement of urinary albumin, serum creatinine, and serum cystatin 
C were performed as previously described 12. 24-hour albuminuria was calculated with the formula 
Urinary Albumin Concentration (mg/L) x Urinary Volume (L) over 24-hours. Since participants 
collected 24-hour urine on two consecutive days, the mean of two 24-hour albuminuria levels was 
taken. The eGFR was calculated with the CKD-EPI creatinine–cystatin C equations, using the serum 
creatinine and serum cystatin C values 15. The outcome of CKD was defined as a combination of an 
eGFR <60ml/min per 1.73m2 and/or 24-hour albuminuria >30mg 12. The development of CKD was 
calculated for each visit separately. 
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Flow chart of the patient selection for the PREVEND cohort and the case-control. 
n: number of subjects; HDP: hypertensive disorder of pregnancy; PIH: pregnancy induced hypertension; PE: preeclampsia; 
HELLP: haemolysis elevated liver enzymes low platelets syndrome
The occurrence of ESRD was defined as women with a history of  dialysis and or kidney transplantation 
(self-reported dialysis at visit 1 and during follow-up by linking with dialysis/kidney transplantation 
national database). Alcohol use was defined as 2-7 glasses a day or more. To calculate the percentage 
of women using anti-hypertensive medication, angiotensin converting enzyme inhibitors (ACE-i), 
and angiotensin receptor blockers (ARB) during follow-up, prescription data from pharmacies 
was collected. Oral contraceptive (OCC) use was based on self-reported use for any reason 
(‘contraception’, ‘climacterium’ or ‘other reason’). Cardiovascular comorbidity includes a history 
of chronic heart disease or cerebrovascular accident. Homeostatic model assessment index was 
calculated using the formula (glucose*insulin)/22.5. 
The PREVEND database could not provide information on delivery dates; therefore no postpartum 
follow-up time was calculated. Consequently, the date of the first PREVEND visit was taken as time-
point ‘0’. The median follow-up time at each visit was calculated from time-point ‘0’ where after 
follow-up time was divided in 4, 6, 9, and 11 years of follow-up. The maximum follow-up time was 
14 years. 
Case-control study in subgroup with obstetric history available 
In order to relate renal function to the severity of the HDP an additional case-control study was 
performed. The PREVEND database had only data on self-reported hypertension and no specific 
details on the obstetric history. To obtain data on obstetric history, the PREVEND database was 
linked to the registry of the Obstetric departments from the two hospitals in the city of Groningen 
(the University Medical Centre Groningen and the Martini Hospital Groningen). Data from women 
who gave birth between 1991 and 2007 could be retrieved. Using a unique patient number or using 
surname combined with date of birth, this case-control data file could be merged with the PREVEND 
database. Within the time frame studied, 536 women that gave birth in one of the two Groningen 
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hospitals could be identified. The linking process resulted in a cohort with detailed information 
regarding the pregnancies, severity of the hypertensive disorder (PIH, PE, and HELLP-syndrome), 
delivery dates, highest DBP, proteinuria, and birth weight of the child. Postpartum follow-up time 
could be calculated by the use of the delivery data collected from the medical records. For this 
subgroup analysis the renal function parameters were used and compared 10 years postpartum. 
Selection of cases
From the data of the 536 women that could be retrieved via record linkage, highest DBP measured 
during pregnancy was used to select women who fulfilled the criteria of a hypertensive disorder of 
pregnancy (DBP ≥ 90 mmHg). Subsequently, data regarding proteinuria was checked to identify the 
former preeclamptic women. Laboratory results, medical letters, electronic health records, and paper 
medical records were used to check for proteinuria. Additionally, laboratory evidence of thrombocyte 
count of ≤100x109/L, aspartate aminotransferase level of ≥50 IU/L, alanine aminotransferase level of 
≥50 IU/L, and lactate dehydrogenase ≥250 IU/L was investigated to identify women with a history of 
HELLP syndrome. Thus, we classified women as: history of pregnancy-induced hypertension (PIH; 
n= 56) or: history of PE and/or HELLP syndrome (PE/HELLP; n=29). PIH was defined as a highest 
DBP ≥90 mmHg. PE was defined as a highest DBP of ≥90 mmHg and proteinuria (≥300 mg/24h 
or a dipstick label ‘> once ++ or once +++’ or ’ > once +++ or >0,5 gr/L’ or ‘>3 times + or once ++’). 
Some women had a history of both PIH and PE in different pregnancies. In these cases, women were 
allocated to the group with PE/HELLP. Some women had a history of more than one hypertensive 
pregnancy. In that case, the pregnancy with the longest follow-up duration was selected.
Selection of controls
Women with a history of normotensive pregnancy (DBP <85 mmHg), birth weight of the newborn 
≥2500 gram and no history of placental abruption were selected (n=319) and served as control 
group. Medical codes and electronic health records were checked to exclude women with any 
relevant comorbidity. All women with a history of diabetes mellitus, cardiovascular and renal disease 
were excluded. Cases of preterm birth, dysmaturity and perinatal mortality were also excluded. Since 
controls were randomly sampled, matching was not performed. In total, 202 controls were selected. 
Statistical analysis 
Data were analysed using SPSS 22.0 (SPSS Inc. Chicago, IL, USA) and GraphPad prism 5.01 
(GraphPad Software Inc. San Diego, CA, USA). Parametric data are presented as mean ± standard 
deviation (SD) or 95% confidence interval (CI) in text, tables and figures and analysed using Student 
t-test or One-Way ANOVA followed by LSD post-hoc analysis. Non-parametric data are expressed as 
median with 25th-75th percentile and analysed using Mann-Whitney U test. The Chi-square test and 
Linear-by-Linear association were used for categorical variables. To assess the validity of maternally 
self-reported hypertension during pregnancy sensitivity and specificity was calculated. Sensitivity 
was calculated as the percentage true hypertensive women (PIH and PE/HELLP) according to the 
medical record reported as hypertensive in the questionnaire. Specificity was calculated as the 
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percentage true non-hypertensive women (Control) reported as no hypertension during pregnancy. 
For comparison of the eGFR decline during follow-up (factor visit) and the effect of a history of HDP 
or non-HDP (factor group), a generalized estimating equations (GEE) analysis was performed with 
the interaction term group*visit and corrected for BMI and age. In order to correct for ACE-i and ARB 
use on eGFR decline between the groups, an interaction term between ACE-i and ARB use and group 
was added in the GEE analysis. Exchangeable was used as correlation matrix and data are presented 
as Estimated Marginal Means (EMM) ± Standard Error (SE). Since a lower eGFR value is a risk factor 
for renal function decline over time in itself, GEE analysis was not corrected for eGFR at time-point 
0. GEE-analysis was also used for comparing anti-hypertensive medication, ACE-i and ARB use, and 
the development of CKD during follow-up. To examine the prospective association between the risk 
of CKD and a history of HDP, Cox proportional hazard regression model was performed to calculate 
the hazard ratio (HR) and 95% confidence interval (CI) with non-HDP as the reference group. In this 
proportional hazard regression model, person time was counted from the date of the first visit until 
the date that CKD was diagnosed, or the date of the last visit, whichever came first. No covariates 
were added into the model. Data from the first PREVEND visit were used as baseline data for the 
case-control sub-study. To evaluate 10 years postpartum risk for the development of CKD in our 
case-control sub-study, logistic regression analysis was performed to calculate the odds ratio (OR) 
and 95% CI with BMI and age correction. In all analysis, a p-value <0.05 was considered significant. 
RESULTS
PREVEND study – baseline characteristics
Table 1 shows the characteristics of the PREVEND population at time point 0. At baseline, women were 
on average 50 years old. Ethnicity, BMI, blood pressure, working status, smoking, anti-hypertensive, 
ACE-i, ARB, and OCC medication use, and cardiovascular comorbidity were significantly different 
between non-HDP and HDP. Laboratory cardiovascular risk markers were all significantly increased 
in HDP vs non-HDP at baseline, eGFR was slightly but significantly lower, and 24-hour albuminuria 
significantly higher in HDP vs non-HDP. No significant difference was found in the percentage of 
women that required dialysis. 
PREVEND study – blood pressure
Although average blood pressure was within the normotensive range in both groups, SBP and DBP 
were significantly higher in HDP than in non-HDP at baseline (Table 1) and during follow-up (Figure 
1A). During follow-up a rise in MAP was observed in the non-HDP group, while there was a trend 
towards an initial decrease and afterwards increase in the HDP group (possible treatment effect, p 
for interaction = 0.04; Figure 1A). The percentage of ACE-i, ARB, and all-anti-hypertensive use during 
follow-up increased significantly in HDP compared to non-HDP women (p for interaction<0.01 and 
p=0.03 respectively, Figure 1B/C). 
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Age (years) 50.1 ± 12 51.0 ± 11 0.05
Caucasian (n (%)) 1700 (94.9) 940 (97.2) <0.01
BMI (kg/m²) 25.8 ± 4.5 27.4 ± 5.0 <0.001
SBP (mmHg) 122 ± 20 130 ± 22 <0.001
DBP (mmHg) 70 ± 9 74 ± 9 <0.001
Birth weight (gram) 3281 ± 613 3283 ± 599 0.95
Job (n (%)) 724 (40.9) 355 (37.0) <0.01
Current smoker (n (%)) 641 (35.5) 301 (30.8) <0.05
Alcohol use (n (%)) 802 (44.6) 449 (46.1) 0.44
Antihypertensive use (n (%)) 181 (11.5) 209 (24.2) <0.001
ACE-inhibitor use (n(%)) 48 (3.0) 68 (7.8) <0.001
Oral contraceptive use (n(%)) 407 (24.2) 182 (20.4) <0.05
Gestational diabetes (n (%)) 40 (2.2) 20 (2.0) 0.77
Cardiovascular comorbidity (n (%)) 42 (2.4) 36 (3.8) <0.05
Medical history (n (%))
Asthma/COPD 174 (9.6) 91 (9.3) 0.78
Thyroid disorders 87 (4.8) 54 (5.5) 0.42
Arthritis 126 (7.0) 74 (7.6) 0.56
Epilepsy 10 (0.6) 6 (0.6) 0.84
Laboratory results 
Glucose (mmol/l) 4.6 (4.2-5.0) 4.7 (4.3-5.1) <0.001
Insulin (mmol/l) 7.4 (5.2-10.7) 8.3 (5.9-12.5) <0.001
HOMA 1.5 (1.0-2.3) 1.7 (1.2-2.8) <0.001
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Cholesterol (mmol/l) 5.5 (4.8-6.4) 5.7 (5.0-6.5) <0.01
Uric acid (mmol/l) 0.25 (0.22-0.30) 0.27 (0.23-0.31) <0.001
Triglycerides (mmol/l) 1.06 (0.8-1.5) 1.13 (0.9-1.6) <0.001
Renal function
Creatinine (mmol/L) 63 ± 13 64 ± 12 0.30
Cystatin C (mg/L) 0.86 ± 0.17 0.87 ± 0.16 0.18
Renal disease requiring dialysis 
(n (%))
7 (0.4) 1 (0.1) 0.18
Data are presented as mean ± SD or median (25th – 75th percentile) unless otherwise stated. BMI: body mass index; 
SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; ACE: angiotensin converting 
enzyme; COPD: chronic obstructive pulmonary disease; HOMA: homeostatic model assessment index; eGFR: estimated 
glomerular filtration rate.
PREVEND study – renal outcomes
Average values for eGFR during follow-up were within the normal range in both groups (Figure 
2A), with, however slightly but significantly lower values in HDP as compared to non-HDP at all 
visits. Moreover, the decline in eGFR was significantly steeper in the HDP compared to the non-
HDP (p for interaction=0.04; Figure 2A). Moreover, from 6 years on into follow-up, the percentage 
decrease in eGFR (eGFR at visit 1 served as reference) was significantly higher in HDP vs non-HDP 
(p for interaction=0.01; Figure 2B). Although significantly more HDP as compared to non-HDP were 
using ACE-i/ARB at baseline (Table 1) and ACE-i/ARB use had a significant effect on eGFR during 
follow-up (lower eGFR in women on ACE-i/ARB, p=0.008), the decline in eGFR was still significantly 
steeper in HDP compared to non-HDP after correcting the GEE-analysis for ACE-i/ARB use (p for 
interaction=0.02). 24-hour albuminuria was significantly higher in HDP compared to non-HDP up 
to 6 years follow-up, were a trend was seen from 9 years on into follow-up (Figure 2C). During the 
complete follow-up, no significant interaction was found between group (HDP and non-HDP) and 
follow-up duration for 24-hour albuminuria (p for interaction=0.09; Figure 2C).
 During follow-up, a total of 407 women developed CKD. The percentage of women 
developing CKD during follow-up showed a trend towards an increased percentage in HDP women 
as compared to non-HPDs women (pgroup=0.09), without an interaction between group and visit (p 
for interaction=0.57). Compared with non-HDP the HR and 95% CI for CKD risk was 1.13 (0.92-1.38; 
p=0.24) for HDP women. During follow-up, no women developed ESRD in either group.
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Figure 1. Prospective data on blood pressure and anti-hypertensive medication use in PREVEND 
cohort.
The estimate marginal means (EMM) ± standard error (SE) of the mean arterial pressure (MAP) (A) in women without 
and with a hypertensive disorder during pregnancy (non-HDP: circle, grey and HDP: square, black; respectively). The 
percentage prescription of angiotensin converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) (B) 
and anti-hypertensive medication (anti-HTN) (C) in women without and with a hypertensive disorder during pregnancy 
(non-HDP: white bar and HDP: black bar; respectively). *p<0.05 vs non-HDP at the respective visit. P for interaction: 
p
group*visit
 HDPs vs non-HDPs (GEE-analysis corrected for age and BMI).
Case-control study – characteristics
Baseline characteristics of the women included in the case-control sub-study at time point 0 (visit 1 
PREVEND study) and pregnancy data corresponding to the pregnancy used for the analysis (index 
pregnancy) are shown in Table 2. In total, 97 women had not had their index pregnancy at time point 
0 (Control n=74, PIH n=14, PE/HELLP n=9). BMI, MAP, antihypertensive use, gestational age at 
delivery, and birth weight in the PIH and PE/HELLP group were different as compared to the Control 
group. At baseline, eGFR and 24-albuminuria were not significantly different between the groups. 
Ten years postpartum, blood pressure was significantly higher in the PIH and PE/HELLP group as 
compared to Control (Table 2 and Figure 3A). 
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Figure 2. Prospective data on renal function and albuminuria in women with and without HDP.
The estimate marginal means (EMM) ± standard error (SE) of the estimated glomerular filtration rate (eGFR) (A), the 
mean ± SD of the percentage decline in eGFR at every visit compared to visit 1 (B), and the EMM ± SE of the 24-hour 
albuminuria levels (C) in women without and with a hypertensive disorder during pregnancy (non-HDP: circle, grey and 
HDP: square, black; respectively). *p<0.05, ^p<0.1 vs non-HDP at the respective visit. P for interaction: p
group*visit 
HDPs 
vs non-HDPs (GEE-analysis corrected for age and BMI).
Case-control study – renal outcomes
Figure 3 also shows renal outcomes of the case-control study 10 years postpartum. eGFR was 
significantly lower in PE/HELLP group compared to Control group 10 years postpartum (99.5±29.9 
vs 108.0±9.1; p=0.01; Figure 3B). No significant difference was found between PIH and Control group 
(105.2±14.5 vs 108.0±9.1; p=0.29). 24-hour albuminuria was significantly higher in PE/HELLP as 
compared to Control group (10.7 (6.3-21.1) vs 7.0 (5.7-10.3); p=0.03; Figure 3C). Although numbers 
are small, 4.1% of the Control group, 7.9% of the PIH group, and 17.4% of the PE/HELLP group 
showed 24-albuminuria levels >30mg/24-hour (Chi-square: p=0.049, Linear-by-Linear Association: 
p=0.02). 10 years postpartum, 7.8% of the Control group, 10.9% of the PIH group, and 19.2% from 
the PE/HELLP group suffered from CKD (Chi-square: p=0.18, Linear-by-linear association: p=0.08; 





Sensitivity was 69%; from a total of 72 hypertensive women, i.e. a history of a HDP according to their 
medical record, 50 women self-reported an HDP in the questionnaire. Specificity was 91%; from a 
total of 150 Control women, 136 women without a history of HDP according to their medical record, 
self-reported not to have had an HDP.
Figure 3. Blood pressure and renal function 10-year post-partum in the case-control.
The mean ± SD of the mean arterial pressure (MAP) (A) and the estimated glomerular filtration rate (eGFR) (B) and 
the median (25th-75th percentile) of 24-hour albuminuria (C) and the percentage (95% CI) of women suffering from 
chronic kidney disease (CKD) (D) 10 years postpartum in control (white bar), in pregnancy induced hypertension (PIH; 
striped bar) and preeclampsia or the HELLP-syndrome group (PE/HELLP; black bar). (D) CKD was defined as as a 
combination of an eGFR <60ml/min per 1.73m2 and/or 24-hour albuminuria >30mg, the p-value of the odds ratio is 
presented.
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Age (years) 34.8 ± 3.9 35.6 ± 4.4 35.4 ± 4.2
Caucasian (n (%)) 187 (92.6) 53 (94.6) 27 (93.1)
BMI (kg/m²) 23.6 ± 3.4 26.4 ± 4.6* 25.4 ± 5.8*
SBP (mmHg) 111 ± 9 122 ± 15* 118 ± 12*
DBP (mmHg) 65 ± 6 72 ± 8* 71 ± 6*
Job (n (%)) 139 (69) 35 (63) 16 (55)
Current smoker (n (%)) 65 (32) 21 (38) 12 (41)
Alcohol use (n (%)) 34 (17) 8 (14) 4 (14)
Antihypertensive use (n (%)) 2 (1) 5 (9)* 4 (15)*
ACE-i and ARB use (n(%)) 0 (0) 0 (0) 0 (0)
Oral contraceptive use (n(%)) 90 (45) 17 (33) 12 (41)
Cardiovascular comorbidity (n ((%)) 0 (0) 1 (2) 0 (0)
Medical history (n (%))
Asthma/COPD 15 (7) 4 (7) 1 (3)
Thyroid disorders 7 (4) 2 (4) 1 (3)
Arthritis 5 (3) 1 (2) 1 (3)
Epilepsy 0 (0) 0 (0) 0 (0)
Laboratory results
Glucose (mmol/l) 4.3 (4.0 - 4.6) 4.4 (4.1-4.9) 4.4 (4.2 - 4.9)
Insulin (mmol/l) 6.7 (5.2 – 9.8) 7.7 (6.1 - 10.6) 8.3 (5.6 - 11.7)









Cholesterol (mmol/l) 4.9 (4.3 - 5.4) 5.1 (4.3 - 5.9) 5.3 (4.5 - 6.0)*
Uric acid (mmol/l) 0.24 (0.22 - 0.27) 0.26 (0.21 - 0.29) 0.26 (0.22 - 0.29)
Triglycerides (mmol/l) 0.89 (0.69 - 1.2) 1.06 (0.73 - 1.37) 1.02 (0.77 - 1.38)
Renal function
Creatinine (mmol/L) 63 ± 9 62 ± 11 67 ± 31
Cystatin C (mg/L) 0.77 ± 0.1 0.79 ± 0.1 0.83 ± 0.3*
eGFR (mL/min/1.73m2) 113 ± 11 111 ± 13 110 ± 19
Albuminuria (mg/24h) 7.4 (5.7-11.1) 9.1 (6.3-14.5) 9.6 (5.9-18.5)
ESRD (n (%)) 0 (0) 0 (0) 0 (0)
Pregnancy data2
Highest DBP during pregnancy 
(mmHg)
74 ± 6 95 ± 7* 101 ± 10*,†
Age at delivery (years) 33.1 ± 4.1 32.6 ± 5.1 33.1 ± 4.9
Gestational age at delivery 
(week+days)
40+3 (39+2-41+2) 39+6 (38+4-40+6)* 38+3 (36+5-40+1)*
Birth weight child (grams) 3554 ± 461 3256 ± 716* 2833 ± 873*,†
Gestational diabetes (n (%)) 35 (17) 8 (14) 8 (28)
10 years postpartum
Age (years) 43.2 ± 4.5 41.6 ± 4.7 43.9 ± 4.9
BMI 24.5 ± 3.7 26.5 ± 4.4* 25.6 ± 6.4
SBP (mmHg) 114 ± 14 119 ± 14* 125 ± 22*
DBP (mmHg) 68 ± 9 73 ± 7* 74 ± 12*
Data are presented as mean ± SD or median (25th – 75th percentile) unless otherwise stated. 1Data from visit 1 of the 
PREVEND study; 2Data corresponding to the complicated pregnancy included in analysis. PIH: pregnancy induced 
hypertension; PE: preeclampsia; HELLP: haemolysis elevated liver enzymes and low platelets syndrome; BMI: body mass 
index; SBP: systolic blood pressure; DBP: diastolic blood pressure; ACE-i: angiotensin converting enzyme inhibitor; ARB: 
angiotensin receptor blocker; COPD: chronic obstructive pulmonary disease; HOMA: homeostatic model assessment 
index; eGFR: estimated glomerular filtration rate; ESRD: end stage renal disease. *p<0.05 vs Control, †p<0.05 vs PIH.
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DISCUSSION
We are the first to show longitudinal data on renal function in relation to hypertensive disorders 
during pregnancy. We found both a lower eGFR and a steeper eGFR decline over time in women 
with a history of a self-reported hypertensive disorder of pregnancy, even after correction for ACE-i 
and ARB use. Our case-control study with details on severity of the hypertensive disorder during 
pregnancy demonstrated a graded effect on renal function in relation to the severity of the HDP, with 
the lowest eGFR and highest albuminuria in the PE/HELLP group 10 years postpartum. Moreover, 
as compared to controls, a higher percentage of women with a history of PE/HELLP met the criteria 
for CKD. The lower postpartum eGFR and accelerated decline in eGFR during follow-up in the HDP 
group fits with the observation that these women are at increased risk for ESRD 3-5. 
 To our knowledge, only one other study investigated renal function decline after an HDP. 
In this study, Spaan et al. suggested that renal function decline with age was comparable between 
formerly preeclamptic women and healthy controls 16. However, their study was cross-sectional in 
design assessing a different cohort of women of 20 years older, and groups were relatively small. 
Several other studies showed either subtle or no abnormalities in renal function in women with a 
history of an HDP at set time points postpartum. Significantly lower para-aminohippurate measured 
effective renal plasma flow was found in formerly preeclamptic women compared to matched controls 
17. A meta-analysis revealed no significant differences in creatinine clearance and eGFR between 
formerly preeclamptic women and healthy controls 7. A recent report showed a high-normal eGFR in 
women with a history of early-onset preeclampsia, 10 years postpartum 8. A high-normal GFR might 
indicate an early stage of hyperfiltration, which is in line with the slightly increased filtration fraction 
observed in formerly early-onset preeclamptic women, in the absence of co-morbidity 9. An increased 
filtration fraction, generally considered an unfavourable renal hemodynamic profile, might provide a 
mechanistic explanation for loss of GFR during long-term exposure 18. Our current finding of a lower 
eGFR and a steeper eGFR decline after HDP in a large population with repeated measurements 
during long term follow-up therefore adds robust and valuable insights on the long-term course of 
renal function after hypertensive pregnancy.
 Data on the development of CKD after an HDP are sparse. Our date clearly suggest that 
women with a history of an HDP have a higher risk for developing CKD at middle age. This is in line 
with large population-based studies investigating the association between a history of an HDP and 
the risk of ESRD 3-5 and a small study focussing on the association between preeclampsia and kidney 
diseases by assessing kidney biopsies 19. Our results of a steeper decline in eGFR plus the increased 
risk for CKD in women with a history of an HDP, suggest an acceleration of the age-related renal 
function decline and more frequent occurrence of CKD.
 This paper is also the first presenting long-term longitudinal albuminuria data postpartum. 
Within our cohort, higher albuminuria levels were found in the HDP group, however, this difference 
trended to resolve 6 years after entry of the study. Resolution of albuminuria might be due to the 
increased ACE-i and ARB use during follow-up in the HDP as compared to the non-HDP group. 
Sampling error in 24-hour urine samples and lost to follow-up could as well been of influence on 
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these data. In addition, a significantly higher albuminuria level 10 years postpartum in women with 
a history of PE/HELLP as compared to controls was found, irrespective of ACE-i and ARB use. This 
is in line with a meta-analysis reporting an occurrence of micro-albuminuria of 31% in formerly 
preeclamptic women 7. Recent studies not included in the meta-analysis reported lower incidences 
of albuminuria in formerly preeclamptic women, varying from no difference 6, 20 to only 1.1% 10 years 
postpartum 8. 
 Postpartum development of hypertension might mediate the association between the 
hypertensive disorder during pregnancy and increased risk for ESRD later in life 5. A recent meta-
analysis showed a relative risk of 3.13 for hypertension in formerly preeclamptic women 21. In our 
study, mean arterial pressure was on average 8 mmHg higher in the HDP group. This is in accord 
with previous large studies 22, 23. Both severity (SBP >160mmHg or DBP >110mmHg) and early-
onset PE (<34 weeks) were shown to increase the risk of cardiovascular diseases even more 24. We 
show the same graded increase, with the highest blood pressure in the PE/HELLP group 10 years 
postpartum. Our longitudinal data do not support a more pronounced increase in blood pressure 
during the complete follow-up in HDP compared to non-HDP women. This might be influenced by 
blood pressure lowering treatment, which showed a significant increase in use over time in the HDP 
group. Whether the increased blood pressure found in the HDP group contributes to the decline in 
renal function during follow-up remains therefore unknown. 
 The exact mechanisms underlying the association between HDP and ESRD need to be 
elucidated. On one hand pre-pregnancy common risk factors for an HDP and renal impairments 
might explain these findings 25, 26, while on the other hand an HDP itself might induce renal 
impairment 27-29, or a combination of both. Unfortunately, we did not have sufficient cases with both 
pre-pregnancy and post-pregnancy data to analyse this important research question in detail. 
 Limitations of our studies are the retrospective character based on self-reported HDP. In 
addition, since the mean age of women included in the case-control study was lower than the mean 
age of the women in the PREVEND cohort, the women studied in the case-control study are not 
representative for the large PREVEND population. More non-HDP were using OCC, which is likely 
due differences in prescription behaviour due to comorbidity. Earlier analysis of the PREVEND study 
showed that OCC use has negative influence on eGFR and albuminuria 30. Since our HDP group, 
with the steeper eGFR decline had less OCC use, this cannot explain our results found. Of note, 
another large study showed no effect on eGFR when analysing post-menopausal use of estrogen 31. 
 Hypertensive disorders in pregnancy complicate around 10% of the pregnancies. However, 
in our cohort, 35% of the women reported a history of an HDP. We considered two main factors that 
might explain this finding. At first, our population was enriched with subjects with microalbuminuria, 
meaning that our population studied is at risk for CVD and CKD, and therefore true incidence for 
HDP is likely to be higher. Our microalbuminuria enriched population might also clarify our higher 
number of women reporting dialysis at baseline as compared to the true incidence in the Dutch 
population (Renine database, the Netherlands). Secondly, over reporting of an HDP could have 
been present, since women visiting for antenatal care might interpret the physiological rise in blood 
pressure towards the end of pregnancy as a hypertensive disorder, as well as influences of recall bias. 
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To validate the maternally self-reported history of an HDP, we conducted a specificity and sensitivity 
analysis by combining our PREVEND cohort with the case-control, showing a specificity 91% and a 
sensitivity of 69%. Our sensitivity analysis also suggests under reporting of an HDP, meaning that 
our non-HDP group includes true HDP women, potentially leading to a reduction of the differences 
found. Accuracy of our data are in accordance with earlier studies 32, but the self-reported nature of 
pregnancy complications clearly is a limitation of our data. 
 In conclusion, women with a history of an HDP have a slightly but significantly lower eGFR 
and steeper long-term decline in eGFR postpartum as compared to women without a history of an 
HDP on long-term follow-up. In addition, we found that women with a history of PE/HELLP have a 
higher risk to develop CKD on average 10-years postpartum. The increased renal function decline 
might contribute to the increased risk for ESRD later in life that has been reported after HDP. Based 
on our high-risk population, regular follow-up of women with a history of severe HDP (PE/HELLP) 
is of importance to take advantage of the window of opportunities for preventive treatment. Future 
studies should explore this risk in the general population in order to obtain more accurate estimates 
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Formerly preeclamptic women have an increased risk for developing end stage renal disease, that 
has been attributed to altered renal hemodynamics and abnormalities in the renin-angiotensin 
aldosterone system. Whether this is due to preeclampsia itself or to co-morbid conditions is 
unknown. Renal hemodynamics and responsiveness to angiotensin II during low sodium (7 days 50 
mmol Na+/24h) and high sodium intake (HS; 7 days 200 mmol Na+/24h) were studied in 18 healthy 
normotensive formerly early-onset preeclamptic women (fPE-women) and 18 healthy controls (fHP-
women), all selected for absence of co-morbidity. At the end of each diet, renal hemodynamics and 
blood pressure were measured before and during graded angiotensin II infusion. Both HS intake 
and former preeclampsia increased filtration fraction (FF) without an interaction between the two. 
FF was highest during HS in fPE-women (0.31 ± 0.12 vs fHP-women: 0.29 ± 0.11, GEE analysis BMI 
corrected, p=0.03). Renal response to angiotensin II infusion was not different between groups. 
In conclusion, fPE-women have a higher FF compared to fHP-women. As this was observed in the 
absence of co-morbidity, preeclampsia itself might exert long-term effects on renal hemodynamics. 
However, we cannot exclude the presence of pre-pregnancy alterations in renal function which in 
itself lead to an increased risk for preeclampsia. In experimental studies, an elevated FF has been 
shown to play a pathogenic role in the development of hypertension and renal damage. Future 
studies, however, should evaluate whether the subtle differences in renal hemodynamics after 
preeclampsia contribute to the increased long-term renal risk after preeclampsia.
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INTRODUCTION
Complicating up to 8% of pregnancies, preeclampsia (PE) is a major cause of maternal and fetal 
morbidity and mortality worldwide 27. PE is characterized by de-novo development of hypertension 
and proteinuria during the second half of pregnancy. Although it is a pregnancy-specific disease, 
evidence has mounted that PE has important long-term implications for maternal health, in 
particular cardiovascular and renal health 2, 24, 33. It is, however, uncertain whether the increased renal 
and cardiovascular risk in formerly preeclamptic women is explained by PE itself, or by underlying 
common (pre-pregnant) risk factors and co-morbidity.
 Recent data showed that formerly preeclamptic women have a five to fourteen fold 
higher risk for developing end stage renal disease (ESRD) 33, 36. Moreover, women who experienced 
multiple preeclamptic pregnancies have an even higher risk for ESRD 33. The risk for developing 
cardiovascular disease (CVD) is especially high for women who have a history of early-onset 
PE (before 34 weeks of gestational age) 2. It is unknown whether this also applies for the risk of 
developing ESRD. However, in a large Norwegian cohort study the association between former PE 
and developing ESRD is stronger in formerly preeclamptic women who had given birth to preterm 
infant or child with low birth weight. Early-onset preeclamptic women often give birth to a preterm 
infant or child with low birth weight. Therefore, this suggests that these women might have a higher 
risk for developing ESRD 33. The exact mechanisms underlying the increased risk for CVD and ESRD 
in formerly preeclamptic women are not completely understood 30.
 There are data, albeit sparse, showing that formerly preeclamptic women have persistent 
abnormalities in renal hemodynamics early and late after pregnancy, as a possible early pathway of 
increased renal risk 25, 29. However, this was mainly found in hypertensive women and thus might 
relate to the hypertension per se, rather than to the former PE specifically. Moreover, it is important 
to note that the renal hemodynamic profile is closely interlinked with sodium homeostasis and the 
renin-angiotensin aldosterone system (RAAS) 31. Sodium intake modulates renal hemodynamics 
in healthy subjects 34 as well as in subjects with hypertension 19. In risk populations like sodium-
sensitive hypertensive and overweight subjects, high dietary sodium intake elicits an unfavorable 
renal hemodynamic profile, which is absent during low sodium diet 8, 13. With regard to blood 
pressure response, both sodium sensitivity and altered response to angiotensin II (ang II) is 
reported in formerly preeclamptic women 12, 23, 37. The role of sodium intake in renal hemodynamics 
and the renal response to ang II in relation to sodium intake in formerly preeclamptic women is still 
unknown. 
 Therefore, in the present study, we investigated the renal hemodynamic profile in women 
with a history of early-onset PE, compared with healthy controls during both low and high sodium 
intake. In order to preclude the effect of differences in co-morbidity between the groups, we carefully 
selected healthy normotensive Caucasian formerly preeclamptic women, without co-morbidity, with 
a body mass index (BMI) < 30 kg/m2 and excluded hypertensive formerly preeclamptic women. 
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In steady state during low and high sodium intake, glomerular filtration rate (GFR), effective renal 
plasma flow (ERPF) and filtration fraction (FF) were measured at baseline and during graded 
ang II infusion. We hypothesized that previous PE would be associated with changes in the renal 
hemodynamic profile, be it or not dependent on sodium intake, as candidate mechanism for the 
increased risk for long-term renal damage in formerly preeclamptic women.
METHODS
Study population
We identified 264 formerly early-onset preeclamptic women (referred to as formerly preeclamptic 
women) one to ten years after delivery from an electronic delivery database of the department of 
Obstetrics and Gynecology at the University Medical Center Groningen (UMCG). Medical records 
were reviewed for accuracy of diagnosis of PE. PE was defined according to the International Society 
for the Study of Hypertension in Pregnancy criteria 6. Early-onset PE was defined as developing PE 
before 34 weeks of gestational age. A total of 224 formerly early-onset preeclamptic women were 
invited by mail to participate in the study. Twenty-four of these women were willing to participate and 
were invited for a screening visit to the UMCG. After the screening visit, one women was excluded 
for using antihypertensive medication, one woman because of high blood pressure during the 
screening visit, one woman was using hormonal suppletion which could not temporarily stopped 
and three woman were excluded for other reasons (pregnancy, time consuming, post-menopausal). 
Each of the 18 remaining formerly preeclamptic women was matched for age and year of index 
pregnancy (within one year) with a parous control (referred to as control group) whose pregnancy 
had been uncomplicated and normotensive. These women from the control group were recruited 
either through the department’s electronic delivery database or by advertisement. Their records were 
evaluated to confirm that pregnancy was indeed uneventful. 
 All women were non-smokers and normotensive, having a sitting systolic blood pressure 
<140 mmHg and diastolic blood pressure <90 mmHg measured at screening by an automatic 
sphygmomanometer (Dinamap®, G.E. Medical Systems, Milwaukee, Winsconsin, USA) and were 
not treated with an antihypertensive drug. Blood pressure was measured at screening at both 
arms to check for presence of a clinical significant difference in blood pressure (present in none 
of the subjects). Physical examination and electrocardiography did not reveal any abnormalities. 
None of the women had (a history of) underlying renal disease or hypertension, nor were they 
obese (i.e. BMI<30 kg/m2 at screening). They also did not have diabetes or a history of gestational 
diabetes, nor were they currently pregnant or lactating or using oral contraception. The study was 
approved by the local medical ethical committee (METc-number: 2010/294) and all women gave 
written informed consent in accordance with the Declaration of Helsinki. The study was registered 
in the Netherlands National Trial Register (www.trialregister.nl; trial registration number: 2635) as 
REsponse To Angiotensin II in formerly Preeclamptic women (RETAP) study.
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Study protocol
This cross-over protocol consisted of two one-week periods with at least four weeks in between, a 
7-day period on low sodium diet (LS; aim: 50 mmol Na+/day) and a 7-day period on a high sodium 
diet (HS; aim: 200 mmol Na+/day). For assessment of dietary compliance and the achievement 
of a stable sodium balance 24-hour urine was collected at day 3 and day 6 during each period. 
During the last day of the dietary week, blood pressure was measured during a period of 24-hours 
by ambulatory blood pressure measurement (ABPM; Spacelabs Healthcare). The cuff was placed 
around the non-dominant arm at the brachial level. The recorders were programmed to measure 
blood pressure at a 20-min interval during daytime and at an hourly interval during nighttime (10pm 
till 6am). Women were asked to fill out a diary during this 24-hour to differentiate between day- and 
nighttime measurements and to correct for intense exercise afterwards. The nocturnal fall in blood 
pressure (dipping) was defined as the percentage decline in nocturnal blood pressure as compared 
to daytime values. In our study, non-dippers were defined as individuals with less than 10% decline 
in nocturnal blood pressure as compared to daytime blood pressure. 
 Both renal hemodynamics and ang II responsiveness are greatly influenced by sex 
hormones 21. To avoid influence of these hormones, all measurements were performed during 
the mid-follicular phase (day 7±2 of menstrual cycle). At day 7 of both study periods, the subjects 
reported at the research unit at 8am after an overnight fast. Body weight, length and waist-to-hip 
ratio were measured at the start of this day. An intravenous cannula was inserted into each forearm, 
one for drawing blood samples, the other for infusion of radio-labeled tracers and ang II. Subjects 
received standardized meals and fluids during the day, with sodium intake adjusted to the prescribed 
diet. To ensure sufficient urine output, infusion of 250 mL/h of 5% glucose was administered and 
every hour 250 mL of oral fluids were provided. 
 GFR and ERPF were measured from the clearance of constantly infused radio-labeled 
tracers, 125I-iothalamate (IOT) and 131I-Hippuran (HIPP), respectively, in semi-supine position 
in a quiet room as described before 1, 35. After drawing a time point-0 blood sample, a priming 
solution containing 20 mL infusion solution (0.04 MBq of IOT and 0.03 MBq of HIPP) plus an 
extra amount of 0.6 MBq of IOT was given at 08.00 h, followed by a constant infusion of 12 mL/h. 
Plasma concentrations of both tracers are allowed to stabilize during 1.5-hour equilibration, which 
is followed by two 2-hour periods for simultaneous clearances of IOT and HIPP. The latter are 
calculated as (U*V)/PIOT and (I*V)/PHIPP, respectively. U*V represents urinary excretion of the 
tracer; I*V, the infusion rate of the tracer, which equals clearance from plasma during steady state; 
P, tracer values in plasma at the end of each clearance period. The plasma clearance (I*V)/PHIPP 
equals its urinary clearance because there is no extrarenal clearance of this tracer. Thus, when plasma 
levels are in steady state, ERPF equals I*V/PHIPP. GFR is calculated as the urinary clearance of IOT, 
corrected for voiding errors: (U*V/P)corr. As urinary clearance of HIPP equals plasma clearance in 
case of perfect urine collection, we routinely use the ratio of plasma-to-urinary clearance of HIPP 
to correct urinary clearance of IOT for voiding errors and dead space. By this method, coefficient of 
variation for GFR is 2.5% and for ERPF 5%. FF was calculated by the ratio of GFR and ERPF. Extra 
cellular volume (ECV) was estimated from the distribution volume of IOT and is calculated from 
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the plasma level of IOT in the body, which equals the amount infused minus the amount excreted. 
It is calculated as ((I*V+B*V)-(U*V))/P. B*V represent the bolus infusion of the tracers 35. GFR, 
ERPF and ECV were indexed for body surface area (BSA), by dividing the raw sample by BSA and 
multiplying it with 1.73m2. BSA was calculated according to the DuBois-DuBois formula 10. 
 Blood pressure and heart rate were measured by using an automated sphygmomanometer 
(Dinamap; GE Medical Systems, Milwaukee, Wisconsin, USA) at 15-min intervals, with subjects 
being in a quiet room, in a semi-supine position, with their arm in resting position. Appropriate 
blood pressure cuff was determined on the basis of arm circumference. Mean arterial pressure 
(MAP) was calculated as diastolic pressure plus one-third of the pulse pressure. Renal blood flow 
(RBF) was calculated as ERPF/(1−hematocrit). Renal vascular resistance (RVR) was calculated as 
MAP/RBF × 80,000. Baseline values for blood pressure and GFR and ERPF were obtained from 10am 
to 12pm. Between 12pm and 3pm ang II (Clinalfa, Merck Biosciences AG, Läufelfingen, Switzerland) 
was administered intravenously, at a constant rate in doses of 0.3, 1 and 3 ng/kg/min each during 
1-hour. During these ang II infusions blood pressure was measured at 5-min intervals. 
Sampling and chemical analysis of urine and blood samples
Fasting blood samples were drawn for analysis of hematocrit (Ht), glucose, HbA1C, sodium, 
potassium, creatinine, and thyroid stimulating hormone (TSH). Measurements were performed by 
the use of an automated clinical chemistry analyzer (Sysmex hematology analyzer (for Ht), Sysmex 
Tosoh G8 (for HbA1c) and Roche Modular). Fasting serum insulin was determined by an automated 
immunoassay analyzer (Architect, Abbott). Homeostasis model assessment (HOMA) was calculated 
by: glucose (mL/L) x insulin (microunits/mL)/22.5. Blood for measuring plasma aldosterone and 
plasma renin activity (PRA) was collected at 11am in precooled tubes and immediately centrifuged 
at 4°C for 10min (3000 rpm). Plasma was subsequently stored in -80°C until analysis. Aldosterone 
was measured with a commercially available radioimmunoassay kit (coat a count RIA, Siemens). 
PRA was determined by a radioimmunoassay kit that detects the production of angiotensin I due to 
the enzymatic activity of plasma renin acting on endogenous plasma angiotensinogen (nanograms 
of angiotensin I produced per liter of plasma per hour; RIA, CisBio International, France). Urine 
samples were drawn from the 24-hour urine collected by all women. The level of urinary sodium, 
potassium, creatinine, and albumin were assessed by the use of an automated clinical chemistry 
analyzer (Roche Modular Basel). As some study subjects were still slightly menstruating during the 
24-hour urine collections, these samples were not suitable for albuminuria measurement. Therefore, 
to test for albuminuria, a random morning urine sample of all subjects was collected after the end of 
the study, at a point in time where subjects were certain not to menstruate to exclude confounding 
by admixture of blood. 
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Statistical analysis
Data were analyzed using SPSS 20.0 (SPSS Inc. Chicago, IL, USA) and GraphPad prism 5.01 
(GraphPad Software Inc. San Diego, CA, USA). Parametric data are presented as mean ± standard 
deviation (SD) in text, tables and figures. Non-parametric data are expressed as median with 25th 
and 75th percentile. Differences in baseline characteristics, blood and urinary parameters between 
formerly preeclamptic women and controls were tested with the Student t-test for parametric data 
and Mann-Whitney U test for non-parametric data. For 24-hour blood pressure data, dipping was 
analyzed with the Chi-square test. For MAP and renal hemodynamics, to separately test the effects of 
sodium intake (factor diet), history of PE or not (factor group), and the interaction between the two 
(factor diet*group), a generalized estimating equations (GEE) analysis was performed. In the GEE 
analysis we corrected FF and MAP for difference in BMI. This repeated measurements analysis is 
appropriate for this small cross-over study with repeated measures in one subject 16. In comparisons 
a p-value <0.05 was considered statistically significant. 
Power calculation
The cross-over design of the study with multiple factors resulted in a multivariate power calculation. 
The main endpoint of the RETAP study was renal response (GFR, ERPF and FF) to ang II after 
low and high sodium diet in formerly preeclamptic subjects compared to healthy controls. In the 
multivariate power calculation 3 factors (response to ang II, low and high sodium diet and control 
group vs. formerly preeclamptic women) and 2 confounders were taken into account. Therefore, 
25 women per group (n=10*5/2) were needed to perform multivariate analysis. Due to the low 
incidence of early-onset PE and the demanding nature of the study, we were not able to include 25 
women per group in our hospital. However, after including 18 women per group and performing an 
interim analysis, we found a significant difference between both groups. 
RESULTS
Baseline characteristics
Baseline characteristics of the two groups are shown in Table 1. There were no statistically significant 
differences in age, number of pregnancies (gravidity), number of births (parity) and time since last 
pregnancy between the two groups. 15 out of 18 women experienced the early-onset PE during their 
first pregnancy, the other three women experienced PE during their second pregnancy. Formerly 
preeclamptic women had a higher weight and consequently a higher BMI compared with the control 
group. Both groups showed an increase of approximately 1.5 kilogram in weight during high sodium 
intake compared to low sodium intake (p<0.001). Waist-to-hip ratio was not significantly different 
between the two groups. 
 The average 24-hour blood pressure values are shown in Table 1 and were similar in 
formerly preeclamptic women and control subjects. Both groups responded to high sodium intake 
reflected by an increased blood pressure. However, the average salt-induced increase in blood 
pressure did not differ between the two groups. Data are presented for 24-hour averages but similar 
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results are present when analyzing diurnal and nocturnal values separately. The number of women 
showing the nocturnal fall of MAP (dipping pattern) was not significantly different between the two 
groups. 
Table 1. Baseline characteristics
Characteristic History of normotensive 
pregnancy (n = 18)
History of preeclamptic 
pregnancy (n = 18)
P
Age, years 36 ± 5 36 ± 5 .951
Gravidity 2.5 ± 1.3 2.6 ± 1.1 .951
Parity 2.0 ± 0.7 2.2 ± 1.0 .589
Time since last pregnancy, years 4.2 ± 2.6 5.3 ± 3.0 .243
Weight LS, kg 66.1 ± 8.3 73.2 ± 10.5 .029
Weight HS, kg 67.9 ± 8.3* 74.9 ± 11.0* .039
BMI LS, kg/m2 22.6 ± 2.6 25.3 ± 3.3 .010
BMI HS, kg/m2 23.2 ± 2.7 25.9 ± 3.5 .015
Waist-to-hip ratio 0.83 ± 0.04 0.84 ± 0.06 .443
24-h MAP LS, mmHg 87 ± 5 88 ± 8 .89
24-h MAP HS, mmHg 90 ± 7* 90 ± 8* .71
Dipping MAP LS no/yes (%yes) 1/17 (94 %) 3/13 (81%) .23
Dipping MAP HS no/yes (%yes) 3/15 (83%) 5/11 (69%) .32
Data are presented as mean ± SD. BMI, body mass index; MAP, mean arterial blood pressure; LS, low sodium; HS, 
high sodium. *p<0.05 vs low sodium within the group. 
Blood and urinary parameters
Blood and urinary parameters are shown in Table 2. No statistically significant differences in 
hematocrit, fasting glucose, insulin, HOMA, HbA1C, plasma sodium, plasma potassium, plasma 
creatinine, and TSH were found between the two groups. In both groups, plasma creatinine was 
significantly lower during high sodium intake compared with low sodium intake (p=0.001).
 No statistically significant differences in urinary sodium excretion, potassium excretion and 
urea excretion were found between the groups; this reflects an equal intake of sodium, potassium 
and proteins between the two groups. Formerly preeclamptic women had a higher urinary creatinine 
excretion compared with control subjects. 
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 No differences in PRA and aldosterone were found between the groups. In both groups, a 
significant decrease in PRA and aldosterone was found during high sodium intake compared to low 
sodium intake (p<0.001), which reflects that in both groups the systemic RAAS is adequately and 
similarly modulated by sodium intake. 
 There were no differences in urinary albumin/creatinine ratio between the groups. 
Table 2. Blood and urinary parameters
Parameter History of 
normotensive 
pregnancy (n = 18)
History of 
preeclamptic 
pregnancy (n = 18)
P
Hematocrit LS, l/l 0.40 ± 0.02 0.40 ± 0.03 .460
Hematocrit HS, l/l 0.38 ± 0.03 0.38 ± 0.03 .634
Glucose LS, mmol/L 5.1 ± 0.7 5.0 ± 0.5 .628
Glucose HS, mmol/L 5.0 ± 0.5 5.0 ± 0.3 .605
Insulin LS, µU/mL 8.35 (5.60-9.90) 8.50 (6.50-12.80) .542
Insulin HS, µU/mL 7.10 (4.70-9.30) 7.65 (4.60-10.80) .525
HOMA LS 1.91 (1.26-2.16) 1.83 (1.33-3.01) .636
HOMA HS 1.55 (0.97-2.15) 1.69 (1.08-2.30) .369
HbA1c LS, mmol/mol 35 (31.75-36.00) 33 (32.50-35.00) .134
HbA1c HS, mmol/mol 35 (32.75-37.25) 34 (30.75-35.25) .203
Plasma sodium LS, mmol/L 140 ± 1.6 140 ± 1.9 .853
Plasma sodium HS, mmol/L 142 ± 1.8 141 ± 2.4 .164
Plasma potassium LS, mmol/L 4.0 ± 0.2 3.9 ± 0.3 .604
Plasma potassium HS, mmol/L 3.9 ± 0.2 3.9 ± 0.2 .287
Plasma creatinine LS, µmol/L 66.5 ± 9.2 70.1 ± 9.0 .242
Plasma creatinine HS, µmol/L 61.1 ± 7.0* 65.7 ± 9.3* .090
Plasma TSH LS, mU/L 1.29 ± 0.6 1.60 ± 0.9 .245
Plasma TSH HS, mU/L 1.48 ± 0.5 1.47 ± 0.9 .975
Urinary sodium LS, mmol/24 h 38.9 ± 14.0 45.1 ± 22.8 .326
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Parameter History of 
normotensive 
pregnancy (n = 18)
History of 
preeclamptic 
pregnancy (n = 18)
P
Urinary sodium HS, mmol/24 h 220.8 ± 63.5* 258.4 ± 85.9* .145
Urinary potassium LS, mmol/24 h 66.2 ± 21.3 76.3 ± 25.2 .202
Urinary potassium HS, mmol/24 h 79.8 ± 33.5 73.3 ± 14.7 .459
Urinary creatinin LS, mmol/24h 9.8 ± 1.9 11.1 ± 1.0 .013
Urinary creatinin HS, mmol/24h 9.8 ± 1.9 11.5 ± 2.4 .013
Urinary urea LS, mmol/24h 264 ± 91 306 ± 63 .119
Urinary urea HS, mmol/24h 339 ± 89* 340 ± 65 .973
PRA LS, nmol Ang-I/L/h 0.80 (0.50-1.20) 0.85 (0.70-1.50) .501
PRA HS, nmol Ang-I/L/h 0.20 (0.10-0.50)* 0.20 (0.09-0.30)* .584
Aldosterone LS, pmol/L 255 (204-395) 341 (214-477) .161
Aldosterone HS, pmol/L 71 (29-93)* 59 (35-96)* .839
Urinary albumin/creatinine, g/mol 0.6 ± 0.3 0.5 ± 0.4 .212
Data are expressed as mean ± SD or as median (25th-75th percentile). LS, low sodium; HS, high sodium; HOMA, 
homeostatic model assessment index (HOMA was calculated as [glucose*insulin/22.5]); TSH, thyroid stimulating 
hormone; PRA, plasma renin activity;  Ang-I, angiotensin I. *p<0.05 vs low sodium within the group.
Blood pressure and renal function at baseline
Blood pressure and renal function during high and low sodium intake are shown in Table 3 and Table 
4, and Figure 1. By performing GEE analysis, we found no differences in MAP between both groups 
(p
group





=0.414, no interaction between diet and group). 
With regards to renal hemodynamics, no differences were found in GFR (p
group
=0.688) and ECV 
(p
group
=0.973) between both groups. Formerly preeclamptic women have a slightly lower ERPF 
compared to control subjects, but this did not reach statistical significance (p
group
=0.253). However, FF 
was significantly higher in formerly preeclamptic women compared to healthy controls (p
group
=0.035). 


















=0.683). The higher 
FF in formerly preeclamptic women was not explained by MAP; no significant correlation could be 
detected between MAP and FF (r=0.095; p=0.581). 
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Blood pressure and renal function during ang II infusion 
Graded ang II infusion showed in both groups a dose-dependent rise in blood pressure during 
both high and low sodium intake (Table 4). No significant differences were found in absolute blood 
pressure values during ang II infusion between both groups. Figure 2 demonstrates ERPF during 
ang II infusion. Both groups showed a dose-dependent decrease in ERPF during ang II infusion 
(p
dose
<0.001). No differences were found in the responses of ERPF to ang II between the groups 
(p
group
=0.337). Sodium intake did not affect the response of ERPF to ang II infusion (p
diet
=0.562).
Table 3. Baseline renal function parameters
Parameter History of 
normotensive 
pregnancy (n = 18)
History of 
preeclamptic 
pregnancy (n = 18)
P
RVR LS, dyne*s/cm5 10985 ± 2936 11026 ± 2017 .962
RVR HS, dyne*s/cm5 11248 ± 3071 11461 ± 2388 .819
ERPF LS, mL/min/1.73m2 625 ± 146 622 ± 99 .949
ERPF HS, mL/min/1.73m2 642 ± 149 621 ± 105 .623
Creatinine clearance LS, mL/min 107 ± 28 111 ± 17 .591
Creatinine clearance HS, mL/min 114 ± 24* 124 ± 25* .220
eGFR LS, mL/min/1.73m2 102 ± 14 97 ± 15 .368
eGFR HS, mL/min/1.73m2 109 ± 10* 103 ± 15* .117
Data are presented as mean ± SD. LS, low sodium; HS, high sodium; RVR, renal vascular resistance; ERPF, effetive 
renal plasma flow; eGFR, estimated glomerular filtration rate (eGFR was calculated by using CKD-epi formula 15). 
*p<0.05 vs low sodium within the group.
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Table 4. Blood pressure at baseline and during angiotensin II infusion
MAP during ang II infusion History of normotensive 
pregnancy (n=18)




 Baseline, mmHg 81 ± 7 83 ± 8 .375
 0.3 ng/kg/min, mmHg 81 ± 8 82 ± 8 .745
 1.0 ng/kg/min, mmHg 86 ± 9 87 ± 9 .705
 3.0 ng/kg/min, mmHg 92 ± 12 95 ± 10 .477
 Recovery, mmHg 85 ± 8 87 ± 10 .612
High sodium 
 Baseline, mmHg 85 ± 8 86 ± 9 .714
 0.3 ng/kg/min, mmHg 84 ± 9 85 ± 10 .601
 1.0 ng/kg/min, mmHg 89 ± 9 93 ± 11 .260
 3.0 ng/kg/min, mmHg 99 ± 8 100 ± 10 .646
 Recovery, mmHg 89 ± 8 89 ± 11 .981
Data are presented as mean ± SD. MAP, mean arterial pressure; ang II, angiotensin II
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Figure 1. Renal hemodynamics during low and high sodium diet in control women and in formerly 
preeclamptic women.
Glomerular filtration rate (GFR) (A), effective renal plasma flow (ERPF) (B), filtration fraction (FF) (C) and extra 
cellular volume (ECV) (D) at baseline during low sodium (white bars) and high sodium (black bars) diet in women 
with history of normotensive pregnancy (control) and in formerly preeclamptic women (fPE). Data are expressed as 
mean ± SEM * p<0.05 low vs high sodium intake, **p<0.05 control vs fPE (GEE analysis; FF is corrected for BMI). No 
interaction between dietary sodium response and group.
Figure 2. Effective renal plasma flow in response to angiotensin II.
Effective renal plasma flow (ERPF) during angiotensin II infusion during low sodium (A) and high sodium (B) in 
formerly preeclamptic women (fPE) and women with history of normotensive pregnancy (control). No significant 




This is the first study investigating renal hemodynamics in healthy formerly early-onset preeclamptic 
women compared with women with a history of a normotensive pregnancy, during a low and high 
sodium diet with graded ang II infusion. Although blood pressure was not different, a slightly, but 
significantly higher FF was present in formerly early-onset preeclamptic women on either sodium 
intake. There was no difference in renal response to ang II infusion during either low or high sodium 
intake. Thus, healthy women with a history of early-onset PE, in the absence of co-morbidity, have 
slight but persistent subtle differences in renal hemodynamics compared to matched controls, 
irrespective sodium intake. Whether differences in renal hemodynamics resulted from the previous 
PE, or were already present pre-pregnancy,  cannot be derived from our data. 
 Our study is the first to report altered renal hemodynamics in healthy formerly preeclamptic 
women in the absence of co-morbidity. Indeed, 24-hour blood pressure and blood pressure response 
to sodium intake were all in the normal range and comparable between the two groups. Prior studies 
in formerly preeclamptic women described more pronounced changes in renal hemodynamic profile, 
but in these studies co-morbidity, namely hypertension, might well explain the renal hemodynamic 
findings of a higher FF and RVR with lower ERPF 25, 29. A recent study in women 5-10 years after 
severe early-onset PE showed marked increased sodium sensitivity 17. In line, previous studies with 
mixed phenotypes and co-morbidity, reported increased blood pressure responsiveness to ang II 
postpartum 12, 23, 26. 
  The hypothesis that PE per se may predispose to altered renal function and kidney damage 
is in line with other findings. Vikse et al. reported that familial aggregation of risk factors does not 
explain the increased ESRD risk after PE 32. Furthermore, Chambers et al. demonstrated impaired 
endothelial function in women with a history of PE, independent of established risk factors 9. Yet, 
these data do not exclude the possibility of pre-pregnancy changes in renal hemodynamics that 
predispose to both PE and later renal damage. Animal studies could provide a clean model of PE to 
elucidate whether ESRD and cardiovascular damage after PE are causally related to PE itself. In for 
example an experimental sFlt-1 mice model, levels of proteins involved in several vascular diseases 
were increased postpartum 7.
 Microalbuminuria is thought to persist in a substantial amount of women after PE, reported 
in a meta-analysis with a mixed patient population (including diabetes mellitus) 18. However, in a 
recent large Norwegian study, PE was not associated with microalbuminuria 22. In line with the 
results from Sandvik et al, a morning urine sample collected after completion of our study did not 
show a difference in albuminuria between the groups; all women had albuminuria values within the 
normal range. 
 A higher FF, even within the normal range, can be considered a candidate mechanism 
for development of hypertension and renal damage, proposed by Brenner et al. 5, mainly based 
on micropuncture studies in rats. Based on these studies, an increased FF is assumed a proxy for 
elevated glomerular capillary pressure, thus contributing to progressive renal damage during long-
term exposure 11. Data on the pathogenic role of elevated FF in human are scarce, but we previously 
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showed that a mildly elevated FF is independently associated with worse long term renal outcome 
and mortality in renal transplant recipients 3. 
 The mechanism underlying the higher FF in the current study cannot be established with 
certainty, as this would require micropuncture. Hemodynamic as well as structural differences of the 
glomerular microvasculature are possible. The nominally lower ERPF in the formerly preeclamptic 
women is compatible with a shift towards more efferent vasoconstriction relative to afferent 
vasotonus. Several neurohumoral factors could elicit such a pattern, alone or in combination, 
including the sympathetic nervous system, vasopressin, natriuretic peptides and/or other factors, 
and increased activity of the RAAS 11. A reduction of increased intraglomerular pressure by the use of 
RAAS blockade in healthy subjects reinforces the role of the RAAS in impaired renal hemodynamics, 
i.e. hyperfiltration 20. However, we found no differences in circulating parameters of RAAS-activity or 
in ang II renal responsiveness. A higher BMI, even in the non-obese 4, and central fat distribution 
14 have also been associated with hyperfiltration, but in our study body fat distribution was similar 
between the groups, and the slight difference in BMI could not explain the difference in FF, as tested 
by multivariate analysis. Alternatively, a redistribution of renal blood flow towards juxtacortical 
glomeruli, with a higher FF, could be present. Differences in sodium and protein intake are not likely 
to have elicited the difference in FF since urinary sodium and urea levels, reflecting intake of sodium 
and protein, were comparable between the groups. Finally, structural microvascular differences 
could be involved, although the reduction in FF during sodium restriction demonstrates that there is 
at least a partial hemodynamic component. So far, it is thought that glomerular changes (glomerular 
endotheliosis, accompanied by decreased GFR) during PE resolve completely after PE 28.
 High sodium intake induced an increase in FF in both groups. This renal hemodynamic 
response is in line with studies in sodium-sensitive hypertensive individuals and overweight 
subjects, where sodium elicited hyperfiltration 8, 13. We did not find an interaction between the effect 
of sodium intake and previous PE on FF. However, considering the aligned role of increased FF in 
long-term renal risk, our data suggest that sodium restriction, and/or RAAS-blockade, could exert 
a beneficial effect on long-term renal risk. Obviously long-term studies are required to substantiate 
such an assumption. 
 Our study has several limitations. Firstly, due to our strict inclusion and exclusion criteria 
our sample size is relatively small. In addition, the range in years post-partum is relatively broad 
although not different between the two groups. Furthermore, our data do not provide a mechanism 
for the differences in renal hemodynamics, as we found no differences in RAAS-parameters, we did 
not assess parameters of the sympathetic nervous system, and diet was not standardized for protein 
intake. Finally, our data cannot distinguish between an effect of previous PE on renal hemodynamics, 




 In conclusion, formerly early-onset preeclamptic women, have a slightly, but significantly 
higher FF than controls, in the absence of co-morbidity. Theoretically, a slightly higher FF contributes 
to the increased renal risk that has been reported after PE, but this assumption requires substantiation 
by future long-term studies. Furthermore, prospective studies, preferably starting pre-pregnancy, 
should elucidate whether the higher FF is induced by the previous PE, or was already present pre-
pregnancy.  
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Formerly preeclamptic women have an increased risk for cardiovascular and renal diseases later in 
life. Whether this is due to preeclampsia itself or co-morbid conditions is unknown. Our aim was to 
establish, in a translational approach, whether the increased angiotensin II sensitivity in preeclampsia 
persists postpartum and whether preeclampsia itself plays a role. In 18 formerly healthy early-onset 
preeclamptic and 18 formerly healthy pregnant women (controls) baseline blood pressure and 
responses to angiotensin II (0.3, 1.0, and 3.0ng/kg/min) were measured. Simultaneously, in never-
pregnant, formerly healthy pregnant, and formerly experimental preeclamptic rats, angiotensin II 
sensitivity was studied; in-vivo by measuring changes in blood pressure and proteinuria during 
angiotensin II infusion with osmotic minipumps (200ng/kg/min), and ex-vivo by vascular reactivity 
measurements. In humans, no difference in baseline mean arterial blood pressure was seen (85 
± 8 vs 86 ± 9; p=0.71), while 1.0ng/kg/min angiotensin II showed a trend towards an increased 
response in formerly preeclamptic women vs controls (p=0.057). In rats, chronic infusion of 
angiotensin II showed a trend towards a larger rise in systolic blood pressure (69.4% vs 53.8%; 
p=0.068) and a significantly higher systolic blood pressure at termination in formerly preeclamptic 
vs never-pregnant rats (159.5 ± 29.5 vs 136.7 ± 16.8; p=0.046). In response to angiotensin II, there 
was a significant increase in proteinuria in formerly preeclamptic rats only. In conclusion, healthy 
formerly early-onset preeclamptic women and formerly experimental preeclamptic rats exhibit subtle 
persistent increased angiotensin II sensitivity. Together, these data support a role for preeclampsia 
itself in altered angiotensin II sensitivity postpartum. 
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INTRODUCTION
Preeclampsia is a pregnancy specific syndrome, clinically characterized by the presence of 
hypertension and proteinuria in the second half of pregnancy 1. It is a leading cause of maternal and 
perinatal mortality. Women that suffered from preeclampsia, especially early-onset preeclampsia, 
have an increased risk for cardiovascular- and renal diseases later on in life 2-5. 
 The common hypothesis is that pre-existing vascular and metabolic risk factors cause both 
preeclampsia and later cardiovascular and renal disease 6. Data, however, from the Hunt-cohort 
showed that only approximately 50% of the increased risk after preeclampsia could be explained by 
common risk factors 7. Indeed, it has been demonstrated that preeclampsia itself could lead to kidney 
and endothelial damage since in a large cohort familial aggregation did not explain the increased 
risk for end-stage renal disease (ESRD) 8. These studies suggest that preeclampsia itself may also 
contribute to the increased risk to develop cardiovascular and renal damage after preeclampsia. 
However, studies above are epidemiological studies, which are not optimal to answer the question 
whether preeclampsia itself contributes to the increased vascular risk. 
 Mechanistic studies in formerly preeclamptic women have shown that the increased 
angiotensin II (ang II) sensitivity, which is present during preeclampsia 9, persisted after preeclampsia; 
albeit more subtle 10, 11. However, the formerly preeclamptic women in these studies had multiple 
comorbidities, such as hypertension and obesity, which makes it difficult to discriminate between 
the effect of common risk factors and the effect of preeclampsia itself. Furthermore, sodium intake, 
menstrual cycle period and time-after pregnancy were not completely standardized in these studies 
and may have been of influence. 
 We hypothesized that preeclampsia itself may play a role in the persistent increased ang 
II sensitivity. Therefore, we investigated blood pressure response upon ang II infusion in healthy, 
normotensive, formerly early-onset preeclamptic women, selected for absence of comorbidity and 
without signs of underlying diseases. Furthermore, we performed a rat study; to test the hypothesis 
that preeclampsia itself may induce persistent increased ang II sensitivity. We used healthy rats 
in which we induced preeclampsia by infusion of low dose lipopolysaccharide (LPS) 12 during 
pregnancy, and measured blood pressure and renal responses to chronic ang II infusion as well as 
ex-vivo ang II sensitivity in the aorta postpartum.
MATERIALS AND METHODS 
Human study
Study population
The study was approved by the local medical ethical committee (METc-number: 2010/294) and all 
women gave written informed consent in accordance with the Declaration of Helsinki. The study 
was registered in the Netherlands National Trial Register (www.trialregister.nl; trial register number: 
2635) as REsponse To Angiotensin II in formerly Preeclamptic women (RETAP) study. 
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Thirty-six healthy, normotensive postpartum Caucasian women were studied at the University 
Medical Center Groningen (UMCG); 18 healthy women with a history of early-onset preeclampsia 
(fPE-women) and 18 healthy women with a history of uncomplicated, normotensive pregnancy 
(fHP-women) were used as a control group. 264 women with a history of early-onset preeclampsia 
one to ten years ago were selected from an electronic delivery database of the UMCG Obstetrics 
department. Medical records were reviewed for accuracy of diagnosis of preeclampsia, which was 
defined according to the definition of the International Society for the Study of Hypertension in 
Pregnancy 13. Early-onset preeclampsia was defined as developing preeclampsia before 34 weeks 
of gestation. Women with a history of renal disease, using any antihypertensive medication, with a 
BMI>30 kg/m2 at screening, with diabetes or a history of gestational diabetes were excluded. Also 
current pregnancy, current lactation, being post-menopausal, and use of oral contraception 14, 15 were 
used as exclusion criteria. 
 224 early-onset fPE-women were invited by mail to participate in the study. In total, 24 of 
these women were willing to participate and were invited for a screening visit to the UMCG. After 
the screening visit, one woman was excluded for using antihypertensive medication and one woman 
was using hormonal suppletion which could not be temporarily stopped, one woman was excluded 
because of hypertension measured during the screening visit, and 3 women were excluded for other 
reasons (pregnancy, time-consuming protocol, post-menopausal). Each of the remaining fPE-women 
was matched for age and year of index pregnancy (within one year) with a parous control whose 
pregnancy had been uncomplicated and normotensive. These fHP-women were recruited either 
through the department’s electronic delivery database or recruited amongst hospital/department 
employees and their family members. Their records were evaluated to confirm that their pregnancy 
was indeed uneventful. Exclusion criteria as described above for the cases were applied. All subjects 
were non-smokers and normotensive at screening, having a sitting systolic blood pressure (SBP) 
<140mmHg and diastolic blood pressure (DBP) <90mmHg measured by Dinamap (the average of 
three measurements was taken). Physical examination and electrocardiography did not reveal any 
abnormalities.
Study protocol
In the week prior to the measurements, women were asked to use a sodium standardized diet (aim: 
200 mmol Na+/24-hour urine) starting from day one of their menstrual cycle. To assess dietary 
compliance, 24-hour urine was collected at day 3 and day 6 of the dietary week and results were 
discussed with all women. During the last day of the dietary week, blood pressure was measured 
during a period of 24-hours by ambulatory blood pressure measurement (ABPM; Spacelabs 
Healthcare). The cuff was placed around the non-dominant arm at the brachial level. The recorders 
were programmed to measure blood pressure at a 20-min interval during daytime and at an hourly 
interval during nighttime (10pm till 6am). Women were asked to fill out a diary during this 24-
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 At the study day, women reported at the research unit at 8.00am after an overnight fast. 
Body weight was measured at the start of this day. An intravenous cannula was inserted into each 
forearm, one for drawing blood samples, the other for infusion of ang II. During the measurements, 
women were sitting in semi-supine position in a quiet room. All women received standardized 
meals and fluids during the day. Blood pressure and heart rate were measured by the use of an 
automated sphygmomanometer (Dinamap; GE Medical Systems, Milwaukee, Wisconsin, USA) at 
15-min intervals. Mean arterial pressure (MAP) was calculated as 2-times DBP plus SBP divided by 
3. Baseline values for blood pressure were obtained from 10.00am to 12.00pm. Between 12.00pm 
and 3.00pm ang II (Clinalfa, Merck Biosciences AG, Läufelfingen, Switzerland) was administered 
intravenously, at a constant rate in doses of 0.3, 1.0, and 3.0 ng/kg/min each during 1-hour. During 
the ang II infusions blood pressure was measured at 5-min intervals.
Blood and urine sampling and analysis
Fasting blood samples were drawn for analysis of hematocrit (Ht), glucose, glycated hemoglobin 
(HbA1C), insulin, and creatinine. Measurements were performed by the use of an automated 
clinical chemistry analyzer (Roche Modular; Sysmex heamatology analyzer (for Ht) and Sysmex 
Tosoh G8 (for HbA1C)). Fasting serum insulin was determined by an automated immunoassay 
analyzer (Architect, Abbott). Homeostasis model assessment (HOMA) was calculated by: (glucose 
x insulin)/22.5. Blood samples for baseline assessments (non-fasting samples) were drawn at 
10.00am. These plasma samples were collected in pre-cooled tubes and immediately centrifuged 
at 4°C, 956g for 10 min and subsequently stored at -80°C until analysis of aldosterone and plasma 
renin activity (PRA). Aldosterone was measured with a commercially available radioimmunoassay 
kit (coat a count RIA, Siemens). PRA was measured with a radioimmunoassay that detects the 
amount of angiotensin I produced per hour in the presence of excess endogenous angiotensinogen 
(nanograms of angiotensin I produced per liter of plasma per hour; CisBio International, France). 
To analyze auto-antibodiess against the angiotensin II type I receptor (AT1-AA) IgG fractions for the 
neonatal cardiac contraction assay were prepared and isolation and cultivation of the neonatal heart 
cells were performed as described previously 16. Using the chronotropic responses to AT1-R mediated 
stimulation of cultured neonatal rat cardiomyocytes coupled with receptor-specific antagonists the 
AT1-AA were detected 17. 
 Urine samples were drawn from the 24-hour urine collected at day 6 of the dietary week by 
all women. The levels of sodium, creatinine and albumin were assessed by the use of an automated 
clinical chemistry analyzer (Roche Modular Basel). The creatinine clearance was then calculated 
using the formula: (urinary creatinine/24h*1000)/plasma creatinine. The estimated glomerular 
filtration rate (eGFR) was calculated using the CKD-epi formula 18. This creatinine-based equation 
has been shown to accurately estimate the GFR in a healthy population. As some study subjects 
were still slightly menstruating during the 24-hour urine collections, these samples were not suitable 
for albuminuria measurement. Therefore, to test for albuminuria, a random morning urine sample 
was collected after completion of the study, at a point in time where subjects were certain not to 




This study was originally designed to assess both blood pressure and renal response to ang II after 
low and high sodium diet in formerly preeclamptic women compared to healthy controls. The cross-
over design of the study with several main end-points resulted in a multivariate power calculation. 
In the multivariate power calculation 3 factors (response to ang II, low and high sodium diet and 
control group vs. formerly preeclamptic women) and 2 confounders were taken into account. We 
calculated the total number of participants by n=10*5 (3 factors and 2 confounders). Therefore, 
25 subjects per group were needed. Due to the low incidence of early-onset preeclampsia and 
the intensiveness of the study protocol, we were not able to include 25 women per group in our 
hospital. However, after including 18 women per group and performing an interim analysis, we 
found a significant difference on our renal function end point between both groups (not shown 
in this paper). Therefore, we decided to stop including at n=18 after an interim-analysis. Since we 
describe our secondary endpoint in this paper, as an explorative study, no separate power analysis 
was performed.
Data analysis
Statistical analysis was performed using SPSS for Windows (Version 20.0) on a standard computer. 
Parametric data are presented as mean ± standard deviation (SD) in text, table and figures, unless 
otherwise stated and analyzed using Student t-test. Nonparametric data are presented as median 
(25th-75th percentile) and analyzed using Mann-Whitney U. Chi-square was used to analyze the 
AT1-AA and Pearson Correlation to test the correlation of AT1-AA with time since index pregnancy. 
Univariate linear regression was performed to test whether BMI was of influence on the differences 
found. Blood pressure responses upon the different ang II infusion steps was analyzed using the 
general estimating equations (GEE-analyses; mixed model analysis). Baseline blood pressure, BMI 
and an interaction term (group (fHP and fPE) * ang II infusion step) were entered as covariates, and 
exchangeable was chosen as correlation matrix. GEE-analyses was also performed to test whether 
the presence of AT1-AA and “time since index pregnancy” was of influence on the ang II sensitivity. 
In all cases, differences were considered significant if p<0.05.
Animal study
Animals
Experiments were conducted under protocols approved by the Animal Ethical Committee of the 
University of Groningen. Wistar rats (Harlan Inc, Horst, the Netherlands) were kept in a 12-hour 
light-dark cycle and constant room temperature, with food and water freely available in the home 
cages. Until selection for experiments vaginal smears were taken daily. Rats were rendered pregnant 
by housing them on pro-oestrus with fertile males for one night. Day 0 of pregnancy was documented 
by the presence of spermatozoa in the vaginal smear. Subsequently, pregnant rats were randomly 
allocated into two groups; healthy pregnant rats (HP-rats, n=19) or experimental preeclamptic rats 
(PE-rats, n=22). As controls, rats that have never been pregnant were used (NP-rats, n=25). 
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All rats were equipped with a permanent cannula inserted into the right jugular vein under isoflurane/
oxygen anesthesia on day 0 of pregnancy, according to standard methods 19. The permanent jugular 
vein cannula allows stress free infusion of lipopolysacharide (LPS;E-Coli, 0.55: B5, Whittaker MA 
Bioproducts, Walkerville, Md.) or saline.
Experimental set up
At day 14 of pregnancy, rats received a 1-hour low dose LPS infusion or a 1-hour saline infusion. 
Non-pregnant rats received saline infusion 2 weeks after cannulation. To study the long-term effects 
of experimental preeclampsia the following experimental set-up was chosen. Six weeks postpartum 
and nine weeks after cannulation in NP-rats, baseline values for blood pressure and proteinuria 
were assessed. Then, in each group of rats, 50% of the rats received ang II infusion continuously 
via an osmotic minipump, whereas the other 50% received a sham pump for three weeks. Blood 
pressure, proteinuria and creatinine clearance (only after 3 weeks) were measured weekly during 
this infusion period in all rats. Subsequently, after three weeks of infusion rats were sacrificed and 
kidneys and aortas were collected. Kidneys were checked for kidney inflammation (macrophages 
influx) and kidney damage (deposition of αSMA). To evaluate whether the in-vivo effect of ang II was 
due to increased vascular responsiveness to ang II, the aortas of the rats with sham pumps were 
used for aortic contraction experiments.
Induction of experimental preeclampsia
On day 14 of pregnancy pregnant rats randomized for the experimental preeclampsia group 
were infused with LPS (1µg/kg bw in 2 ml saline in 1-hour) according to standard methods 12; 
rats allocated to the healthy pregnant group were infused with only saline (2 ml in 1-hour). Non-
pregnant rats received saline infusion according to the same protocol. After delivery, pups were 
immediately dissociated from their mothers to avoid an effect of lactation. The number of alive and 
dead pups was counted and weight and length of the pups that were alive, i.e. moving at time of 
measurements, were measured. Two weeks after delivery, the permanent jugular vein cannulas were 
surgically removed by a small incision under isoflurane/oxygen anesthesia.
In-vivo ang II infusion and sacrifice of the rats
Six weeks after delivery, the NP-rats, the fHP-rats, and the fPE-rats were further randomly divided in 
a control group (c-NP, n=12, c-fHP, n=10, and c-fPE, n=11) receiving sham pumps intraperitoneally 
(ip) for 3 weeks and a group receiving an osmotic minipump with ang II ip (infusion rate: 200ng/
min/kg in saline containing 0.01 N acetic acid; A-NP, n=13; A-fHP, n=9; and A-fPE, n=11; Alzet, 
Cupertino, CA, model 2004) for 3 weeks. Blood pressure and proteinuria were measured weekly. 
Three weeks after pump implantation, rats were anesthetized and aortic blood pressure (see below) 
was measured before termination by heart puncture. After termination, the left kidney was harvested 
and parts of the kidney were placed in 4% paraformaldehyde in PBS or snap frozen. The thoracic 
aorta was also harvested. Small parts of the thoracic aorta were fixed in 4% paraformaldehyde or 
snap frozen. Since we were interested in the effect of former preeclampsia on the ex-vivo vascular 
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reactivity, without confounding by prior chronic ang II infusion, we used the thoracic aortas of the 
rats treated with sham pumps for vascular reactivity experiments.
Measurement of blood pressure
Blood pressure was measured at baseline (i.e. 6 weeks after delivery) and weekly for 3 weeks during 
sham or ang II infusion using an indirect tail-cuff plethysmographic method with a rat tail blood 
pressure monitor (Apollo 179; IITC Life Science, Woodland Hills, California, USA). All rats were 
conscious during the measurements. In order to reduce spontaneous variation in blood pressure, 
rats were extensively trained for a period of four weeks on a daily basis. Prior to blood pressure 
readings, rats were optimally warmed using a warmth lamp to induce vasodilation of the tail vein. 
Readings were repeated ten times and after excluding the lowest value the average of the lowest three 
remaining values for SBP was used for further analysis. In addition, blood pressure was measured at 
termination (i.e. after 21-days of infusion) using a bed-side monitor (Datex-Ohmeda, Cardiocap/5). 
Rats were anesthetized with isoflurane/oxygen and the abdominal cavity was opened (100% O
2
, 
0.8mL/min, 5% isoflurane for induction followed by 2%). A catheter was inserted in the abdominal 
aorta and the blood pressure was noted after 20 seconds of recording.
Blood and urine sampling and analysis
Rats from all groups were placed in metabolic cages for 24-hour urine collection prior to implantation 
of the osmotic minipumps, to assess baseline proteinuria. After pump implantation, proteinuria 
was measured weekly for 3 weeks. Urinary concentrations of protein (Pyrogallol Red – Molybdate 
Complex) were determined as previously described 20 and 24-hour excretion rates were calculated. 
To determine creatinine, a blood sample was collected in a pre-cooled tube at termination (day 
21) and immediately centrifuged at 4°C, 956g for 10min and plasma was subsequently stored at 
-80°C until analysis. Urinary and plasma creatinine concentrations were determined (CREA plus, 
cobas, Roche Modular, Basel) from samples collected on day 21 and creatinine clearance was 
calculated according to the standard formula ((urinary creatinine (mmol)*1000)/plasma creatinine 
(µmol)*(urine volume/1440)).
Immunohistochemistry
After paraformaldehyde fixation, renal tissue was processed for paraffin embedding according 
to standard methods. For immunohistochemistry, 2µm sections were cut. Total macrophages/
monocytes (ED-1) and M2-like macrophages were identified by staining for CD68 (1:100 diluted, 
clone ED1, AbD Serotec, Düsseldorf, Germany) and CD206 (1:1000 diluted; Abcam, Cambridge, 
UK) respectively according to standard methods 21. The pre-fibrotic marker for myofibroblast 
transformation alpha-smooth muscle actin (αSMA) was detected using a murine monoclonal 
antibody (αSMA; clone 1A4; Sigma) as previously described 22.
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Morphometric analysis of immunohistochemical staining
Interstitial ED-1 and CD206 positive cells were determined by manually analysing 30 randomly 
selected cortical fields per kidney (40x magnification), excluding fields with glomeruli in a view. 
For each cortical field, the number of positive cells was counted. Sections stained for αSMA were 
scanned using an Aperio ScanScope CS and analyzed with Aperio ImageScope v10.2.2.2319 (Aperio, 
Vista, CA, USA). The ‘Positive pixel Count V9’ algorithm was used to analyse αSMA-positive pixels 
after excluding vessels. The total positive surface area of all fields, was divided by the total area of 
all fields measured, providing a number of αSMA positive pixels corrected for the area analyzed. 
Researchers were blinded for group allocation of the rats while analysing the kidney slides.
mRNA expression analysis
Total aortic and kidney RNA was isolated with TRIzol Reagent (Invitrogen) following manufacturer’s 
instructions. Total RNA was quantified using a NanoDrop ND1000 spectrophotometer (NanoDrop 
Technologies Inc., Wilmington, DE). cDNA synthesis was performed as described before 23. Real 
time quantitative PCR was performed using Lightcycler 480 (Roche, Applied Science) and Applied 
Biosystems reagents according to the manufacturer’s instructions. Expression levels were normalized 
to those of 18S ribosomal RNA, which was analysed in separate runs. Primers and probes for the 
AT1-R and AT2-R were obtained from Applied Biosystems (TaqMan Gene Expression Assays, AT1-R: 
Rn00578456_m1 and AT2-R: Rn00560677_m1).  The sequences for 18S (M11188) (sense primer, 
antisense primer, and probe, respectively; all from 5’ to 3’) were: CGGCTACCACATCCAAGGA, 
CCAATTACAGGGCCTCGAAA, CGCGCAAATTACCCACTCCCGA.
Protein expression analysis
Kidney lysates (20 µg per lane) were run on 9% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and then transferred onto polyvinylidine difluoride membranes.
Membranes were rinsed with tris buffered saline (TBS) containing 0.05% Tween 20 (TBST) then 
blocked with TBST containing 5% bovine serum albumin (BSA) for 1-hour at room temperature 
(RT). Blots were then incubated with primary antibodies (AT1-R: ab124734 (Abcam), AT2-R: Mab 
3659 (R&D systems, Inc, Minneapolis)) diluted in TBST containing 1% BSA overnight at 4 °C. The 
blots were then rinsed with TBST (3 times) for 5 min at RT and incubated with the appropriate 
secondary antibody (Polyclonal Goat anti Rabbit HRP; P0448 (Dako Netherlands bv) diluted in TBST 
containing 1% non-fat dry milk and 2% normal rat serum for 1-hour at RT. The blots were rinsed 
another 3 times for 5 min with TBST before visualization was done by enhanced chemiluminescence 
(ECL), according to standard procedures with a molecular imager geldoc XR system from Bio-Rad 
(Bio-Rad Laboratories, Inc). After that, blots were stripped by incubating in 25 mM Glycine, 2% 
SDS, (pH 6.7) for 30 min at RT. Stripped blots were then rinsed extensively with TBST and reprobed 
as described above with a β-Actin antibody (SC-47778 (Santa-Cruz Biotechnology, Inc.). Using the 
expression of β-Actin as reference, protein bands were quantified with Image-lab 4.0.1 from Bio-Rad. 
The ratio of AT1-R or AT2-R to β-Actin was calculated.
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Aortic ring contraction experiment
Drugs and chemicals
Krebs buffer was freshly made before the start of each experiment and contained in mmol/L: 120 











O, and 2.52 CaCl
2
. All Krebs ingredients were purchased from E. Merck (Darmstadt, 
Germany). The stock solutions for phenylephrine (Sigma, St. Louis, MO, USA), ang II (Bachem AG, 
Bubendorf, Zwitzerland), PD-123319 (Park-Davis), Losartan (Merck Research laboratories, Rahway, 
USA), and NG-nitro-L-arginine methyl ester (L-NMMA; Calbiochem Brand of EMD Biosciences, Inc., 
La Jolla) were prepared in saline (0.9%NaCl in distilled water).
Ex-vivo aortic reactivity to ang II
The ex-vivo sensitivity to ang II in aortic tissue was studied in isolated aortic rings of the c-NP, 
c-fHP, and c-fPE-rats, using standard isotonic contraction experiments as previously described 24. 




. The aortic rings were equilibrated for 30 minutes before they were primed and checked 
for viability by evoking a contraction with KCl (60mM) for 10 minutes twice. To study the ang II 
sensitivity per se, a cumulative ang II concentration-response curve (10-10M-10-6M) was obtained. 
10-5M phenylephrine was added after completing the ang II concentration-response curve to assess 
total aortic ring contraction. The ang II-mediated contraction was then expressed as a percentage of 
the maximum contraction after 10-5M phenylephrine. Response to ang II via the ang II type 1 (AT1-R) 
and/or type 2 receptor (AT2-R) were studied as described previously 24. In short functional response 
of the AT1-R to ang II was studied after incubation with 10-6M PD-123319 (AT2-R antagonist) and 
selective nitric oxide (NO) synthase inhibitor L-NMMA (10-4M) to prevent any confounding effects 
by the basal release of NO 25. Then, a cumulative ang II concentration-response curve (10-10M-
10-6M) was obtained according to standard methods 26. 10-5M phenylephrine was added after 
completing the ang II concentration-response curve to assess total aortic ring contraction. The ang 
II-mediated contraction was then expressed as a percentage of the maximum contraction after 
10-5M phenylephrine. The functional response of the AT2-R to ang II was studied after incubation with 
10-5M losartan (AT1-R antagonist). After pre-contraction with 10-6M phenylephrine, the cumulative 
ang II concentration-response curve (10-10M-10-6M) was obtained. The ang II-mediated relaxation 
was then expressed as a percentage of the maximum pre-contraction with phenylephrine.
Data analysis
Statistical analysis was performed using SPSS for Windows (Version 20.0) and area under the 
curve (AUC) was calculated using GraphPad Prism 5, on a standard computer. Parametric data are 
presented as mean ± standard deviation (SD) in text, table and figures, unless otherwise stated and 
analyzed using Student t-test. Nonparametric data are presented as median (25th-75th percentile) 
and analyzed using Mann-Whitney U. For multiple testing, One-way ANOVA followed by LSD post-
hoc analysis was used. The increase in systolic blood pressure and proteinuria was calculated as 
the percentage increase three weeks after minipump implantation as compared to baseline systolic 
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blood pressure and proteinuria. To test for significant correlations, the Spearman’s rho correlation 
test was used. In all cases, differences were considered significant if p<0.05.
RESULTS
Human study
Baseline characteristics of the women
There were no statistically significant differences in most of the characteristics between the two 
groups (Table 1). However, fPE-women had a significantly higher BMI and office blood pressure 
at intake, all within the healthy range. Importantly, 24-hour ABPM and baseline blood pressure at 
the study day were not different between the groups. Analysis of blood parameters revealed no 
differences (Table 2). 
Table 1. Baseline characteristics
fHP-women (n = 18) fPE-women (n = 18) p-value
Age (years) 36 ± 5 36 ± 5 0.951
Gravidity 2.5 ± 1.3 2.6 ± 1.1 0.951
Parity 2.0 ± 0.7 2.2 ± 1.0 0.589
Elapsed time since index pregnancy (years) 4.2 ± 2.6 5.3 ± 3.0 0.243
BMI (kg/m2) 23.2 ± 2.7 25.9 ± 3.5 0.015
Waist/Hip ratio 0.83 ± 0.04 0.84 ± 0.06 0.443
Urinary sodium (mmol/24h) 221 ± 64 258 ± 86 0.145
Urinary albumin/creatinine 0.6 ± 0.3 0.5 ± 0.4 0.212
MAP (mmHg)
Screening visit1 90 ± 7 97 ± 8 0.01
24-hour2 90 ± 7 90 ± 8 0.997
Baseline3 85 ± 8 86 ± 9 0.714
fHP-women, formerly healthy pregnant women; fPE-women, formerly early-onset preeclamptic women; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure. 1Average of three blood pressure 
measurements assessed by the Dinamap during the screening visit in the hospital; 2blood pressure measured using 
ambulatory blood pressure measurement for 24-hours at the end of the dietary week; 3baseline blood pressure measured 
at study day, measured for 2 hours with a 15-min interval. Data are presented as mean ± SD.
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Table 2. Blood parameters
fHP-women (n = 18) fPE-women (n = 18) p-value
Hematocrit 0.38 ± 0.03 0.38 ± 0.03 0.634
Glucose (mmol/L) 5.0 ± 0.5 5.0 ± 0.3 0.605
HbA1c (mmol/mol) 35 (32.75-37.25) 34 (30.75-35.25) 0.203
Insulin (uU/mL) 7.1 (4.7-9.3) 7.65 (4.6-10.8) 0.525
HOMA1 1.55 (0.96-2.21) 1.69 (1.08-2.37) 0.369
Creatinin clearance (mL/min)2 113 ± 24 123 ± 25 0.220
eGFR (mL/min/1.73m2)3 109 ± 10 103 ± 15 0.117
PRA (nmol Ang I/L/h) 0.20 (0.10-0.50) 0.20 (0.09-0.30) 0.584
Aldosteron (pmol/L) 71 (29-93) 59 (35-96) 0.839
fHP-women, formerly healthy pregnant women; fPE-women, formerly early-onset preeclamptic women; HOMA, 
homeostatic model assessment index; eGFR, estimated glomerular filtration rate; PRA, plasma renin activity. 
1Calculated using the formula: (glucose*insulin)/22.5; 2calculated using the formula: ((urinary creatinine excretion/24h 
* 1000)/plasma creatinine); 3calculated using the CKD-epi formula 18. Data are presented as mean ± SD as median 
(25th-75th percentile).
Increased blood pressure response to ang II infusion in fPE-women
In response to 1.0 ng/kg/min ang II infusion, a trend towards an increased DBP response upon ang 
II in fPE-women as compared to fHP-women was present. DBP after 0.3 and 3.0 ng/kg/min ang II 
was not different between both groups (Figure 1B). Similar results were found for MAP responses 
upon ang II infusion (Figure 1C). No significant differences in SBP response were observed between 
the two groups during the subsequent ang II infusion doses (Figure 1A). Heart rate was not 
significantly different after ang II infusion between the two groups (data not shown). Studying the 
AT1-AA showed that 44.4% of the fPE-women and 16.7% of the fHP-women were positive for AT1-AA 
(8 vs 3 respectively; p=0.070). Serum from fPE-women increased the overall cardiomyocyte-beating 
rate, although not significant compared to fHP-women (median change in bpm: fPE-women: 6.4 
(0.5-16.7) vs fHP-women: 0.68 (0-5.4); p=0.139). No significant correlation was found between the 
presence of AT1-AA and the degree ang II sensitivity or time after index pregnancy (data not shown).
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Figure 1. Blood pressure response upon angiotensin II infusion in women. 
The mean (±SD) of the systolic blood pressure (A), diastolic blood pressure (B), and mean arterial pressure (C) at 
baseline and after 0.3, 1.0, and 3.0 angiotensin II (ng/kg/min) respectively as compared to baseline in fHP-women 
(circle) and in fPE-women (square, dotted line). Data were analyzed using the general estimating equations and 
corrected for baseline blood pressure and BMI. fPE: formerly preeclamptic women; fHP: formerly healthy pregnant 
women. P-values are presenting the difference between the two groups at 1.0ng/kg/min angiotensin II.
Animal study
Rat characteristics
At the end of pregnancy, HP-rats weighed significantly more compared to the PE-rats (Table 3A). 
The total number and weight of pups was not significantly different, however, the length of the pups 
was significantly decreased in PE-rats as compared to HP-rats. Moreover, one pup from one PE-rat 
and eight pups from another PE-rat were born dead (Table 3B). Baseline SBP, i.e. six weeks after 
delivery, was slightly but significantly lower in the fPE-rats as compared to the NP-rats. No difference 
in baseline proteinuria was found between the three groups.
Increased blood pressure response upon ang II infusion in fPE-rats
In the control rats, i.e. rats treated with sham pumps, no significant changes in SBP were observed 
in the three weeks of treatment (not shown). However, SBP increased in all groups of rats following 
three weeks of continuous ang II infusion (Figure 2A), with the highest increase in A-fPE-rats. The 
percentage increase in SBP in A-fPE-rats was higher (borderline significant), as compared with A-NP-
rats (Figure 2A). SBP increase after one and two weeks of ang II infusion revealed no differences 
between the three groups of rats (not shown). SBP at time of termination (under anesthesia) 
was significantly higher in A-fPE-rats as compared to A-NP-rats (Figure 2B), with no significant 
differences between the three groups of sham treated rats (not shown). 
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Table 3. Rat characteristics during pregnancy (A) and postpartum (B)
A - PREGNANCY CHARACTERISTICS
HP-rats (n = 19) PE-rats (n = 22) p-value
Rat maternal weight1 (g) 383 ± 24 361 ± 26 0.013
Number of pups2 12.4 ± 3.4 10.7 ± 3.9 0.150
Length of pups2 (mm) 50.6 ± 1.4 49.2 ± 2.7 0.034
Weight of pups2 (g) 6.1 ± 0.3 6.0 ± 0.8 0.556
B - POSTPARTUM CHARACTERISTICS
NP-rats (n = 25) fHP-rats (n = 19) fPE-rats (n = 22)
Rat maternal weight3(g) 269.7 ± 17.9 274.9 ± 17.8 276.4 ± 12.8
Baseline SBP4 (mmHg) 129.9 ± 9.5 127.5 ± 9.8 122.9 ± 9.1*
Baseline proteinuria4 (mg/24h) 4.3 ± 1.2 4.2 ± 2.3 3.3 ± 1.8
HP, healthy pregnant; PE, experimental preeclampsia; fHP, formerly healthy pregnant; fPE, formerly experimental 
preeclampsia; NP, never pregnant; SBP, systolic blood pressure. 1Weight at the day before delivery; 2only pups that 
were moving were measured; 3weight at the time of osmotic minipump implantation (six weeks postpartum); 4baseline 
values measured six weeks postpartum (fHP- and fPE-rats) or at the same time-interval for the NP-rats. Data are 
presented as mean (± SD). *: p<0.05 vs NP-rats.
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Figure 2. Blood pressure response upon chronic angiotensin II infusion in rats.
(A) The mean ± SEM of the percentage increase in systolic blood pressure (SBP) after three weeks of 200ng/kg/
min angiotensin II (ang II) compared to baseline SBP in the never pregnant rats (A-NP; white bar), the formerly 
healthy pregnant rats (A-fHP; black bar), and in the formerly experimental preeclamptic rats (A-fPE; striped bar). 
Blood pressure was measured by the use of a tailcuf device. Data were analyzed using One-Way ANOVA followed by 
LSD post-hoc analysis. (B) The mean ± SEM of the SBP at termination after three weeks of 200ng/kg/min ang II in 
the never pregnant rats (A-NP; white bar), the formerly healthy pregnant rats (A-fHP; black bar), and in the formerly 
experimental preeclamptic rats (A-fPE; striped bar). Data were analyzed using One-Way ANOVA followed by LSD 
post-hoc analysis. 
Changes in sensitivity of the thoracic aorta to ang II: aortic ring contraction experiment
Ex-vivo ang II sensitivity was studied in aortic rings in the sham treated rats. Although the area 
under the curve (AUC) showed no significant differences between the three groups (Figure 3 A1 
and A2), logEC
50
, was significantly lower in the c-fHP-rats as compared with c-fPE-rats (Table 4). No 
significant difference in AT1-R mediated vasoconstriction was observed between the three groups 
of rats (Figure 3 B1 and B2). It can be seen that AT2-R mediated relaxation, as measured by AUC 
(area of the positive peaks) was significantly impaired in the c-fPE-rats as compared to the c-NP-rats 
(Figure 3 C2). 
Significant increase in proteinuria following ang II infusion in fPE-rats
No significant increase in proteinuria over the three weeks of treatment was seen in rats that received 
a sham osmotic minipump (not shown). After three weeks of continuous ang II infusion, proteinuria 
increased in all three groups, with a trend towards increased proteinuria in fPE vs fHP-rats (data 
not shown). At this time point, the percentage increase in proteinuria as compared to baseline was 
significantly higher in A-fPE as compared to A-fNP and A-fHP (Figure 4A). Creatinine clearance (mL/
min) was not significantly different between the rats implanted with a sham osmotic minipump 
(cNP 2.5 ± 0.5 vs c-fHP 2.8 ± 0.7 vs c-fPE 2.5 ± 0.7; p = 0.408). Also no difference was seen between 
the rats receiving ang II (A-NP 2.2 ± 0.6 vs A-fHP 2.3 ± 0.5 vs A-fPE 2.3 ± 0.4; p = 0.859). 
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Figure 3. Ang II dose-response curves in the thoracic aorta.
The mean ± SEM of the cumulative angiotensin II (ang II) dose-response curves in the thoracic aorta from never 
pregnant rats (NP; circle; n=12), formerly healthy pregnant rats (fHP; square; n=10), and formerly experimental 
preeclampsia rats (fPE; pyramid upward; n=11). (A) ang II was added with no inhibitor present; (B) ang II was added 
after incubation with the AT2-R antagonist PD123319 and L-NMMA; (C) ang II was added after incubation with the 
AT1-R antagonist losartan. (A2, B2, C2): mean ± SEM AUC of the cumulative ang II dose-response curves in never 
pregnant rats (NP; white bar), formerly healthy pregnant rats (fHP; black bar), and formerly experimental preeclampsia 
rats (fPE; striped bar). Data were analyzed using One-Way ANOVA followed by LSD post-hoc analysis.  *:p<0.05
Table 4. logEC50 and Emax dose response curves
c-NP-rats (12) c-fHP-rats (10) c-fPE-rats (11)
log EC
50
Ang-II -7.29 (± 0.18) -7.45 (± 0.23) -7.25 (± 0.24)*
Ang-II contraction -7.29 (± 0.30) -7.42 (± 0.24) -7.29 (± 0.28)
Ang-II relaxation1 -8.11 (± 1.04) -8.66 (± 0.62) -8.13 (±1.14)
E
max
Ang-II 26.06 (± 13.59) 25.81 (±9.62) 23.93 (± 13.09)
Ang-II contraction 22.14 (± 10.54) 18.64 (± 8.27) 17.84 (± 7.08)
Ang-II relaxation1 4.60 (± 5.00) 6.31 (± 9.77) 4.80 (±10.11)
c-NP, control never pregnant rats; c-fHP, control formerly healthy pregnant rats; c-fPE, control formerly experimental 
preeclampsia rats. 1for fPE group only 7 rats were included in analyses. Data are presented as mean ± SD. *: p <0.05 
vs c-fHP.
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Increased inflammation of the kidney in fPE-rats in response to ang II
Ang II infusion did not affect the number of interstitial monocytes/macrophages in NP and fHP-
rats. However, three weeks after ang II infusion of fPE-rats the amount of interstitial monocytes/
macrophages was significantly higher as compared to sham treated fPE-rats (Figure 4B). No 
differences were seen after sham or ang II infusion between NP-, fHP-, and fPE-rats in the number 
of CD206 positive macrophages (data not shown). In all groups, treated for three weeks with ang II, 
we found a significant increase in the number of positive pixels per area for αSMA as compared to 
the sham treated rats (data not shown), with no differences between these groups. 
Figure 4. Proteinuria and macrophages influx upon chronic angiotensin II infusion.
(A) The mean ± SEM of the percentage increase in proteinuria (mg/24h) after three weeks of 200ng/kg/min angiotensin 
II (ang II) compared to baseline proteinuria in the never pregnant rats (A-NP; white bar), the formerly healthy pregnant 
rats (A-fHP; black bar), and in the formerly experimental preeclamptic rats (A-fPE; striped bar). Data were analyzed 
using One-Way ANOVA followed by LSD post-hoc analysis. *: p<0.05
(B) The median with 25th-75th percentile of the number of CD68-positive macrophages (ED1-macrophages) in the 
interstitial part of the kidney and in sham operated never pregnant rats (c-NP), formerly healthy pregnant rats (c-fHP) 
and, formerly preeclamptic rats (cfPE). and in never pregnant rats (A-NP), formerly healthy pregnant rats (A-fHP), 
and formerly preeclamptic rats (A-fPE) infused with 200ng/kg/min ang II for three weeks. Data were analyzed using 
Mann-Whitney U test. *: p<0.05
AT1- and AT2-receptor mRNA expression and protein expression in the aorta and kidney
The increased blood pressure and proteinuria response upon infusion of ang II could be due to a 
different regulation of the AT1-R and AT2-R upon chronic ang II infusion between the three groups. 
Therefore, the mRNA expression of the AT1-R and AT2-R in the thoracic aorta and the kidneys of 
all groups were measured. We observed a trend towards an increased mRNA expression of the 
AT1-R (Figure 5A) in the thoracic aorta of the A-fPE-rats as compared to c-fPE-rats. This effect of 
chronic ang II infusion was not observed in ang II treated NP-rats and fHP-rats. No differences were 
seen in AT2-R mRNA expression in the thoracic aorta between the different groups (Figure 5B). No 
difference in mRNA expression for the AT1-R and the AT2-R was found between the three groups of 
rats with sham pumps. 
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 The mRNA expression of the AT1-R and the AT2-R in the kidney of sham treated rats 
was comparable between the three groups. Moreover, no effect of chronic ang II infusion upon 
expression of either AT1-R mRNA or AT2-R mRNA was observed. However, after chronic ang II 
infusion, AT1-R mRNA expression was significantly lower in the fPE-rats as compared to the NP-rats, 
with no differences in AT2-R mRNA expression (Figure 5C and Figure 5D). 
 Protein expression of the AT1-R in the kidney of sham treated rats was comparable between 
the three groups (Figure 5E). After chronic ang II infusion, AT1-R protein expression showed a trend 
towards a lower expression in the fPE-rats as compared to the NP-rats (Figure 5E). Very low levels of 
AT2-R protein expression were found in the kidney extracts. However, AT2-R protein expression was 
significantly increased in sham treated fPE-rats as compared to sham treated fHP-rats (Figure 5F). 
Also, after chronic ang II infusion, protein AT2-R expression was significantly increased in fPE-rats 
as compared to fHP-rats (Figure 5F). Unfortunately, due to a lack of aorta material, we were not able 
to study AT1-R and AT2-R protein expression in the aorta.
DISCUSSION
This is the first translational study that analyses ang II sensitivity in formerly early-onset 
preeclamptic women without any comorbidity and in healthy rats after experimental preeclampsia. 
We demonstrated increased blood pressure response to ang II infusion, albeit subtle (borderline 
significant) in formerly early-onset preeclamptic women as compared with formerly healthy pregnant 
women. Moreover, after experimental preeclampsia we observed an increased blood pressure, 
proteinuria and macrophage influx into the kidney after chronic infusion of ang II as compared with 
formerly healthy pregnant rats. Since we studied women without any comorbidity and rats that were 
healthy and identical pre-pregnancy, our data suggest that (experimental) preeclampsia itself may 
have induced the persistent increased ang II sensitivity in the present studies. This increased ang II 
sensitivity postpartum might be one of the pathophysiological mechanisms leading to the increased 
risk for cardiovascular and renal diseases in fPE-women.
 Blood pressure appeared to increase more in response to ang II in fPE-women compared 
to fHP-women, however, this was just not significant. Our data appear to be in line with a study 
of Hladunewich et al., however, they found more pronounced differences. This may be due to 
the fact that they studied women 6-18 months postpartum rather than 1-10 years postpartum 11. 
Furthermore, their study group showed increased baseline blood pressure, BMI and age compared 
with controls. Similarly, differences between our study and the study of Spaanderman et al. 27 and 
Saxena et al. 10 may be explained by differences in study design, such as a mixture of phenotypes and 
increased blood pressure in the study group, the ang II concentration and low sodium intake used, 
and no standardization of menstrual cycle in both studies. Although in the present study, the fPE-
women showed a higher BMI, the waist/hip ratio, which is a superior risk factor for cardiovascular 
disease than BMI 28, was not different between the groups. The white-coat effect observed in our 
study may be related to the increased risk for cardiovascular disease 29.
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Figure 5. mRNA and protein expression. 
The mRNA expression of the AT1-R (A, C) and the AT2-R (B, D) in the thoracic aorta (A, B) and the kidney (C, D) 
and the protein expression of the AT1-R (E) and the AT2-R (F) in the kidney in sham operated never pregnant rats 
(c-NP), formerly healthy pregnant rats (c-fHP), and formerly preeclamptic rats (c-fPE), and in never pregnant rats 
(A-NP), formerly healthy pregnant rats (A-fHP), and formerly preeclamptic rats (A-fPE) infused with 200ng/kg/min 
angiotensin II for three weeks. Representative western blot analysis of AT1-R and AT2-R and the associated β-actin 





 To investigate cause and effect relationships between preeclampsia and postpartum ang 
II sensitivity in a clean model, we studied blood pressure and kidney response to chronic ang II 
infusion after experimental preeclampsia, induced by infusion of low dose LPS 12. Previous studies 
have shown that LPS-infused pregnant rats develop a preeclampsia like syndrome, as characterized 
by hypertension and proteinuria 12, 30, 31. Since the sensitivity to ang II is increased in this experimental 
preeclampsia model during pregnancy 24, this appears to be an appropriate model to study the 
relationship between the increased ang II sensitivity during and after preeclampsia. In accordance 
with our human data, in fPE-rats we found no baseline hypertension or proteinuria. In fact, fPE-rats 
even showed a significantly lower SBP before implantation of the minipumps, compared with the 
NP-rats. This might be related to the decreased vascular response to ang II found in the aorta of 
these fPE-rats (see below). Still, three weeks after chronic ang II infusion we observed an increased 
blood pressure and proteinuria response upon ang II in fPE-rats as compared to NP-rats and fHP-
rats. Our data are in line with a study in preeclamptic mice (due to overexpression of soluble fms-
like tyrosine kinase-1 (sFlt-1)), in which no long-term differences in blood pressure and vascular 
function were observed 32, while different expression of plasma proteins involved in cardiovascular 
function was seen, indicating postpartum effects induced by experimental preeclampsia 33. In our 
animal model, preeclampsia-like symptoms are induced by LPS via activation of Toll-like receptor 4. 
Many other animal models for preeclampsia exist, for instance overexpressing sFlt-1 34, ATP-infusion 
35, and renin-angiotensin aldosterone system (RAAS) overactivity 36 or genetic adjustments 37, 38. In 
these models, the preeclampsia-like symptoms may be induced via other pathways. Therefore, our 
animal data should be confirmed in other models of preeclampsia.
 To test ex-vivo ang II sensitivity in our rat model, we used the easily accessible aorta, and 
performed aortic ring contraction experiments in response to ang II. The aorta is a conductance 
vessel rather than a resistance vessel. The aorta is therefore not typically involved in blood 
pressure regulation. However, the use of aortic rings is a well-established read-out for vascular 
pharmacological responses, including studying angiotensin sensitivity. Although the total response 
to ang II (i.e. AUC) did not differ between the groups, logEC
50
 was significantly lower in the fHP-rats. 
This suggests, in contrast to our hypothesis, a decreased sensitivity to ang II in the aorta of fPE-rats 
as compared to fHP-rats. The question arises whether this decreased sensitivity in fPE-rats is related 
to the slightly decreased blood pressure measured in these rats at baseline. It may be speculated 
that the decreased ang II sensitivity in the aorta may decrease vascular smooth muscle tone and 
thus aortic stiffness and therefore central blood pressure 39 and possibly peripheral blood pressure. 
Further studies in other vascular beds, such as small resistance or renal arteries are needed to 
confirm that changes in the ang II sensitivity in fPE-rats are linked to blood pressure.
 The ang II response via the AT2-R showed a decreased relaxation upon ang II in fPE-
rats. This was, however, not accompanied by changes in the mRNA expression of the AT2-R in 
the aorta. The decreased ex-vivo responsiveness of the AT2-R to ang II in the fPE-rats might 
contribute to the increased blood pressure response upon ang II. This hypothesis, however, needs 
to be confirmed in resistance vessels. In contrast to differences in AT2-R responses in fPE-rats, 
we did not find differences in the AT1-R responses in fPE-rats. This is in contrast to the situation 
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during experimental preeclampsia, in which the response of the aorta to the AT1-R was increased 
24. Thus, although we have observed changes in ang II sensitivity during and after preeclampsia in 
the rat, during preeclampsia the AT1-R may be involved, while after preeclampsia the AT2-R may be 
involved. Further postpartum follow-up studies, also in other models for preeclampsia, are needed 
to establish the time course of changes and mechanisms in the AT1-R and AT2-R sensitivity.
 We also observed increased proteinuria in response to ang II infusion in fPE-rats without 
differences in serum and urinary creatinine. This rise in urinary protein level was associated with an 
increased influx of interstitial macrophages. Since we found no increase in the number of CD206 
positive macrophages, i.e. M2 macrophages, the increased macrophages are most likely of the 
M1 or inflammatory phenotype. It can be suggested that the increase in interstitial macrophages 
was secondary to proteinuria, since excessive tubular reabsorption of proteins results in tubulo-
interstitial infiltration of monocytes 40. As macrophages themselves may also inflict kidney injury 41, 
this macrophage infiltration may induce a vicious circle of kidney damage leading to proteinuria. 
On the other hand, as infiltration of macrophages in glomeruli and renal interstitium sometimes 
precedes the onset of glomerular injury and interstitial fibrosis leading to proteinuria 42, the infiltrated 
macrophages may also be the cause of proteinuria. Profibrotic changes, as measured by αSMA 
expression, were similarly increased in all groups after ang II infusion. Whether infusion duration or 
higher dosages of ang II would have resulted in more pronounced changes in renal damage in fPE-
rats (i.e. focal glomerular sclerosis) as compared to the other groups, remains to be investigated. 
 The mechanism of increased ang II sensitivity during and after preeclampsia is unknown. 
The study of Hladunewich et al. suggested that the balance between the AT1-R and AT2-R could be 
involved 11. Indeed, our data suggest differential expression and regulation of the AT1-R and AT2-R 
with ang II infusion in fPE-rats as compared with the other groups of rats. However, the present 
results for AT1-R and AT2-R mRNA and protein expression are not conclusive, since differential 
responses of the aorta and kidney were observed. Other RAAS mechanisms like, heterodimerization 
of the AT1-R with the bradykinin B(2)-receptor 43 or alterations in the vasodilatory ang 1-7 acting on 
the MAS-receptor 44 could be involved and should be studied in more detail. Furthermore, increased 
levels of AT1-AA postpartum could be involved in increased ang II sensitivity 17, 45. Indeed in our 
study, although just not significant, more fPE-women tested positive for having AT1-AA as compared 
to fHP-women, but not correlating with ang II sensitivity. It seems unlikely that this contributes in 
our experimental rat model since we did not find AT1-AA in pregnant LPS-infused rats (unpublished 
results) . 
Conclusion Our translational study suggests that preeclampsia per se leads to subtle long-term 
increased blood pressure and proteinuria in response to acute and chronic ang II infusion in 
otherwise healthy humans and rats. However, we cannot rule out that underlying pre-pregnancy 
(risk) factors may also play a role. Preeclampsia might merely identify women with an unfavorable 
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Women with a history of preeclampsia have an increased risk for cardiovascular diseases later in life. 
Persistent vascular alterations in the postpartum period might be a potential mechanism behind 
this increased risk. This study aimed to assess arterial stiffness under low sodium (LS) and high 
sodium (HS) conditions in a healthy well-characterized group of formerly early-onset preeclamptic 
(fPE) women compared to formerly healthy pregnant (fHP) women.
Methods
18 fHP and 18 fPE women were studied in balance on one week of LS (50 mmol Na+/day) and one 
week of HS (200 mmol Na+/day) intake. Arterial stiffness was measured by augmentation index 
(AIx), AIx corrected for heart rate (AIx@75) and pulse wave velocity (PWV). Circulating parameters of 
renin-angiotensin aldosterone system (RAAS) activity, extracellular volume (ECV), nitrate, nitrosated 
species (RxNO) and cyclic GMP (cGMP) were measured to identify pathways underlying adaptation 
of arterial stiffness. 
Results
As compared to HS diet, AIx and AIx@75 upon LS diet were significantly decreased in fHP women 
while there was no effect of LS consumption on AIx and AIx@75 in fPE women. PWV was similar in 
both groups and between diets. In both groups, comparable sodium dependent changes in RAAS, 
ECV and nitrate and were observed.
Conclusions
fPE women have an impaired ability to adapt their arterial stiffness (AIx/AIx@75) upon low sodium. 
The non-adaptation of arterial stiffness occurred independent of blood pressure, RAAS, ECV, 
and nitrates. The pathways involved in impaired adaptation, and its possible contribution to the 
increased long term risk for cardiovascular diseases in fPE women remains to be investigated.
151
Vascular health after preeclampsia
7
INTRODUCTION 
Preeclampsia complicates approximately 1-5% of the all pregnancies 19 and is characterized by new-
onset hypertension and proteinuria during the second half of pregnancy 1. Delivery of the placenta 
is the only therapeutic solution and results in rapid normalization of the maternal manifestations 44. 
Despite normalization of hypertension and proteinuria after termination of pregnancy, a history of 
preeclampsia entails long-term vascular consequences. Over the years, observational cohort studies 
have shown that women with a history of preeclampsia experience an increased risk to develop 
premature cardiovascular and renal diseases in later life 3, 50, 52. 
 Unravelling the underlying mechanisms for the increased cardiovascular and renal risk 
after preeclampsia has been subject of recent studies. The increased risk could be the result of 
pre-existing cardiovascular risk factors as well as long-term effects caused by preeclampsia itself 36, 
40, 49. Since preeclampsia affects the maternal vascular bed, persistent vascular alternations in the 
postpartum period might be a potential mechanism for the increased cardiovascular risk in formerly 
preeclamptic women. 
 Recent studies in formerly preeclamptic women have reported subtle vascular alternations 
such as arterial stiffness as measured by pulse wave analysis (PWA) and pulse wave velocity (PWV)10, 
11, 24, 27, 31, 35, 37, 45, 53. However, these studies show some inconsistencies; differences in study design, 
heterogeneity of the preeclamptic phenotype, and the presence or absence of comorbidities (i.e. 
hypertension, and increased BMI) may explain these contradictory findings. Moreover, none of these 
studies were performed under standardized sodium intake. Sodium restriction has been reported to 
be an important extrinsic factor in the reduction of blood pressure and arterial stiffness by volume 
reduction and reducing oxidative stress 15, 25, 42.  High sodium intake affects arterial stiffness by the 
induction of endothelial dysfunction, stimulation of vascular smooth muscle tone and hypertrophy 
of vascular wall 9, 17. To our knowledge, adaptation or non-adaptation of arterial stiffness by short 
term changes in dietary sodium has not been studied in healthy subjects at risk for development of 
premature vascular diseases. 
 In this study, we aimed to explore arterial stiffness in the healthy formerly early-
onset preeclamptic (fPE) women and formerly healthy pregnant (fHP) women in the absence of 
comorbidity. For this purpose, we measured arterial stiffness in the population of the Response to 
Angiotensin II in Formerly Preeclamptic women (RETAP) study of which we previously reported on 
renal function (RETAP-renal) 46. All women were studied after one week of low sodium (LS) and after 
one week of high sodium (HS) intake to assess the influences of short-term changes in sodium diet 
on arterial stiffness. To identify pathways involved in the adaptation of arterial stiffness in response 
to salt we measured circulating components of the renin-angiotensin aldosterone system (RAAS), 
extracellular volume (ECV; 125I-iothalamate distribution volume) and the endothelial function 





Our study population consisted of 18 formerly early-onset preeclamptic women and 18 previously 
healthy pregnant controls who participated in the Response to Angiotensin II in Formerly Preeclamptic 
women (RETAP) study (The Netherlands National Trial Register www.trialregister.nl; trial registration 
number: 2635). Baseline characteristics of this study group and data on renal function and renal 
response to angiotensin II infusion within this group were published before (RETAP-renal) 46. 
In short, this study showed no differences in GFR (measured by 125I-iothalamate (IOT)) and no 
differences in renal hemodynamic response to angiotensin II infusion between groups, but the study 
did reveal a higher filtration fraction (FF) in the fPE group on both LS and HS diet.  
 The study population was selected from the electronic delivery database of the department 
of Obstetrics and Gynecology at the University Medical Center Groningen. Preeclampsia was defined 
according to the definition of the International Society for the Study of Hypertension in Pregnancy 2 
and early-onset preeclampsia was defined as developing preeclampsia before 34 weeks of gestation. 
Participants without comorbidity were selected by the exclusion of women with renal disease, 
diabetes or a history of gestational diabetes, obesity (BMI>30 kg/m2 at screening) and women using 
any antihypertensive medication. Additional exclusion criteria were pregnancy, current lactation and 
post-menopausal status. None of the included women were using oral contraceptives. The formerly 
preeclamptic women were matched for age and year of index pregnancy (within one year) with a 
parous control whose pregnancy had been uncomplicated and normotensive. All subjects were 
non-smokers and normotensive, having a sitting systolic blood pressure <140mmHg and diastolic 
blood pressure <90mmHg measured by Dinamap (the average of three measurements was taken). 
All patients underwent physical examination and electrocardiography at intake of the study, which 
did not reveal any abnormalities. The study was approved by the local medical ethical committee 
(Medical Ethical Committee UMCG Groningen, the Netherlands; number 2010/294) and all subjects 
gave written informed consent. 
Study protocol
The selected participants underwent a randomized cross-over protocol consisting of two one-week 
periods with at least four weeks in between, a 7-day period on LS diet (aim: 50 mmol Na+/day) and 
a 7-day period on a HS diet (aim:200 mmol Na+/day). For assessment of dietary compliance and the 
achievement of stable sodium balance, 24-hour urine was collected at day 3 and day 6 during each 
period. All women were studied at day 7 of each treatment after an overnight fasting period at day 7 
± 2 of the menstrual cycle. 
 
Blood pressure and arterial stiffness measurements
Blood pressure was assessed at the end of each dietary period. After a two-hour rest in semi-
supine position in a quiet room, blood pressure and heart rate were measured by the use of an 
automated sphygmomanometer (Dinamap; GE Medical Systems, Milwaukee, Wisconsin, USA) 
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at 15-min intervals for two hours (10am till 12am). Arterial stiffness was measured using the 
Sphymocor System. To obtain the augmentation index (AIx), recording of the radial pulse wave 
contour was performed by using applanation tonometry. In short, the artery of interest was pressed 
gently at the site of maximal pulsation with the tip of the tonometer containing a micromanometer 
that accurately records the pressure within the artery (Millar Instruments, Houston, TX). First a 
successive recording of the pressure waveform at the right brachial artery was assessed. These values 
were entered in the program (SphygmoCor; AtCor Medical, Sydney; version 8.2) and subsequently 
three successive recordings were performed on the right radial artery. The SphygmoCor software 
incorporates a quality control feature (operator index) which is displayed on the screen. An operator 
index above 80 was called a successive reading. Peripheral AIx is defined as the ratio of late systolic 
pressure (P2) to early systolic pressure (P1). AIx and AIx corrected for heart rate (AIx@75) were 
automatically calculated by the Sphygmocor. The average of the three successive readings was used 
in the analysis. The SphygmoCor system was subsequently used to assess carotid-femoral pulse 
wave velocity (PWV). The PWV was determined by sequential acquisition of pressure waveforms 
from the carotid and the femoral arteries. The timing of these waveforms was computed with that 
of the R-wave on the simultaneously recorded ECG. To reduce the influence of body contour, the 
proximal distance was measured from the sternal notch to the sampling site on the carotid artery 
and the distal distance was measured from the acromial angle to the sampling site on the femoral 
artery. The average of more than 8 successive measurements was used in the analysis to cover a 
complete respiratory cycle.
Extra-cellular volume measurements
ECV was estimated from the distribution volume of IOT. Assessment of ECV by the constant infusion 
method with IOT was validated and the method was demonstrated to be reproducible 51. A priming 
solution containing 20 ml infusion solution (0.04 MBq) plus an extra amount of 0.6 MBq IOT was 
given at a constant infusion of 12 ml/h. Plasma concentrations of IOT were stabilized during 1.5-h 
equilibration and was followed by a 2-h period of clearance. ECV was calculated as follows: [(I × V + 
B × V) − (U × V)]/P, where I × V is the infusion rate of the tracer, B × V the bolus infusion of the tracer 
and U × V the urinary excretion of the tracer 51. This formula equals the amount infused IOT minus 
the amount excreted IOT. ECV was indexed for body surface area (BSA) by dividing the crude values 
by BSA multiplying it by 1.73 m2. BSA was calculated according to the DuBois-DuBois formula 8. 
Data of uncorrected ECV in this population were published earlier in the RETAP-renal manuscript 46.
Blood and urine sampling and analysis  
Fasting blood samples were drawn for analysis of renin-angiotensin aldosterone system (RAAS) 
activity and endothelial function markers. Aldosterone was measured with a commercially available 
radioimmunoassay kit (Coat-A-count RIA, Siemens). PRA was measured with a radioimmunoassay 
that detects the amount of angiotensin I produced per hour in the presence of excess endogenous 
angiotensinogen (nanograms of angiotensin I produced per liter of plasma per hour; CisBio 
International, France). Plasma cGMP levels were assessed using a competitive enzyme immunoassay 
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(ELISA) according to the manufacturer’s instructions (KGE003; R&D Systems, Minneapolis, MN). 
The concentration of the total pool of nitrosated species (RxNO) and nitrate were measured in 
the laboratory of M. Feelisch, University of Southampton. RxNO was assessed using group-specific 
reductive denitrosation by iodine-iodide in glacial acetic acid, with subsequent detection of liberated 
NO into the gas phase by its chemiluminescent reaction with ozon 12. Plasma nitrates were quantified 
by ion chromatography with reduction of nitrate to nitrite and post-column Griess diazotization 
(ENO20 Analyser; Eicom, Kyoto, Japan) 34. Urine samples were drawn from the 24-hour urine and the 
levels of sodium, potassium and urea were assessed by the use of an automated clinical chemistry 
analyzer (Roche Modular Basel).
Data analysis
Statistical analysis was performed using SPSS for Windows (Version 21.0). Parametric data are 
presented as means ± standard deviation (SD) or Estimated Marginal Means (EMM) ± standard 
error (SE) and non-parametric data as medians with interquartile ranges such as stated in text, table 
and figures. PWV values were log transformed. Generalized Estimated Equations (GEE) analysis was 
performed for AIx, AIx@75, PWV, and ECV to separately test the effects of history of preeclampsia 
(factor group) and sodium intake (factor diet). In addition, this analysis enabled us to separately 
study the changes in parameters in response to change in diet within the fHP and fPE group. The 
same GEE analysis was performed to analyze nitrate, RxNO, and GMP. To determine whether age is 
a determinant of arterial stiffness we used linear regression, which was performed for both LS and 
to HS diet. Differences were considered significant if p<0.05.
RESULTS
Baseline characteristics
Baseline characteristics of our study population are presented in Table 1. No differences were found 
for age, gravidity, parity, and time since last pregnancy (index pregnancy) between the two groups. 
fPE women had a significantly higher BMI compared to fHP-women both during LS and HS diet. Hip 
to waist ratio did not significantly differ between groups. Urinary sodium concentrations showed 
that the dietary compliance during LS and HS diet was excellent in both groups. No statistically 
significant differences in potassium and urea excretion were found between the groups reflecting 
an equal intake of potassium and proteins. Serum sodium did not differ between fHP en fPE during 
both LS and HS diet. No differences in PRA and aldosterone were found between the groups, and 
the change in PRA and aldosterone in response to low sodium intake was similar in both groups. All 
women were normotensive at the time of the screening visit and there were no significant differences 
in mean baseline 2-hour blood pressure and pulse pressure measured after LS diet and HS diet week 
46. Both fHP and fPE women demonstrated a significant increase in blood pressure in response 
to HS as compared to LS, but there were no differences in blood pressure responses to diet (salt 
sensitivity) between the fHP and fPE women.
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Table 1. Baseline characteristics
History of 
normotensive 
pregnancy (n = 18)
History of 
preeclamptic 
pregnancy (n = 18)
p-value
Age (years) 36 ± 5 36 ± 5 0.95
Gravidity 2.5 ± 1.3 2.6 ± 1.1 0.95
Parity 2.0 ± 0.7 2.2 ± 1.0 0.59
Elapsed time since index pregnancy 
(years)
4.2 ± 2.6 5.3 ± 3.0 0.24
Waist/Hip ratio 0.83 ± 0.04 0.84 ± 0.06 0.44
MAP (mmHg)
LS 81 ± 7 83 ± 8 0.38
HS 85 ± 8 86 ± 9 0.71
PP (mmHg)
LS 43± 6 42 ± 5 0.72
HS 44 ± 5 43 ± 5 0.62
HR (beats/min)
LS 67 ± 8 67 ± 9 0.95
HS 67 ± 8 66 ± 10 0.64
BMI (kg/m2)
LS 22.6 ± 2.6 25.3 ± 3.3 0.01
HS 23.2 ± 2.7 25.9 ± 3.5 0.02
Urinary sodium (mmol/24h)
LS 39 ± 14 45 ± 23 0.33
HS 221 ± 64 258 ± 86 0.15
Urinary potassium (mmol/24h)
LS 66 ± 21 76 ± 25 0.20
HS 80 ± 34 73 ± 15 0.46
Urinary urea (mmol/24h)
LS 264 ± 91 306 ± 63 0.12
HS 339 ± 89 340 ± 65 0.97
Serum sodium (mmol/l)
LS 140 ± 1.6 140 ± 1.9 0.36





pregnancy (n = 18)
History of 
preeclamptic 
pregnancy (n = 18)
p-value
PRA (nmol ANG I·l−1·h−1)
LS 0.80 (0.50-1.20) 0.85 (0.70-1.50) 0.50
HS 0.20 (0.10-0.50) 0.20 (0.09-0.30) 0.58
Aldosterone (pmol/L)
LS 255 (204-395) 341 (214-477) 0.16
HS 71 (29-93) 59 (35-96) 0.84
Aldosterone:PRA ratio 
LS 331 (201-450) 456 (250-494) 0.38
HS 224 (151-499 316 (181-517) 0.23
Change in PRA HS to LS (%) 225 (100-350) 325 (160-700) 0.18
Change in Aldosterone HS to LS (%) 320 (187-462) 436 (90-700) 0.48
Data are presented as means ± SD or as medians (25th-75th percentiles). LS: low sodium diet (<50mmol Na+/24h), 
HS: high sodium diet (>200mmol Na+/24h), MAP: mean arterial pressure, PP: pulse pressure, HR: heart rate, PRA: 
plasma renin activity, ANG: angiotensin.
Arterial stiffness
Arterial stiffness in fHP and fPE on LS en HS expressed as AIX and PWV is showed in Figure 1. No 
overall difference in AIx was found between groups and between diets. However, the GEE-analysis 
showed that LS intake was associated with a significant decrease in Aix in fHP women (p
diet
*fHP 
= 0.016) while no effect of LS intake on AIx was observed in fPE women. As for AIx, no significant 
differences in AIx@75 were found between group and diet, but in the fHP women again a significant 
decrease in AIx@75 in response to LS diet (p
diet
*fHP= 0.024) was observed, while there was no effect 
of LS intake on AIx@75 in fPE women. No effect of group (fHP or fPE) and diet (LS or HS) within 
groups was observed for PWV. Linear regression showed a positive relation between age and arterial 
stiffness under both low and high salt conditions (P<0.05 for age*AIx, age*AIx@75 and age*PWV). 
GEE analysis corrected for age showed that differences in age did not affect the adaptation of arterial 
stiffness in response to low salt.
 
Extracellular volume
ECV corrected for body surface area (ECV/BSA) in fHP and fPE on LS en HS is shown in Figure 2. 
ECV/BSA did no differ between groups, but we did observe an overall effect of diet (p
diet
 < 0.001). 





*fPE= 0.01) without differences between the groups.
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Figure 1. Arterial stiffniss during low and high sodium diet.
Augmentation index (AIx, A), Augmentation index corrected for heart rate (AIx@75, B) and log pulse wave velocity 
(PWV, C) during low sodium (LS, white bars) and high sodium (HS, black bars) intake in women with a history of 
healthy pregnancy (fHP) and in formerly preeclamptic (fPE) women. Data are expressed as estimated marginal means 
±  standard error.  *P < 0.05 by generalized estimating equation analysis.
Figure 2. Extra cellular volume during low and high sodium 
diet.
Extra cellular volume corrected for body surface area (ECV/BSA) during 
low sodium (LS, white bars) and high sodium (HS, black bars) intake 
in women with a history of healthy pregnancy (fHP) and in formerly 
preeclamptic (fPE) women. Data are expressed as estimated marginal 
means ±  standard error.  *P < 0.05; by generalized estimating equation 
analysis.
Endothelial function markers
As markers for endothelial function, we measured plasma nitrate, RxNO and cGMP in fHP and 
fPE women (Figure 3). GEE analysis for nitrates showed no significant differences between groups 
while diet did affect plasma nitrates (p
diet
 = 0.008). Low salt intake significantly increased the nitrate 




= 0.04). We did not find differences in RxNO 
and cGMP concentrations between diet and groups but there was a large inter-individual variation 
of these parameters within our data. 
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Figure 3. Endothelial function markers during low and high sodium diet.
Nitrate (A), total total nitrosated species (RxNO, B) and cyclic GMP (cGMP, C) during low sodium (LS, grey circle) 
and high sodium (HS, black square) intake in women with a history of healthy pregnancy (fHP) and in formerly 
preeclamptic (fPE) women. Data are expressed as medians with interquartile ranges. *P < 0.05; by generalized 
estimating equation analysis.
DISCUSSION
This is the first study that assessed arterial stiffness in formerly early-onset preeclamptic women 
without any comorbidity, under standarized low and high sodium conditions. We demonstrated 
that fPE women have an impaired ability to adapt their arterial stiffness (AIx and AIx@75) upon 
low sodium diet compared to fHP women. The non-adaptation of arterial stiffness could not be 
explained by differential responses between fHP and fPE women in blood pressure, extracellular 
volume expansion and plasma availability of nitrate, RxNO, and cGMP, or RAAS-activity. Increased 
arterial stiffness is known to be associated with the development of hypertension and cardiovascular 
diseases 5, 21, 28, 30. An impaired ability to decrease AIx in response to low sodium in fPE women might 
be a first indication of an unfavorable vascular profile.
  While both AIx and PWV were similar in fHP and fPE women on HS diet, LS diet reduced 
the AIx and AIx@75 in fHP-women but not in fPE-women. We are the first to show this effect of non-
adaptation of arterial stiffness in a well-controlled setting, studying subjects at risk for premature 
vascular disease and healthy controls in absence of any comorbidity. LS diet normally reduces arterial 
stiffness; as was shown by a meta-analysis exploring the effect of dietary and nutritional interventions 
on arterial stiffness 32 and by a study in (postmenopausal) female hypertensive subjects 42. Our 
finding of non-adaptation of arterial stiffness in response to LS in fPE thus suggests that fPE women 
lost the capability to adjust arterial stiffness upon LS intake. 
  Previous studies on arterial stiffness in fPE women were not performed under standardized 
dietary conditions and did not standardize for phase menstruation cycle. Assuming that sodium 
intake in the previous studies is in the range of average intake in the western diet, these studies 
are comparable with our HS condition under which we observed no differences in AIx and PWV 
between groups. Under this assumption, our results are in line with two other studies that showed 
no differences in AIx in fPE women compared to controls 24, 37. However, other studies have reported 
increased arterial stiffness as measured by AIx 10, 27, 31, 35, 45, 53 as well as by PWV 31, 35, 45 in fPE women. 
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These conflicting findings probably result from differences in study design, the heterogeneity of the 
preeclamptic phenotype, and the presence of comorbidity (i.e. hypertension and increased BMI). 
The strength of our study is that we studied a well-characterized group of healthy fPE women under 
standardized dietary conditions matched to a control group. Therefore, we can conclude that fPE 
women without comorbidity do not differ in arterial stiffness compared to fHP women on a regular 
western diet. 
 Our finding of non-adaptation of arterial stiffness upon LS diet was only reflected in AIx 
and not in the PWV measurements. This might be explained by the different (age-related) vascular 
responses that these measures represent 29. In general, the AIx is influenced by the resistance of 
the vessels and highly dependent on endothelial function. PWV is affected by structural changes 
such as narrowing and sclerosis of the vessels that occur during the late process of atherosclerosis. 
While PWV is the gold standard for measurement of arterial stiffness 47, AIx might be more accurate 
in detecting early stage vascular dysfunction based on sensitivity to detect functional instead of 
structural abnormalities 7, 48. In our study all women were healthy and relatively young, and therefore 
one might not expect structural vascular abnormalities reflected by differences in PWV. 
  Increased arterial stiffness is a result of aging (changes in extracellular matrix composition) 
22 and is associated with hypertension, diabetes mellitus, atherosclerosis and renal failure 33, 38. We 
carefully excluded these factors from our study design by matching our fPE group with a control 
group of the same age and by the exclusion of women with co-morbidity. To overcome the influences 
of differences in sodium intake on arterial stiffness we had an excellent standardization of the diets 
as observed in the urinary sodium values. On both LS and HS serum sodium did not significantly 
differ between fHP en fPE but interestingly there was a slightly different response of serum sodium 
to the change in diet within groups (fHP LS vs HS p<0.05, while fPE LS vs HS ns; p-values earlier 
not shown). This slight difference might have influenced the non-adaptation of arterial stiffness in 
response to LS in the fPE group.
 Other important determinants of arterial stiffness are the RAAS 14, 43, volume status 20 and 
endothelial function 39.  These determinants are also known to be affected by dietary sodium intake 
and could therefore be mechanisms underlying non-adaptation of arterial stiffness in response to 
sodium 9. However, we did not detect any differences in circulating RAAS components between 
groups and we found that the systemic RAAS was adequately modulated by sodium intake in both 
groups as observed by a similar increase in PRA and aldosterone in response to LS in our study. Our 
ECV data show that both the fHP and fPE group are reducing their ECV upon LS to a similar extent. As 
expected, the volume reduction resulted in reduction in arterial stiffness in fHP women, illustrating 
the ability of healthy vessels to shift stiffness along their compliance curve in response to volume 
reduction. Since non-adaptation of arterial stiffness was observed in fPE women, we hypothesize 
that fPE women have stiffer vessels that already work at the upper end of their compliance having 
less adaptability upon extrinsic factors. 
  In respect to endothelial function, plasma nitrate, RxNO and cGMP did also not differ 
between groups, while both groups showed the expected increase in plasma nitrate on LS.  Plasma 
nitrate, RxNO and cGMP are part of the L-arginine-NO-synthase pathway (nitrate as precursor 
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for NO 26, and cGMP as activated product of the NO-pathway), which play an important role in 
regulation of endothelial function (relaxation). Based on our findings we cannot conclude with 
certainty that endothelial function is not involved in the non-adaptation of arterial stiffness. A 
limitation of our study is that we did not assess flow-mediated dilatation (FMD), the gold standard 
to assess endothelial function. Previous work suggests that fPE women have an impaired FMD 
compared to controls 6, 16, 18, 31, 41, 53 and this might be a mechanism associated with non-adaptation of 
arterial stiffness under LS. 
  Future studies should investigate the mechanistic pathways behind the non-adaptation of 
arterial stiffness in fPE women and should include arterial stiffness measurements in combination 
with FMD. It would be of interest to characterize the structure and character of the vessel wall 
and endothelial surface layer (glycocalyx). The glycocalyx plays an important role in both sodium 
homeostasis and regulation of arterial stiffness. Under high salt conditions the endothelial sodium 
channels are upregulated resulting in an increased sodium influx in the endothelial cells, which 
leads to increased stiffness 23. Defects in the glycocalyx might result in increased arterial stiffening 
under LS condition by increased access of sodium to the sodium channels of the endothelium and 
subsequently reduced NO release causing contracted smooth muscle cells and vasoconstriction 13, 
23.  In addition, the question whether inability to adapt arterial stiffness in response to LS was pre-
existing or induced by preeclampsia remains to be answered. 
 In conclusion, this study is the first to show an effect of non-adaptation of arterial stiffness 
in healthy fPE women in response to LS. We could not explain the non-adaptation by differences 
in blood pressure, plasma RAAS parameters, ECV, plasma nitrate and plasma NO availability. The 
exact underlying pathways involved in the non-adaptation in this fPE group remain therefore to be 
elucidated. However, independent of the underlying mechanisms, impaired adaptation of the arterial 
stiffness in response to LS might be a marker of subclinical vascular damage in fPE women without 
comorbidity. We propose that non-adaptation in response to LS is a first sign of unfavorable vascular 
alterations in fPE women, which might put them at risk to develop hypertension and cardiovascular 
disease. 
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Preeclampsia is a syndrome affecting maternal and fetal health during gestation that also has an 
impact on the long-term health of women. Formerly preeclamptic women are more susceptible 
to cardiovascular and renal disease later in life as compared to women with a history of a healthy 
pregnancy. Whether it is preeclampsia per se or shared risk factors for preeclampsia and cardiovascular 
and renal disease inducing this increased risk is unknown. In addition, the mechanisms behind this 
increased susceptibility remain to be elucidated. Both questions were addressed in this thesis. 
 We hypothesized that increased angiotensin II (ang II) sensitivity and endothelial 
dysfunction might be involved. We first validated a rat model for preeclampsia for these specific 
features assumed to be involved in the postpartum increased risk for cardiovascular and renal 
disease (Chapter 2). Thereafter, we performed postpartum studies in formerly preeclamptic 
women and formerly experimental preeclamptic rats (Chapter 3-7). We aimed to assess whether 
disturbances seen during preeclampsia, i.e. altered renal hemodynamics, increased ang II sensitivity, 
and endothelial dysfunction, persisted postpartum in order to elucidate whether these mechanisms 
might be involved in the increased susceptibility to cardiovascular and renal disease (Figure 1). 
Elucidating these mechanisms will not only help to explain why formerly preeclamptic women are 
more susceptible for cardiovascular and renal disease, but will also be an important step towards 
structured follow-up and specific preventive treatment of these women. 
The angiotensin II sensitivity and endothelial function in experimental preeclampsia 
In this thesis, we used the low-dose endotoxin rat model for preeclampsia. This model is based on 
the increased inflammatory status seen in human preeclampsia and is pregnancy specific 1. In this 
model, the two main preeclampsia-like features, hypertension and proteinuria, have been described 
extensively by our group and others 1-5. Previous studies found glomerular inflammation 6 and 
increased activation of circulating monocytes and granulocytes 7, 8. In addition, fetal and placental 
involvement have been shown 4, 5. 
 In Chapter 2 we studied ang II sensitivity and endothelial function in pregnant rats with 
low-dose endotoxin induced preeclampsia 1, both characteristics of the multifactorial disease of 
preeclampsia 9-11. In healthy pregnancy, sensitivity to ang II is decreased 12, while during preeclampsia, 
ang II sensitivity is increased 9, 10. In addition, healthy pregnancy is characterized by an altered 
regulation of the endothelial-derived vasodilating factors leading to increased vasodilation, while 
in preeclampsia endothelial dysfunction occurs, leading to impaired vasodilation 11. To assess ang 
II sensitivity and endothelial (dys)function, ex-vivo isotonic contraction experiments in the thoracic 
aorta were performed. 
 Similar to the human situation, decreased ang II sensitivity was seen during healthy 
pregnancy in the rat and sensitivity to ang II was increased during experimental preeclampsia. 
Interestingly, the experimental preeclamptic rats responded similarly to ang II as non-pregnant rats, 
suggesting maladaptation to pregnancy in experimental preeclampsia. In human pregnancy, the 
maladaption in ang II sensitivity seen in preeclampsia, is already present during the first trimester of 
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pregnancy 9. Since endotoxin was infused on day 14 of rat pregnancy (i.e. second half of pregnancy) 
and ang II sensitivity was assessed at the end of gestation, it can be suggested that pregnancy-specific 
adaptations are reversed in experimental preeclampsia. Increased ang II sensitivity may cause 
generalized vasoconstriction in the vascular system and therefore contribute to the development of 
hypertension seen in preeclampsia 13. Moreover, the increased ang II sensitivity in this model might 
also contribute to the development of other preeclampsia-like features since blocking the ang II type 
I receptor (AT1-R) ameliorated hypertension, proteinuria, and fetal outcome in this model 5. 
 Although several mechanisms have been proposed to be involved in the changes in ang 
II sensitivity, in Chapter 2 we mainly focused on the role of the AT1-R and the ang II type II receptor 
(AT2-R) in the ang II sensitivity. The AT1-R mediated vascular constriction and AT2-R mediated 
vascular relaxation were increased in experimental preeclampsia as compared to healthy pregnancy 
and an increased AT1-R/AT2-R mRNA balance in the thoracic aorta of the experimental preeclamptic 
rat was found. The recently suggested phenotypic change of the AT2-R towards a constrictor 
receptor during preeclampsia, thereby contributing to the enhanced ang II responsiveness 
in preeclampsia 10, seemed not to be present in our animal model for preeclampsia. We found 
increased AT2-R mediated vasodilation in experimental preeclampsia as compared to the healthy 
pregnant rats. Since experimental preeclampsia was induced in the second half of pregnancy and 
ang II sensitivity was studied at day 19 of gestation, studying in-vivo and ex-vivo responses of ang 
II via the AT2-R, at different time points during gestation, is of interest. In rat the uterus 14, 15 and 
the rat kidney 16 for example, it has been shown that ang 1-7, ACE2, and AT2-R expression varied 
throughout gestation. Therefore, it can be suggested that in order to adapt to the pregnancy-induced 
maternal hemodynamic changes, the magnitude and site of expression of the ang II receptors varies 
during gestation, thereby affecting ang II responses and receptor function. During preeclampsia 
this ingenious RAAS regulation might then be disturbed via for instance endothelial dysfunction, 
secreted factors from the stressed placenta directly influencing the RAAS (i.e. soluble fms-like 
tyrosine kinase-1 (sFlt1)) or via AT1-R auto-antibodies (AT1-AA) influencing receptor activity and 
expression.
 In Chapter 2, in addition to the role of the RAAS, the role of endothelial (dys)function on 
vascular tone was assessed during pregnancy and in experimental preeclampsia. The increased 
role of NO in the pregnancy-induced vasodilation 17 was not seen in our study. This coincides with 
the lack of differences in eNOS and iNOS mRNA expression found in our study. The absence of 
the increased role for NO in vasodilation suggests that in these rats, NO is of less importance in 
the pregnancy-induced vasodilation. To study this in more detail, NO metabolites (nitrate, nitrate) 
and NO activity (cGMP) should be assessed in future studies. In addition, the role of NO in the 
vasodilation of mesenteric arteries can be studied in order to elucidate whether pregnancy-induced 
changes are vascular bed dependent and is different in restrictive vessels. Whereas the role of NO 
was not affected by pregnancy, we did observe involvement of the prostanoids and EDHF during 
pregnancy as we found an increased role for vasodilating prostaglandins and a decreased role 
for EDHF. In experimental preeclampsia, these pregnancy-specific adaptations of the different 
endothelial-derived factors were absent. The experimental preeclamptic rats showed similar 
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vasodilating responses as the non-pregnant rats. This emphasizes again a reversal of the vascular 
adaptations to pregnancy during experimental preeclampsia. To elucidate this in more detail, in 
futures studies it would be useful to assess endothelial-dependent vasodilation at different time 
points during gestation.
 Overall, in Chapter 2, we have shown that in the endotoxin model for preeclampsia 
changes in the RAAS and endothelial function occur. These changes, increased ang II sensitivity 
and endothelial dysfunction, are also seen in human preeclampsia, suggesting that this model 
for preeclampsia resembles the human situation in these characteristics. We did not study the 
mechanisms by which increased ang II sensitivity and endothelial dysfunction were induced. 
However, it may be suggested that the inflammatory response, induced by the low-dose endotoxin 
infusion 18, may be involved since inflammatory responses are associated with endothelial cell 
activation 19, 20, potentially leading to endothelial dysfunction, and ang II mediated inflammatory 
responses have been described 21. We were not able to detect increased sFlt1 levels in this model 
(unpublished data), however, the exact role of other angiogenic factors, i.e. placental growth factor, 
vascular endothelial growth factor (VEGF), or soluble endoglin, need to be examined. For example, 
VEGF deficiency might play an important role in the development of endothelial dysfunction since 
VEGF is important in maintaining endothelial health 22. Since ang II sensitivity and endothelial 
dysfunction have been shown to be present, this animal model is appropriate to specifically study 
these impairments postpartum in order to elucidate the role of preeclampsia on the postpartum 
endothelial function and ang II sensitivity.
Renal function, RAAS, and cardiovascular system after preeclampsia
It has been known for some time now, that formerly preeclamptic women are more prone to develop 
end-stage renal disease later in life 23-25. In Chapter 3 we described potential mechanisms involved 
in this increased renal risk. We reviewed several studies that have investigated renal function, renal 
hemodynamics, and the RAAS in women after a pregnancy complicated by preeclampsia. These 
studies suggest (subtle) persistent impairments. However, since most studies were performed early 
after pregnancy, it is unknown whether these (sub)clinical impairments are still present, or even 
worsen, during follow-up at middle age. In addition, the mechanisms involved in the increased 
long-term risk for cardiovascular and renal disease need to be elucidated in order to make the step 
towards prevention. 
 Therefore, we first longitudinally assessed renal function and renal function decline in 
women with a history of a hypertensive disorder during pregnancy (Chapter 4). Renal function data 
from women with a history of a (hypertensive) pregnancy collected in the PREVEND (Prevention of 
REnal and Vascular ENdstage Disease) study, a general population based prospective observational 
cohort study, were used. In addition, renal function parameters 10-years postpartum were compared 
in a sub-cohort of women following a healthy pregnancy, following pregnancy induced hypertension 
(PIH) and following preeclampsia and/or HELLP-syndrome (Chapter 4) to study whether severity 
of the hypertensive disorder was associated with more prominent effects on renal function. Next, 
we tested the hypothesis that following preeclampsia, (renal) hemodynamic changes (including 
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endothelial function) and changes in the RAAS occur. Such changes may be involved in the increased 
renal risk following an early-onset preeclamptic pregnancy (Chapter 5-7; the RETAP (REsponse To 
Angiotensin II in formerly Preeclamptic women) study). 
 To elucidate the mechanisms involved in the increased long-term renal risk following 
preeclampsia, it is of importance to discriminate between the role of pre-pregnancy risk factors and 
preeclampsia-induced factors, to distinguish whether preeclampsia itself or common pre-pregnancy 
risk factors are involved in the postpartum susceptibility to renal disease after preeclampsia. The 
optimal study design would obviously require pre-pregnancy assessment, but his is extremely 
difficult to realize in clinical practice. As an alternative, studying formerly preeclamptic women in 
the absence of cardiovascular risk factors could also shed light on the role of preeclampsia per se. 
In the RETAP study, we therefore carefully selected formerly early-onset preeclamptic women who 
were otherwise healthy, i.e. normotensive with a healthy body weight and without cardiovascular 
or renal diseases or current drug use (Chapter 5, 6, and 7). To study postpartum effects of 
preeclampsia in a fully clean model, animal studies are more practical; therefore, the endotoxin 
model for preeclampsia studied in Chapter 2 was also used to study the effects of experimental 
preeclampsia on the postpartum RAAS (Chapter 6). Since in this model increased ang II sensitivity 
and endothelial dysfunction was found, it is a suitable model to study these particular impairments 
postpartum following experimental preeclampsia. In addition, no hypertension or proteinuria was 
found postpartum in our rats following experimental preeclampsia, showing that indeed healthy rats 
were studied. 
 In the next section, we will first elaborate on longitudinal renal function data collected 
during the PREVEND study in women following a hypertensive disorder during pregnancy (Chapter 
4). Thereafter, the mechanisms suggested to be involved in the increased renal risk following 
preeclampsia that were studied in the RETAP study will be discussed (Chapter 5-7). 
Renal function decline following a hypertensive disorder during pregnancy 
Since formerly preeclamptic women exhibit an increased renal risk postpartum on the long-run, it 
is of interest to longitudinally assess renal function for an extended period of time. So far, only one 
study intended to investigate long-term renal function following preeclampsia. This cross-sectional 
small study suggested that age-dependent renal function decline was not affected by a history of 
preeclampsia 26. In Chapter 4 we presented unique longitudinal data from the PREVEND study. We are 
the first  to show an accelerated renal function decline (assessed by estimated glomerular filtration 
rate (eGFR)) in women after a self-reported history of a hypertensive disorder during pregnancy. In 
addition, these women had slightly, but significantly lower eGFR as compared to controls, within the 
normal range. Both the steeper decline in renal function and the lower eGFR fit in the observation 
that these former hypertensive women were more susceptible to develop chronic kidney disease 
(CKD). However, as shown previously, the absolute risk for renal disease following preeclampsia is 
relatively low 23-25. Also, the observed abnormalities in renal function after preeclampsia were subtle. 
Although our study highlights the importance of longitudinal follow-up, it remains questionable 
whether it is of additive value to assess renal function (i.e. eGFR) during follow-up in all women 
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following a hypertensive disorder of pregnancy. Importantly, formerly hypertensive women exhibited 
higher blood pressure values, lower renal function, and were using more anti-hypertensive drugs 
as compared to healthy controls, indicating that women with a history of hypertensive disorder of 
pregnancy carry a high-risk profile for future cardiovascular and renal disease. Whether this is a 
cause or a consequence of their hypertensive disorder during pregnancy and long-term increased 
health risk remains to be investigated in future studies. 
 As part of the women from the above mentioned PREVEND study delivered in one of the 
two hospitals in Groningen, we retrieved medical records from these women in order to obtain 
verified information on the severity of the hypertensive disorder during pregnancy (PIH, the HELLP 
syndrome, and preeclampsia). This allowed us to compare renal function data from women with 
PIH, HELLP or preeclampsia with healthy controls 10-years post-partum in a case-control set-up 
study (Chapter 4). The renal function data showed that women with former preeclampsia or HELLP 
syndrome had the highest risk for renal function impairment and CKD 10-years postpartum. It must 
be stated here that the prevalence of hypertensive disorders in the PREVEND cohort was higher than 
reported in other studies 27, possibly due to oversampling of subjects with albuminuria, by design of 
the PREVEND study. Consequently, our findings require confirmation in other cohorts. 
 If our data can be confirmed, this could provide a basis for recommendations to screen 
for renal abnormalities (i.e. plasma creatinine, eGFR, and/or albuminuria) at middle age (i.e. 
from postmenopausal onwards) in women with a history of preeclampsia or HELLP syndrome. 
In addition, in line with our national guideline for cardiovascular risk management (CVRM 28), it 
should be strongly considered to establish a risk profile in all women with a history of (early-onset) 
preeclampsia/HELLP syndrome. However, before recommendations of standardized renal follow-up 
in women following a hypertensive disorder during pregnancy can be made, the exact time course 
at which, for example, renal function decline becomes evident, needs to be identified in long-term 
longitudinal studies. Furthermore, more mechanistic insight is necessary in order to interfere in this 
decline by the use of therapeutic interventions. 
From preeclampsia to renal disease; a mechanistic role for an altered renal hemodynamic profile?
Several studies suggest persistent impairments in renal hemodynamics after preeclampsia 29-31, 
which might subsequently contribute to the increased renal risk in later life. However, this was mainly 
found in formerly preeclamptic women that were hypertensive at the time of study, and thus might 
be related to the hypertension per se. Therefore, these studies cannot discriminate between the role 
of comorbidities and the role of the former preeclampsia in inducing renal function impairments. 
Moreover, these prior studies did not standardize for sodium status or stage of menstrual cycle, 
both known to exert substantial effects of renal hemodynamics. In Chapter 5, we therefore assessed 
renal hemodynamics in healthy formerly pregnant women and healthy formerly early-onset 
preeclamptic women, during standardized sodium conditions (i.e. on low and high sodium intake), 
and during standardized stage of the menstrual cycle. We observed subtle long-term changes in 
renal hemodynamics, i.e. increased filtration fraction, in formerly preeclamptic women on both 
sodium intakes. Since healthy women were studied, this may suggest a role for preeclampsia itself 
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on postpartum renal hemodynamics. However, pre-pregnancy changes cannot be ruled out in the 
human situation as mentioned earlier. 
 The increase in filtration fraction found relatively short (1-10 years) after preeclampsia, 
might underlie the increased long-term renal risk in these women. Indeed, a high filtration fraction 
has been independently associated with progressive renal damage in CKD 32, 33. Other potential 
mechanisms of renal function loss could be the higher blood pressure, and/or presence of additional 
cardiovascular risk factors, as these are generally associated with an increased risk for long-term renal 
function loss. As described previously and studied in Chapter 4, in formerly preeclamptic women 
the rate of renal function decline with aging is more pronounced than in control women. This could 
potentially lead to overt CKD on long-term, as supported by the observed higher prevalence of CKD 
in the formerly preeclamptic women in our case-control study. Ideally, one would therefore assess 
postpartum renal hemodynamics longitudinally, in order to elucidate the time-course of these 
changes in renal hemodynamics. In addition, although the changes observed 1-10 years postpartum 
were relatively subtle, these changes can become of clinical significance with further progress at a 
more advanced age. 
 Several mechanisms could potentially be involved in the increased filtration fraction found 
in formerly preeclamptic women. An increase in vasoconstriction of the efferent arteriole relative 
to the afferent arteriole is one of the renal hemodynamic changes leading to an increased filtration 
fraction 34. The RAAS is a known pathway that could induce this particular pattern 34. However, no 
differences in renal ang II responses or RAAS parameters were seen in the formerly preeclamptic 
women studied in Chapter 5. To assess the mechanisms underlying changes in filtration fraction with 
certainty and to verify the role of the vasotonus in the arterioles, micropuncture studies 35 in animals 
that suffered from experimental preeclampsia may gain more insight. Studying renal hemodynamics 
in animals also allows standardizing conditions, i.e. sodium and RAAS status, body weight, and pre-
pregnancy renal function. With regards to the structural impairments, animal studies are also ideal 
to assess whether glomerular lesions are present following experimental preeclampsia and whether 
they affect renal hemodynamics. In addition, mechanisms involved in inducing these glomerular 
lesions can be assessed, i.e. inflammation, imbalance in angiogenic factors or local RAAS activity. 
From preeclampsia to renal disease;  a mechanistic role for the renin-angiotensin aldosterone 
system?
As observed in Chapter 2 and earlier mentioned studies, during preeclampsia ang II sensitivity is 
increased and therefore it can be suggested that increased ang II sensitivity persists postpartum. 
Postpartum increased ang II sensitivity might then contribute to the increased renal risk. This can 
for example be directly via renal vascular tone regulation, or indirectly via increasing systemic blood 
pressure. So far, three studies investigated ang II sensitivity in women with a history of PIH or 
preeclampsia 36-38. In general, all three suggest an increased ang II sensitivity postpartum. However, 
co-morbidity, i.e. hypertension or overweight, was present and studies were not standardized for 
sodium status or menstrual phase, both factors known to play a role in the activity of the RAAS. 
Therefore, one cannot conclude that is was preeclampsia itself that induced this postpartum 
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increased ang II sensitivity. 
 In order to investigate whether postpartum RAAS alterations are present after preeclampsia, 
blood pressure response upon ang II infusion was studied (Chapter 6). Although subtle, our data 
suggested an increased blood pressure response upon ang II infusion postpartum in women after an 
early-onset preeclamptic pregnancy. To further substantiate between the effect of co-morbidity and 
a history of preeclampsia on the increased ang II sensitivity postpartum, blood pressure and kidney 
response upon ang II infusion were studied in an experimental rat model for preeclampsia (Chapter 
6). In line with the human study, also rats did not show hypertension or proteinuria following a 
healthy pregnancy or experimental preeclampsia. And again, increased responsiveness upon ang 
II was found in formerly experimental preeclamptic rats. Together, our human and experimental 
data suggest persistent ang II sensitivity following (experimental) preeclampsia which subsequently 
might contribute to the increased renal risk. In addition, since healthy women and pre-pregnancy 
identical rats were studied, it can be hypothesized that preeclampsia itself induces this increased 
ang II sensitivity postpartum.  
 To assess the mechanisms behind the increased ang II sensitivity postpartum, the function 
and role of the aligned receptors for ang II is of interest. Since in our experimental work we have 
shown an increased AT1-R response during preeclampsia (Chapter 2) while a diminished AT2-R 
response was seen after preeclampsia (Chapter 6), it may not merely be a persistence of ang II 
sensitivity following preeclampsia, there also appears to be a transition in the balance between these 
receptors. In addition, the postpartum presence of AT1-AA (which we found in women following 
preeclampsia (Chapter 6)) might play a direct role in the increased ang II sensitivity or indirectly 
influences this receptor balance.
From preeclampsia to renal disease; a mechanistic role for altered arterial stiffness?
Increased arterial stiffness is an independent precursor of cardiovascular diseases 39, 40 and could 
be a candidate mechanism for the increased renal and cardiovascular risk in formerly preeclamptic 
women. Several studies have reported increased arterial stiffness in women with a history of 
preeclampsia 41-43. However, these studies show inconsistencies and in the most recent studies no 
differences in arterial stiffness were reported. However, none of the studies were performed under 
standardized sodium conditions. Since a high sodium intake increases arterial stiffness 44 while 
a low sodium intake reduces arterial stiffness 45, 46 in Chapter 7, arterial stiffness was assessed in 
healthy formerly preeclamptic women under low and high sodium intake. Although baseline blood 
pressure and blood pressure responses to the change in sodium intake were comparable between 
the groups, formerly preeclamptic women did not adapt arterial stiffness during the change in 
sodium intake. This non-adaptation of arterial stiffness has not been described previously, neither 
in normotensive subjects 47 nor in hypertensive subjects 46. In line with previous studies, although 
now under standardized conditions, i.e. a high sodium intake (corresponding to the normal Western 
diet), no differences were observed between formerly healthy women and formerly preeclamptic 
women. However, after challenging women with a low sodium diet, differences between the groups 
became apparent. 
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 The mechanism behind this non-adaptation of arterial stiffness in formerly preeclamptic 
women needs to be elucidated. Several mechanisms have been suggested to be involved in arterial 
stiffness regulation. Aging increases arterial stiffness probably via changes in the extracellular matrix 
composition 48. Also hypertension, diabetes mellitus, atherosclerosis, and renal failure increases 
arterial stiffness 49, 50. Since in Chapter 7 only women without comorbidity were studied and women 
were in the same age range, these mechanisms are not likely to have influenced our results. Both 
the RAAS 51, 52 and volume status 53 are important determinants of arterial stiffness. Our data 
presented in Chapter 7 suggest that in our study, the RAAS was not mechanistically involved in the 
non-adaptation of arterial stiffness since no differences in systemic RAAS parameters were found 
between groups. Although low sodium reduced volume status in both groups to a similar extent, 
only formerly healthy pregnant women were capable in reducing arterial stiffness. We feel that in 
our study, sodium status may have been the factor determining arterial stiffness. Indeed, sodium 
status is suggested to regulate arterial stiffness 46, 54, 55 and we found sodium status to differently 
affect arterial stiffness. Future studies thus should aim on exploring the mechanism behind this 
regulation. For example, serum sodium response was slightly different between our groups studied 
and this might have influenced the non-adaptation of arterial stiffness in formerly preeclamptic 
women. 
 With increased arterial stiffness, signs of endothelial dysfunction might be expected 56. The 
gold standard to assess endothelial function is by measuring the flow-mediated dilatation (FMD). 
Since previous studies found an impaired FMD in formerly preeclamptic women 41, 57, 58, endothelial 
dysfunction can be suggested as a mechanism behind the non-adaptation of arterial stiffness in 
formerly preeclamptic women. As in human preeclampsia it has been suggested that endothelial 
dysfunction is associated with decreased NO bioavailability 11, 59. We hypothesized that postpartum 
increased arterial stiffness is partly caused by decreased NO availability or activity. However, 
assessment of nitrate and cyclic GMP, surrogates for NO production and activity, could not confirm 
this in our formerly preeclamptic women (Chapter 7). Whether other endothelial-dependent 
(i.e. prostanoids or EDHF) or endothelium-independent (i.e. smooth muscle cells) factors are 
involved deserves further research. In line with the suggestion of endothelial dysfunction following 
preeclampsia, animal work in our group, has shown subtle signs of disturbed endothelial-dependent 
relaxation in formerly preeclamptic rats (unpublished results). In the absence of increased blood 
pressure postpartum, the contribution of the vasoactive factors to relaxation of the thoracic aorta 
differed between formerly healthy pregnant rats and formerly preeclamptic rats, i.e. more NO and 




Our studies in formerly preeclamptic women and (formerly) experimental preeclamptic rats in this 
thesis demonstrated long-term consequences of preeclampsia. Our studies point toward a role for 
preeclampsia per se on the postpartum impairments in women with a history of preeclampsia, 
thereby increasing the susceptibility of these women to develop cardiovascular and renal disease 
later in life. Our studies demonstrated that postpartum changes in renal hemodynamics, persistent 
increased ang II sensitivity, endothelial dysfunction, and arterial stiffness all provide leads for further 
research into the exact mechanisms behind this increased susceptibility (Figure 1). Using a history 
of preeclampsia as an early marker to identify young women at risk for premature cardiovascular 
and renal disease opens a window of opportunities for preventive treatment in this specific group of 
women, even in the absence of known cardiovascular risk factors.
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Figure 1. Simplified version adapted for this thesis of proposed and studied mechanisms involved 
in the long-term renal health risk following preeclampsia. 
So far, it is unknown whether women who develop preeclampsia during pregnancy, exhibit prior to pregnancy an altered 
cardiovascular health status, i.e. pre-existing cardiovascular and renal disease risk factors. These pre-existing factors 
might increase a woman’s risk to develop preeclampsia during pregnancy. Preeclampsia is clinically characterized by 
hypertension and proteinuria, with alterations in ang II sensitivity, endothelial function, renal function, and arterial 
stiffness involved. Our thesis has demonstrated that these specific alterations persist postpartum and we hypothesize 
that these persistent alterations increase the susceptibility of these women to develop renal disease late postpartum. 
In addition, traditional cardiovascular risk factors, possibly already present pre-pregnancy, might add to this increased 
long-term renal risk.
BP: blood pressure, BMI: body mass index, ang II: angiotensin II, GFR: glomerular filtration rate, FF: filtration fraction, 




Experimental preeclampsia; what can we learn from it and what should be the next step? 
Our animal work has shown pregnancy specific adaptations of the vascular bed with preeclampsia 
leading to maladaptation. Changes in the contribution of endothelial derived vasoactive factors 
induced by pregnancy were seen, while during preeclampsia regulation of endothelial-derived 
vasodilatory factors was altered, suggesting endothelial dysfunction. Also, a pregnancy-specific 
decrease in ang II sensitivity was observed, which was absent during experimental preeclampsia. 
However, how experimental preeclampsia affects ang II sensitivity and the endothelial cells has still 
not completely been elucidated. Therefore, future studies should focus on the intriguing interaction 
between (experimental) preeclampsia and the vascular bed. By unraveling the exact mechanisms 
and pathways behind the changes in the vascular bed to pregnancy, via more experimental animal 
work, future studies can then be conducted focusing on protecting the vascular bed from these 
changes, and hence from preeclampsia.
 Since preeclampsia is a multifactorial disease, with, as we have shown, the inflammatory 
system, endothelial dysfunction, renal function, and the RAAS involved, combining these pathways 
in a future animal model, for instance low-dose endotoxin infusion and RAAS over activity combined, 
might provide more insight into its multifactorial origin. Combining these pathways in a future 
animal model might hypothetically exaggerate preeclampsia-like features, i.e. hypertension and 
endothelial dysfunction, via inducing a common final pathway following these distinct but coinciding 
pathways. Hypothetically, when symptoms exaggerate, it can be stated that the pathways are either 
independently involved and/or reinforce each other.
Long-term consequences of preeclampsia; from a mechanistical point of view
Since we have shown persistent impairments in renal function, RAAS activity, and vascular function 
in women with a history of preeclampsia that hypothetically induce their susceptibility to renal 
disease later in life, more studies are warranted that elucidate the mechanisms involved in more 
detail. 
 From a renal perspective, the ultimate goal is to protect formerly preeclamptic women 
from long-term renal disease. Therefore, to gain more mechanistic insight into renal function 
decline and altered renal hemodynamics, micropuncture studies in animals following preeclampsia 
focusing in detail on the role of the glomerular pressure and glomerular lesions in the increased 
filtration fraction should be performed. It addition, longitudinal studies should be performed in 
order to investigate which women, i.e. women with a specific cardiovascular/renal risk profile or 
lifestyle, suffer the highest risk for renal function decline on the long-run and to test whether for 
example RAAS-blockade, protects against the suggested switch from hyperfiltration to hypofiltration 
that eventually leads to renal function decline.  
 With regards to the increased ang II sensitivity, the potential of RAAS blockade in reducing 
the long-term risk should be assessed in for example experimental preeclampsia. In addition, 
longitudinal ang II sensitivity studies in (experimental) preeclampsia during gestation (ex-vivo) 
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and postpartum (in-vivo and ex-vivo) are of interest to perform in order to test whether phenotypic 
changes in ang II receptors occur, to verify the time course of these possible changes, and to assess 
the mechanisms behind the differentially involved AT1-R and AT2-R in the ang II sensitivity during 
and after preeclampsia. 
 Although no sodium-sensitivity of blood pressure was observed in formerly preeclamptic 
women, low sodium diet distinguished formerly preeclamptic women from healthy women with 
respect to arterial stiffness. Therefore, the effect of sodium status on the endothelial function 
following (experimental) preeclampsia is of interest to study. To further substantiate whether the 
increased arterial stiffness under low sodium intake is caused by impairments in the endothelial-
dependent or endothelial-independent vasodilation, flow mediated dilation (FMD) and glyceryl 
trinitrate-induced vasodilation assessments can be performed respectively. Also, since oxidative 
stress is associated with endothelial dysfunction and inflammation, it is of interest to study oxidative 
stress markers, especially in combination with a low and a high sodium diet. To further verify the 
role of oxidative stress, studying the effect of anti-oxidants on arterial stiffness can be suggested. 
For example, arterial stiffness and FMD can be assessed under different sodium conditions, in the 
presence and absence of anti-oxidant treatment. 
 In addition to longitudinal studies, women with a history of preeclampsia more than 
10 or 20 years postpartum can be studied to assess whether the differences we found become 
more pronounced over-time. Since the menopause is of influence on women’s cardiovascular risk, 
menopausal women specifically following preeclampsia are of interest to study. In addition, since 
pregnancy is suggested to be a stress-test for life, future studies should also include a group of 
women that has never been pregnant.
The ideal future perspective: evidence-based structured follow-up and preventive treatment 
in women with a history of preeclampsia
A history of preeclampsia serves as a risk marker for future premature cardiovascular and renal 
disease. Preeclampsia history provides an opportunity for early identification of young women at 
increased risk, even in the absence of classical cardiovascular risk factors. Postpartum follow-up of 
these women can therefore detect early subclinical damage and gives the opportunity for preventive 
treatment and interventions at a younger age than usual. This thesis gives insight in renal function 
after preeclampsia and gives insight into mechanisms involved. To further elucidate the exact renal 
risk, more prospective case-control studies preferably at a high age, or retrospective studies in large 
non-selected population based cohorts, i.e. the LifeLines study in which pre-pregnancy data are 
available, are warranted.
 Next to elucidating the effectiveness of lifestyle interventions in these women, it is of 
importance to verify the most optimal timing to start these interventions, i.e. directly postpartum 
or several years after the preeclamptic event. Longitudinal follow-up studies are therefore necessary 
to clarify the time course of cardiovascular and renal impairments to subsequently be able to detect 
the time point at which an adverse cardiovascular profile can be identified. The American Heart 
Association (AHA) and the American Stroke Association (ASA), both guidelines on prevention 
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of cardiovascular diseases, have recently included a history of preeclampsia as a women-specific 
risk factor for cardiovascular diseases. Both the AHA and ASA have implemented follow-up and 
treatment of formerly preeclamptic women in their guidelines 60, 61. In addition, the Netherlands 
implemented a guideline on cardiovascular risk management after reproductive disorders in women 
62. However, the recommendations on screening and treatment are based on a low level of evidence. 
Therefore, more insight into the mechanisms behind this increased risk is necessary, since there is 
currently no real evidence how and whom to screen and which drugs and interventions will be of real 
benefit. 
 Preventive treatment can include both lifestyle interventions and pharmacotherapy. Since 
overweight and the metabolic syndrome are linked with both preeclampsia and cardiovascular 
diseases, a healthy diet and exercising should always be a general advice. Considering the effect of 
high sodium on renal hemodynamics, blood pressure, and the role of an increased filtration fraction 
in long-term renal risk, advice on sodium restriction should be incorporated into the dietary advices. 
Since ang II seems mechanistically involved in these women´s increased risk, the effectiveness of 
pharmacotherapy directed towards RAAS-blockade deserves further investigation on effectiveness. 
Albuminuria and increased blood pressure, both endangering cardiovascular and renal health, can 
effectively be treated by RAAS-blockade. Whether this is beneficial and in which subcategory at what 
age this should be started, needs to be elucidated. In line with the suggested persistent endothelial 
dysfunction, increasing the bioavailability of nitric oxide or supplementation of anti-oxidants can be 
suggested as a preventive treatment. 
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Preeclampsia, a pregnancy specific disorder, complicates up to 8% of the pregnancies worldwide. In 
the Netherlands, this is approximately 2%. The exact pathophysiology is still unknown, it is, however, 
generally accepted that preeclampsia is a two-stage disease with the placenta being organ of origin. 
The first stage of preeclampsia is characterized by poor placentation and during the second stage 
the placenta secretes several factors, which subsequently induce the maternal response; clinically 
characterized by hypertension and proteinuria.
 Apart from termination of pregnancy there is no treatment option to cure preeclampsia. 
For a long time, it has been thought that preeclampsia is a completely reversible syndrome. However, 
it has been shown that women with a history of preeclampsia have an increased risk to develop 
cardiovascular and renal disease later in life. Although several mechanisms have been suggested to 
be involved in this increased risk, the exact mechanisms need to be elucidated. Whether common 
constitutional risk factors for both preeclampsia and cardiovascular disease are involved or whether 
preeclampsia itself induced the increased this risk is currently still unknown. 
 To gain more insight into the mechanisms behind the increased postpartum risk for 
cardiovascular and renal disease, we first evaluated angiotensin II sensitivity and endothelial 
function in an excisting rat model for preeclampsia (Chapter 2). Then, Chapter 3-7 describes long-
term renal function after preeclampsia and after experimental preeclampsia, together with studies 
investigating suggested mechanisms behind the postpartum increased risk for cardiovascular and 
renal disease in women with a history of preeclampsia.
An animal model for preeclampsia; focus on angiotensin II sensitivity and endothelial 
function
Pregnancy is characterized by major maternal hemodynamic changes. Blood volume increases and 
systemic vascular resistance decreases. The renin-angiotensin aldosterone system is an important 
system involved in this volume and tonus regulation. Healthy pregnant women show decreased 
sensitivity for the actions of the vasoconstrictor angiotensin II (ang II). In contrast, preeclampsia 
is characterized by increased sensitivity for ang II, contributing to hypertension and proteinuria. In 
Chapter 2 we showed that in the low-dose endotoxin rat model for preeclampsia both endothelial 
dysfunction and alterations in the renin-angiotensin system are present. Healthy pregnant and non-
pregnant rats were compared with pregnant rats infused with a low-dose endotoxin. Isolated aortic 
rings were used to perform isotonic contraction measurements. Acetylcholine dose-response curves 
were used to study endothelial dysfunction and ang II dose-response curves were used to evaluate 
ang II sensitivity and the role of the ang II type I and type II receptor (AT1-R and AT2-R respectively). 
We observed an increased role for the vasodilator prostaglandin and ang II sensitivity was decreased 
in healthy pregnant rats. This was associated with decreased responses of the AT1-R and AT2-R. 
However, these pregnancy adaptations were absent in rats with experimental preeclampsia. 
Therefore, the lack of vascular adaptations to pregnancy may play a role in the development of 
hypertension in this model. Accordingly, the low-dose endotoxin rat model is therefore a suitable 
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model to study potential treatment options interfering with the endothelium and ang II and to 
unravel the mechanisms behind these changes. Moreover, this model can be used to assess ang 
II sensitivity following experimental preeclampsia to investigate whether increased ang II persists 
postpartum as a mechanism behind the increased risk for cardiovascular and renal disease in 
formerly preeclamptic women.  
Renal function, RAAS, and cardiovascular system after preeclampsia
Chapter 3 reviews the current understanding of the association between preeclampsia and the 
subsequently increased risk of developing chronic kidney disease (CKD). This review first elaborates 
on the increased renal risk in formerly preeclamptic women and provides an overview of the literature 
focusing on microalbuminuria and renal hemodynamics in these women. Next, we commented 
on angiogenic factors and the renin-angiotensin aldosterone system as suggested mechanisms 
by which the risk of CKD is increased in formerly preeclamptic women. Levels of soluble fms-like 
tyrosine kinase-1 (sFtl1), the antiangiogenic factor involved in the pathogenesis of preeclampsia, is 
suggested to be elevated postpartum and via impairing the vascular health might contribute to the 
development of reno-vascular diseases in later life. In addition, the presence of auto-antibodies to 
the AT1-R in formerly preeclamptic women and persistent increased ang II sensitivity postpartum is 
discussed. Unfortunately, it remains still unknown whether the association between preeclampsia 
and the increased risk for renal diseases can be explained by deleterious effect of preeclampsia itself 
on the kidney or by underlying risk factors that make women more susceptible to both preeclampsia 
and renal disease. 
 Using data from the Pevention of REnal and Vascular ENd-stage Disease (PREVEND) 
study allowed us to study long-term renal function and renal function decline over time in women 
with a history of hypertensive disorder during pregnancy (Chapter 4). Women with a history of 
a self-reported hypertensive disorder during pregnancy and women without a history of a self-
reported hypertensive disorder during pregnancy were identified. Data on estimated glomerular 
filtration rate, albuminuria, and the prevalence of CKD over a time-period of 14-years were collected. 
Next, detailed information on pregnancy history were collected from the women that delivered in 
the two local hospitals and a case-control study was performed. In this case-control study, renal 
function parameters 10-years postpartum were analyzed and compared between healthy controls, 
pregnancy-induced hypertension and formerly preeclamptic women in order to analyze whether the 
severity of the disease was related to the long-term renal function loss. We found that a history of a 
hypertensive disorder during pregnancy was associated with an increased decline in renal function 
over time. In addition, 10-years postpartum, estimated glomerular filtration rate was significantly 
reduced in formerly preeclamptic women as compared to healthy controls. Moreover, almost 20% 
of the formerly preeclamptic women fulfilled the definition of having CKD 10-years postpartum as 
compared to 8% of the control women. To gain more insight into the exact mechanism behind this 
increased risk for CKD, more studies focusing on renal hemodynamics in formerly preeclamptic 
women are warranted. In addition, we suggest regular clinical follow-up of women with a history 
of a hypertensive disorder during pregnancy to create a window of opportunities for preventive 
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treatment. This follow-up should be based on evidence-based mechanisms found to be involved 
in women’s increased susceptibility to renal disease, i.e. assessing renal function parameters 
(albuminuria, eGFR and/or creatinine).
 Persistent impairments in the renal hemodynamics postpartum could be involved in the 
increased risk for end stage renal disease in women with a history of preeclampsia. In Chapter 
5 renal hemodynamics were studied in healthy formerly pregnant women and healthy formerly 
early-onset preeclamptic women 1-10 years postpartum. To measure glomerular filtration rate and 
effective renal plasma flow, the clearance of constantly infused radio-labeled tracers, 125I-iothalamate 
and 131I-Hippuran was assessed under standardized low sodium and high sodium conditions. In 
addition, ang II infusion was performed to investigate whether renal ang II sensitivity was increased, 
as an additional pathogenic mechanism behind the increased renal risk. We found that both the 
intake of high sodium and a history of preeclampsia increased filtration fraction. The renal response 
to ang II was not different between the groups. Thus, we demonstrated that preeclampsia has 
persistent effects on renal hemodynamics, even in the absence of co-morbidity. An elevated filtration 
fraction has been suggested to be involved in the development of hypertension and renal damage. 
Therefore, our results fit in the assumption that persistent disturbances in renal hemodynamics 
after preeclampsia, could be involved in the mechanism of the long-term increased risk for renal 
disease, independent of co-morbidity.
 Persistent increased systemic ang II sensitivity postpartum is another suggested 
mechanism behind the increased risk for cardiovascular and renal disease in women with a history of 
preeclampsia. Chapter 6 described a translational study investigating ang II sensitivity as the pressor 
response to ang II infusion, in healthy formerly pregnant women and healthy formerly early-onset 
preeclamptic women 1-10 years postpartum. Baseline blood pressure and blood pressure response 
upon ang II infusion were measured. Simultaneously, ang II sensitivity was studied both in-vivo and 
ex-vivo in never pregnant, formerly healthy pregnant, and formerly experimental preeclamptic rats. In 
both women and rats, baseline blood pressure was not affected after (experimental) preeclampsia. 
However, the pressor response to ang II was increased in formerly preeclamptic women and formerly 
experimental preeclamptic rats. Moreover, in response to ang II, only formerly preeclamptic rats had 
a significant increase in proteinuria. Since we only included healthy formerly preeclamptic women 
(without comorbidity) and all rats were healthy pre-pregnancy, our results support the hypothesis 
that preeclampsia itself plays an important role in the altered ang II sensitivity post-partum. This 
persistently increased ang II sensitivity might contribute to the increased cardiovascular and renal 
risk of formerly preeclamptic women in later life. 
 Arterial stiffness, described to be increased during preeclampsia, has also been suggested 
to be a mechanism behind the increased cardiovascular and renal risk in women with a history of 
preeclampsia. Chapter 7 assessed arterial stiffness by measuring pulse wave analysis and pulse 
wave velocity under low and high sodium diet in formerly healthy pregnant women and formerly 
early-onset preeclamptic women in the absence of co-morbidity. We showed that formerly healthy 
pregnant women are able to modulate their arterial stiffness in response to a reduction of sodium 
intake. However, this modulation was absent in formerly preeclamptic women, independent of 
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blood pressure. To further elucidate the mechanisms, NO metabolites were measured as a reflection 
of endothelial (dys)function, and volume status response was analyzed. Differences in volume 
regulation or endothelial markers could not explain this non-modulation, so the mechanism behind 
















Preeclampsie, in de volksmond bekend als zwangerschapsvergiftiging, komt wereldwijd in 
ongeveer 8%, en in Nederland in ongeveer 2% van de zwangerschappen voor. Preeclampsie is een 
zwangerschap-specifiek syndroom gekenmerkt door nieuw-ontstane hypertensie (hoge bloeddruk) 
en proteïnurie (eiwit verlies in de urine) in de tweede helft van de zwangerschap. Hoe preeclampsie 
ontstaat, is niet exact bekend. Wetenschappers erkennen preeclampsie als een syndroom dat zich 
ontwikkelt in twee stappen waarbij de placenta (moederkoek) een centrale rol speelt. De eerste stap 
kenmerkt zich door een verminderde aanleg van de placenta. Tijdens de tweede stap scheidt deze 
zieke placenta verschillende factoren uit in de moederlijke bloedbaan. Dit leidt in het lichaam van de 
moeder tot hypertensie en proteïnurie.
 Preeclampsie is een gevaar voor de gezondheid van de moeder en het ongeboren kind, maar 
er bestaat helaas geen goede behandeling voor. De enige behandeling bestaat uit de geboorte van 
het kind, spontaan of door inleiden, of met een keizersnede. Lange tijd dacht men dat preeclampsie 
een voorbijgaand syndroom was en dat de moeder geheel genezen was na de bevalling. Echter, 
verschillende onderzoeken laten zien dat vrouwen die preeclampsie hebben doorgemaakt een 
verhoogd risico hebben op het ontwikkelen van hart-, vaat- en nierziekten later in het leven. Het 
mechanisme daarvan is onbekend. Evenmin is bekend of preeclampsie en hart- en vaatziekten het 
gevolg zijn van gemeenschappelijke aanlegfactoren, of dat preeclampsie zelf het risico op hart-, vaat- 
en nierziekten verhoogt. 
 Om meer inzicht te krijgen in het ontstaansmechanisme van preeclampsie en om 
mogelijke mechanismen achter het postpartum langtermijnrisico voor hart-, vaat- en nierziekten 
te onderzoeken, onderzoeken we eerst in een diermodel voor preeclampsie of  er veranderingen 
optreden in het renine-angiotensine aldosteron systeem (RAAS) en in de endotheelfunctie. Daarna 
laten we de nierfunctie zien in vrouwen die preeclampsie hebben doorgemaakt 10 tot 15 jaar na 
de zwangerschap. Tevens beschrijven we studies (in bovenbeschreven diermodel en in de mens) 
waarin mogelijke mechanismen (waaronder het RAAS en endotheelfunctie) die bijdragen aan het 
verhoogde postpartum risico voor hart-, vaat- en nierziekten in vrouwen die preeclampsie hebben 
doorgemaakt zijn onderzocht. 
Een diermodel voor preeclampsie; zijn de angiotensine II gevoeligheid en endotheelfunctie 
veranderd?
Zwangerschap kenmerkt zich door grote veranderingen in de hemodynamiek van de moeder. 
Het bloedvolume neemt toe en de weerstand van het systeemvaatbed neemt af. Het RAAS is een 
belangrijk systeem dat betrokken is bij zowel de volume regulatie als bij de regulatie van de vaattonus. 
Gezonde zwangere vrouwen hebben een verminderde gevoeligheid voor het vasoconstrictieve 
hormoon angiotensine II (ang II), de belangrijkste component van het RAAS. Bij vrouwen met 
preeclampsie daarentegen, heeft het vaatbed een verhoogde gevoeligheid voor ang II, hetgeen kan 




experimenteel model voor preeclampsie in de rat – het endotoxine model – om na te gaan of dit 
model endotheel dysfunctie met veranderingen in het RAAS vertoont, zoals bij de mens. In deze 
studie vergeleken we gezonde zwangere en niet zwangere ratten met zwangere ratten geïnfundeerd 
met endotoxine. Zwangere ratten geïnfundeerd met endotoxine ontwikkelen een ziektebeeld dat 
veel lijkt op preeclampsie, dat wil zeggen; ze ontwikkelen hypertensie en proteïnurie. De ang II 
gevoeligheid en endotheelfunctie werden onderzocht in geïsoleerde aorta ringetjes van deze groepen 
ratten, door middel van isotone contractie experimenten met concentratie-response curves met 
acetylcholine (endotheel functie) en ang II. Bij de gezonde zwangere ratten was er een toename van 
de vaatverwijdende prostaglandines en een verminderde response op ang II. Deze zwangerschap-
specifieke aanpassingen zagen we niet in ons preeclampsie model. Op basis hiervan gaan we er 
vanuit dat verminderde vasculaire adaptatie aan de zwangerschap een rol speelt in de ontwikkeling 
van hypertensie in dit diermodel voor preeclampsie. Bovendien tonen deze resultaten dat het 
endotoxine preeclampsie model een geschikt model is om behandelingsopties te onderzoeken die 
invloed hebben op het endotheel en de verhoogde ang II gevoeligheid. Ook is het een geschikt 
model om het mechanisme van de verhoogde ang II gevoeligheid tijdens preeclampsie verder te 
onderzoeken, en om na te gaan of de verhoogde ang II gevoeligheid aanwezig blijft na afloop van de 
zwangerschap, als mogelijk mechanisme voor het verhoogde langetermijnrisico op hart-, vaat- en 
nierziekten na preeclampsie. 
De nierfunctie, het RAAS en het cardiovasculaire systeem na preeclampsie
Hoofdstuk 3 geeft een overzicht van de huidige inzichten in de relatie tussen preeclampsie en 
het daarmee samenhangende verhoogde risico op chronische nierziekten. Het beschrijft eerst 
het toegenomen renale risico in vrouwen die preeclampsie hebben doorgemaakt en geeft een 
overzicht van de literatuur betreffende microalbuminurie en renale hemodynamiek in deze vrouwen. 
Vervolgens bespreken we de angiogene factoren en het RAAS als mogelijke mechanismen achter het 
verhoogde risico op chronische nierziekten na preeclampsie. De anti-angiogene factor soluble fms-
like tyrosine kinase-1 (sFlt1; een receptor voor vascular endothelial growth factor (VEGF)) is verhoogd 
in preeclampsie en speelt mogelijk een rol bij de ontwikkeling van preeclampsie. Verhoogde sFlt1 
levels zorgen voor endotheel dysfunctie in het vaatbed, waardoor het mogelijk bijdraagt aan de 
ontwikkeling van hart-, vaat- en nierziekten later in het leven. Ook bespreken we de aanwezigheid 
van auto-antilichamen gericht tegen de ang II type I receptor in vrouwen die preeclampsie hebben 
doorgemaakt en bespreken we de blijvend verhoogde ang II gevoeligheid postpartum. Helaas weten 
we nog steeds niet of de relatie tussen preeclampsie en het verhoogde postpartum risico op hart-, 
vaat- en nierziekten verklaard wordt door de schadelijke effecten van preeclampsie zelf op de nieren, 
of dat onderliggende risicofactoren, zoals hoge bloeddruk, insuline resistentie en overgewicht, die 
voor de zwangerschap al aanwezig waren, een rol spelen bij zowel preeclampsie als nierziekten, 
deze associatie verklaren. 
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 Door gebruik te maken van de gegevens van de PREVEND studie (Prevention of Renal 
and Vascular End-Stage Disease), waren we in staat om de langetermijnnierfunctie en nierfunctie 
achteruitgang te onderzoeken over een langere periode in vrouwen die wel of geen hypertensieve 
aandoening (zwangerschapshypertensie of preeclampsie) tijdens de zwangerschap hadden 
doorgemaakt (Hoofdstuk 4). Uit de PREVEND studie zijn vrouwen geselecteerd met en zonder een 
(zelf-gerapporteerde) voorgeschiedenis van een hypertensieve aandoening tijdens de zwangerschap. 
Van deze vrouwen hebben we de gegevens van de geschatte glomerulaire filtratie snelheid, 
eiwitverlies (albuminurie) en het vóórkomen van chronische nierziekten over een tijdsperiode van 
14 jaar verzameld, en de nierfunctie en albuminurie tussen de twee groepen vergeleken. Wij zagen 
gedurende follow-up een versnelde achteruitgang in de nierfunctie in vrouwen die een hypertensieve 
aandoening tijdens de zwangerschap gerapporteerd hadden. 
 Om betere gegevens te verkrijgen over de zwangerschappen, hebben we voor de 
vrouwen uit de PREVEND studie die waren bevallen in de twee grote ziekenhuizen uit de stad 
Groningen, gedetailleerde zwangerschapsgegevens verzameld. Daarmee is een case-control studie 
uitgevoerd, die verschillende nierfunctie parameters 10-jaar postpartum tussen gezonde controles, 
vrouwen met zwangerschapshypertensie en vrouwen met preeclampsie in de voorgeschiedenis 
vergelijkt. Hiermee hebben we inzicht gekregen in de relatie tussen de ernst van de hypertensieve 
zwangerschapsaandoening, en het langetermijnrisico op nierschade. De geschatte glomerulaire 
filtratie snelheid was significant lager in vrouwen die preeclampsie hadden doorgemaakt vergeleken 
met de gezonde controles 10 jaar postpartum. Tien jaar postpartum voldeed ongeveer 20% van de 
vrouwen die preeclampsie had doorgemaakt aan de definitie van chronische nierziekte vergeleken 
met 8% van de gezonde controle vrouwen. Deze resultaten rechtvaardigen vervolgonderzoek naar 
de mogelijkheden van reguliere klinische follow-up van vrouwen die een hypertensieve aandoening 
hebben doorgemaakt tijdens de zwangerschap om zo hopelijk in de toekomst preventieve 
interventies en een geschikte behandeling aan te kunnen bieden. 
 Om meer inzicht te krijgen in het exacte mechanisme achter de versnelde achteruitgang in 
nierfunctie, zijn meer gegevens nodig over de renale hemodynamiek in vrouwen die preeclampsie 
hebben doorgemaakt. Blijvende verslechtering van de renale hemodynamiek postpartum is een 
van de mogelijke mechanismen achter het toegenomen risico op eindstadium nierfalen in vrouwen 
die preeclampsie hebben doorgemaakt. In Hoofdstuk 5 is de renale hemodynamiek onderzocht 
in gezonde ex-zwangere vrouwen en gezonde vrouwen die early-onset preeclampsie (ontwikkelen 
van preeclampsie voor de 34e zwangerschapsweek) hebben doorgemaakt 1-10 jaar postpartum. 
Wij hebben gekozen om alleen gezonde vrouwen te includeren, dus vrouwen zonder hypertensie, 
overgewicht of insuline resistentie, om zo het effect van co-morbiditeit op onze resultaten te 
beperken. Om de exacte glomerulaire filtratiesnelheid en effectieve renale plasma doorstroming te 
bepalen, is de klaring van de continue geïnfundeerde radioactief gelabelde tracers, 125I-iothalamaat 
en 131I-Hippuran bepaald. Dit is in alle proefpersonen tweemaal gedaan, namelijk tijdens een 
laag natrium dieet en tijdens een hoog natrium dieet, omdat natrium een belangrijke modulator 
is van zowel het RAAS als van de renale hemodynamiek. Dit natriumdieet werd verkregen door 




bovendien gemeten tijdens infusie van ang II om te onderzoeken of de renale ang II gevoeligheid is 
toegenomen als een mogelijk mechanisme voor het verhoogde renale risico na preeclampsie, maar 
deze bleek niet verschillend tussen de groepen. Wel vonden we dat zowel een inname van een hoog 
natrium als het hebben doorgemaakt van preeclampsie leidde tot een hogere filtratie fractie, dat wil 
zeggen dat vrouwen 1-10 jaar na preeclampsie hyperfiltreren. Deze resultaten laten dus zien dat in 
de afwezigheid van bovengenoemde co-morbiditeit, preeclampsie blijvende gevolgen heeft op de 
renale hemodynamiek. Omdat uit andere studies bekend is dat een verhoogde filtratie fractie kan 
bijdragen aan nierschade en hypertensie op de lange termijn, zou de toegenomen filtratie fractie bij 
vrouwen die preeclampsie hebben doorgemaakt mogelijk betrokken kunnen zijn bij de ontwikkeling 
van hypertensie en nierschade op de lange termijn bij deze vrouwen. Onze resultaten ondersteunen 
de veronderstelling dat een eerder doorgemaakte preeclampsie zelf een oorzakelijke factor zou 
kunnen zijn bij het verhoogde langetermijnrisico op nierschade, los van co-morbiditeit.
 Blijvende verhoogde ang II gevoeligheid postpartum is een ander mogelijk mechanisme 
voor het verhoogde risico op hart-, vaat- en nierziekten na preeclampsie. In Hoofdstuk 6 
onderzochten we daarom in een humane- en dierstudie de ang II gevoeligheid van het vaatbed en de 
bloeddruk, in gezonde ex-zwangeren en in gezonde vrouwen die preeclampsie hebben doorgemaakt 
1-10 jaar geleden, en in een ratmodel voor preeclampsie. Zowel de vrouwen als de ratten hadden 
een normale bloeddruk postpartum en waren verder gezond. In de vrouwen die een preeclampsie 
hadden doorgemaakt, was echter de bloedrukrespons op ang II infusie sterker dan in de controles. 
In de ratten die experimentele preeclampsie hadden doorgemaakt, was dit ook het geval. In de ratten 
die preeclampsie hadden doorgemaakt was er bovendien een significante toename in proteïnurie 
tijdens ang II infusie. Omdat onze vrouwen geen co-morbiditeit hadden en onze ratten gezond 
waren, ondersteunen onze resultaten de hypothese dat preeclampsie zelf een belangrijke rol speelt 
in de postpartum verhoogde ang II gevoeligheid, in zowel het systeemvaatbed als in de nier. Deze 
blijvende verhoogde ang II gevoeligheid kan bijdragen aan het verhoogde risico op hart-, vaat- en 
nierziekten in het latere leven in vrouwen na het doormaken van preeclampsie. 
 Arteriële vaatstijfheid, verhoogd tijdens preeclampsie, is ook een mogelijk mechanisme 
achter het verhoogde risico op hart-, vaat- en nierziekten na preeclampsie. In Hoofdstuk 7 
hebben we de vaatstijfheid bepaald met behulp van de pulse wave analysis en pulse wave velocity 
onder laag en hoog natrium in vrouwen na een gezonde zwangerschap en in gezonde vrouwen 
die preeclampsie hebben doorgemaakt 1-10 jaar postpartum en wederom in de afwezigheid van 
co-morbiditeit. Wij hebben laten zien dat gezonde ex-zwangere vrouwen in staat zijn de arteriële 
vaatstijfheid te moduleren op natriuminname. Deze modulatie was echter afwezig in vrouwen die 
preeclampsie hadden doorgemaakt, onafhankelijk van bloeddruk verschillen. De afwezigheid van 
vaatstijfheid modulatie zou een gevolg kunnen zijn van endotheel dysfunctie of van een afwijkende 
volume regulatie. Daarom hebben we stikstof metabolieten in het plasma gemeten als afspiegeling 
van endotheel (dys)functie en is de respons van de volume status op natriuminname bepaald. 
Verschillen in volume regulatie in respons op de natrium inname kon de gevonden non-modulatie 




Daarom moet het mechanisme achter deze afwezige vaatstijfheid modulatie in vrouwen die 
preeclampsie hebben doorgemaakt nog opgehelderd worden. 
Conclusie
De studies beschreven in dit proefschrift, uitgevoerd in vrouwen na preeclampsie en in ratten na 
experimentele preeclampsie, waren opgezet om mogelijke mechanismen achter het langetermijnrisico 
op hart-, vaat- en nierziekten in vrouwen na preeclampsie te onderzoeken. Wij hebben laten zien 
dat postpartum veranderingen in renale hemodynamiek, ang II gevoeligheid, endotheel functie en 
vaatstijfheid, betrokken kunnen zijn bij het verhoogde risico op hart-, vaat- en nierziekten in vrouwen 
die preeclampsie hebben doorgemaakt. Onze resultaten wijzen er bovendien op dat preeclampsie 
zelf een rol zou kunnen spelen in deze verhoogde kwetsbaarheid. 
 Door een voorgeschiedenis van preeclampsie te gebruiken als vroege risicofactor kunnen 
jonge vrouwen geïdentificeerd worden die kwetsbaar zijn voor het ontwikkelen van hart-, vaat- en 
nierziekten. Hoewel het noodzakelijk is meer onderzoek uit te voeren naar de door ons gevonden 
potentiële mechanismen achter dit verhoogde risico, zouden deze veranderingen aangrijpingspunten 
kunnen zijn voor preventie- en behandelingsstrategieën in deze specifieke groep jonge vrouwen, ook 
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Terug naar het allereerste begin, 2006. Als jonge studente word ik op weg geholpen door de 
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Immunologie. Dank voor jullie geduld en inzet mij het begin van de weg te wijzen in de wereld van 
het onderzoek. Wat volgde was de overstap naar de Hematologie waar dr. van Imhoff en prof. dr. 
van den Berg mij ontzettend goed begeleid hebben bij mijn eerste eigen onderzoeksproject. Bedankt 
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beste Gerda. Door jou bevlogenheid en passie voor de vrouwen met pre-eclampsie tijdens ons eerste 
contact bij de mentorgroepen van geneeskunde ben ik eigenlijk echt begonnen aan dit avontuur. De 
oversteek naar de andere kant van de wereld, naar Australië, die jij mogelijk gemaakt hebt, heeft 
gezorgd voor een onvergetelijk, leerzaam en uitdagend jaar en is een kans geweest die ik nooit had 
willen missen! Bedankt voor al jouw hulp en steun in zowel werk als privé zaken onder het genot 
van vele koppen verse muntthee bij de Buurvrouw. Dit heb ik altijd zeer gewaardeerd. Via Marijke en 
Gerda werd ik gekoppeld aan Marjon om samen een dierproef op te zetten en uit te voeren. Marjon, 
wat heb ik een geluk gehad met jou te mogen samenwerken! Wat een geweldige tijd heb ik samen 
met jou gehad, van biggetjes eten op  het lab met vliegen bij de darmen, regenwormen bij de thee 
met Binkie op schoot, congressen in Melbourne en Rome tot samen liedjesproza schrijven bij de 
stamppot rauw andijvie. En sorry voor mijn grote waslijst aan eten dat ik niet lustte, ik ben blij dat jij 
toch altijd bereid was hier een mouw aan te passen. Ik hoop dat wij nog heel vaak samen gaan eten! 
Ook de andere collegae waar ik mee heb mogen samenwerken tijdens mijn wetenschappelijke stage 
wil ik bedanken voor de leerzame en gezellige tijd op de vierde verdieping van het UMCG. Janna, wat 
heb jij toendertijd als een  speer jouw klinische studie opgezet en uitgevoerd, wat een bewondering 
had ik daarvoor! Jelmer, jij zat aan de andere kant naast mij, verhalen uit Adelaide kreeg ik van jou 
en wanneer het werk even het werk kon blijven vermaakten wij ons prima met treintjes en woorden 
maken. Welmoed, Elsbeth en Meike, jullie ook bedankt voor de mooie tijd samen met koekjes, thee 
en de SPSS hulpdienstlijn. Tijdens mijn Wetenschappelijke Stage ook kennis mogen maken met 
Torsten Plösch. Aan het begin was het wennen aan jouw Duitse, gemene grapjes, maar wat was jij 
behulpzaam op het lab. Laagdrempelig kon ik bij jouw in de kamer binnenvallen met nieuwe vragen 
over PCRen, veel kennis en kunde heb ik daardoor opgedaan. In de jaren die volgden hebben goed 
contact gehouden, wat heeft geleid tot goede samenwerking en gezelligheid op feestjes, maar ook 
dat ik af en toe in mijn eentje op zondagochtend in de quarantaine opgesloten zat priegel weefsel 
voor jou te verzamelen. Om de vertaalslag te maken van lab resultaten en klinisch verzamelde 
gegevens naar tabellen, figuren en analyses ben ik al deze jaren perfect ondersteund door dr. Groen. 
Beste Henk, dank dat jij altijd klaar stond voor een belletje, mailtje, skypegesprek of overleg aan de 
tafel om mij te ondersteunen in de statistiek. 
Klinische Farmacologie, met een propedeuse Farmacie in mijn zak, was een uitstapje naar dat 




Azuwerus en Jan de kneepjes van de vaatexperimenten onder de knie gekregen. Bubbels die het 
niet doen,  zuurstofkraan kapot, aorta stuk geknipt, touwtje los, NaCl op, weegschuitjes weg, afwas 
opgespaard? Niks was te gek, voor alles stonden jullie klaar! Bedankt voor jullie hulp, en bedankt dat 
wij koffie, gebak, fruit, broodjes en snoepjes mochten eten tijdens het werk op het lab. Hendrik, na 
de experimentele fase kwam de fase van het uitwerken van al die getallen. Samen achter de computer 
en met veel geduld heb jij mij goed weten uit te leggen hoe ik moet rekenen met de uitkomsten. Ook 
met het corrigeren van papers was jij altijd snel en nauwkeurig. Dank voor al jouw hulp. 
Via mijn wetenschappelijke stage kwam ik in de ‘Zeeman-groep’. Dames, ik heb warme en goede 
herinneringen aan onze gezamenlijke projecten, overleggen, tripjes, congressen, etentjes en 
promotie-feestjes. Teelkien, als fan van Amerika hebben wij een prachtige trip gemaakt langs de 
Great Ocean Road in Australië met het bezoek aan de Grampians. Daar hoogst verbaasd over de 
Belgen met het spel ‘ik ga op reis en neem mee een pilleke voor de Kodak’, presentatie oefenen en de 
thuisblijvers de schrik op het lijf jagen met het verzoek een poster af te drukken omdat de inkt in de 
Grampians op was. Snap jij het nou dat zij dat echt geloofden? Gelukkig was jij in ons midden dan 
kwam er nog iets terecht van de teksten op de verschillende liedjes. Bedankt voor jouw gezelligheid! 
Ineke, samen op congres in Melbourne en Geneve, goede herinneringen aan onze samenwerking. 
Annet, de moeder van de groep en toch wel meest reislustige van het hele gezelschap slaapt het 
liefst onder een roze fleecedeken. Dank dat ik van jou mocht leren en voor jouw enthousiasme voor 
het onderzoek. Mèlanie, je eigen weg gegaan na een start in Groningen. In Melbourne enthousiast 
over de pinguïns en nu goed op weg, bewondering voor hoe je het hebt aangepakt! 
My next adventure took place Down Under, in the beautiful city of Adelaide. Guus Dekker, I was so 
happy to receive your e-mail that it was ‘okay’ to come over to Adelaide. A warm welcome to gain 
experience in the English language and conduct a clinical study. Thank you very much for letting 
me love and enjoy the beautiful country Australia! And Alphons Roex, thank you for your help, 
enthusiasm, and invites for the BBQ-lunches at your beautiful place in the Hills! I would also like 
to thank Claire Roberts for her expert opinion in the field of research. And all the other people that 
were very helpful during my stay at the Leyll McEwin Hospital, especially the Midwives of the O&G 
department, Dylan, and Vicky Clifton. In addition to the people I have worked with during my stay in 
Adelaide, I really want to thank St. Ann’s college and all the Australian friends I have met during my 
stay there for their patience, help and inspirational attitude! You all made my year, I cannot imagine 
how it would have been without you all having around! Sorry I can’t name you all, but you were all 
great! Thanks Cassa, mister Cassegrain for being my buddy and great friend, thank you Nora and 
Jimmy for being great friends to camp, drink, chat, sport and laugh with. Max and Jonno, friends, 
for being welcome to stay in your house and explain cricket, T-Roy great friend and neighbour, Xiang 
being friends and tutor. Jeremy being an inspiration, great to cycle through the Barossa with while 
tasting wine, surfing, eating Sushi, etc. Mel and Nick, even though you two were from the opposite 




Lieve Eva, ook jou heb ik leren kennen in mijn tijd in Adelaide. Wat aan het begin wat onwennig ging, 
is gelukkig snel omgezet in een vriendschap voor het leven. Wat een mooie tripjes hebben wij samen 
gemaakt in Red Skippy, slapen in de swag, achterop de fiets door Adelaide, salsa dansen (hoewel geen 
succes voor mij), liedjes zingen door Red Center, met kacheltje in de camper op Tasmanië, en ‘wat 
is het hier mooi!’ bleef altijd maar klinken. Bedankt voor jouw hulp, enthousiasme en gezelligheid in 
Adelaide, het was een top tijd! Om een goed vervolg te geven aan de opgezette studie in Adelaide, 
kwam Nina naar de andere kant van de wereld. Nina, bedankt dat jij voor een weekje overkwam 
naar Down Under om zo mee te kunnen kijken. Daarna heb jij met groot enthousiasme en met een 
enorme werkinzet ontzettend veel vrouwen geïncludeerd. Bedankt voor de fijne samenwerking!  
Terug uit Adelaide was daar hét begin van mijn MD/PhD-traject. Mijn kamer was bij de Medische 
Biologie waar ik warm verwelkomd werd door de groep van Marijke Faas. Floor, jij hebt nooit een 
blad voor de mond, heerlijk! Wat heb ik met en om jou gelachen en wat kan jij soms evil zijn zonder 
dat je boos op jou kan worden. Bedankt voor als jouw hulp bij de dierproeven en op het lab. Nu op 
avontuur in Canada, trots op je dat je die stap gemaakt hebt! Leonie, harde werker, nooit gesnapt 
hoe jij kan werken op een bureau zo vol dat je de kleur van het bureaublad moet raden. Bedankt 
voor jouw hulp met plaatjes maken, de auto-uitleen service en gezelligheid! Bart, wanneer gaan we 
weer bowlen en ‘één’ biertje drinken? Doe je dan alleen je eigen schoenen aan en gooi je de bal niet 
weer door het plafond? Of samen weer fietsen, wat kon jij hard! Bedankt voor jouw hand-en-span 
diensten op het lab! Marlies, mijn lieve optimaliseer/FACs/kleur/muizen collega! Wat heb jij een 
engelengeduld en doorzettingsvermogen. Geniet op jullie eigen stek in het uitgestrekte landschap 
van Lucaswolde. Eelke, volleybal- en cola fanaat, kort met je samengewerkt, maar bedankt voor je 
gezelligheid. Sandra en  Gea, ook jullie bedank voor de gezelligheid, een altijd luisterend oor en 
de fijne samenwerking. Neha and Genaro, thanks for sharing the room with you guys! You were 
great having around, laughing with you while watching you-tube movies and teaching the Dutch 
language. And Genaro, a special thanks for you with helping to eat all the cookies and snoopies 
and sorry that I really don’t like the Mexican candies. Susana, we have been roommates for a little 
while, but it was good. Thanks for your time and advices when I was struggling. Floris, ook wij waren 
niet zo heel lang kamergenoten, maar ik wil jou ook zeker bedanken voor je adviezen en luisterend 
oor. Maaike, bedankt voor de samenwerking en de gezellige sinterklaas vieringen bij jou thuis! Paul 
jij ook bedankt voor de samenwerking en je gemene grapjes. Het secretariaat van de Medische 
Biologie, Annet en Susan, en Hans van de financiën, bedankt dat jullie altijd klaarstonden om gelijk 
te helpen. 
De Medische Biologie en Pathologie zijn nauw met elkaar verbonden. Vandaar dat ik het geluk 
gehad heb samen te mogen werken met collegae van daar. Anne-Roos, wat was ik blij dat wij samen 
konden beginnen aan de immense klus van het trainen van ratten om netjes een minuut of 5 stil 
te liggen. Wat kon ik goed met jou samenwerken op zowel het dierenlab als het gewone lab, wat 
een priegelwerk om die pompjes te vullen. Altijd was jij enthousiast en wat kan jij lange werkdagen 




succes gewenst nu in Almere. Kim, wat ben jij een slimmerd op het lab en fijn om mee samen te 
werken! Graag ga ik  weer met je naar een congres waar we slapen in een hostel, genieten van echt 
Italiaans ontbijt (aangevuld met Hollandse gewoonten, anders krijg je toch echt honger!), wandelend 
een stad verkennen en heerlijk uit eten kunnen gaan. Ook tijdens onze laatste dierproef samen 
heb ik mogen ervaren wat een talent voor onderzoek, plannen en vooruitplannen jij hebt! Tot in de 
puntjes was het voorbereid. Ik was heel blij dat wij het laatste jaar nog samen hebben kunnen werken 
en dat jij altijd klaar stond om mij de laatste fase van mijn onderzoek door te helpen en te motiveren. 
Heel veel succes met je nieuwe baan en wie weet gaan we in de toekomst weer samenwerken in het 
onderzoek. Prof. H. van Goor, beste Harry, laagdrempelig was jij te benaderen bij uiteenlopende 
vraagstukken, verzoeken en voor hand-en-spandiensten. Bedankt dat ik van jou heb mogen leren en 
dat ik gebruik heb kunnen maken van jou enorme kennis! 
De dierproeven die ik heb uitgevoerd waren niet gelukt zonder de expertise van Pieter Klok en Arjen 
Petersen. Pieter, bedankt voor jouw kundige hulp bij de kleine chirurgische ingrepen in de ratjes, de 
aanwijzingen en tips die jij mij hebt gegeven. Ik vind het nog steeds bewonderingswaardig hoe jij 
met jouw grote handen dat kleine werk zo knap kan. Bedankt voor de tijd samen op het dierenlab. 
Arjen, kundig en met veel plezier heb jij geholpen met de naald en de spuit, geen staartvene was 
te klein. Ook de microchirurgen André, Michel en Annemieke, bedankt dat ik altijd op jullie kon 
rekenen. Zonder dierverzorgers ook geen dierproef, dus bedankt allemaal! Speciale dank naar Ar, 
wat was ik blij dat jij mij zo goed kon helpen in de quarantaine van het dierenlab en later met het 
dagelijks injecteren van onze ratjes. Annemiek, Sander en Maurice, ook jullie verzorging heb ik zeer 
op prijs gesteld! Bedankt allemaal dat jullie zo goed voor de ratjes gezorgd hebben. En Ramon, altijd 
gezellig om tegelijkertijd met jou op het dierenlab te zijn en nooit te beroerd even een handje te 
helpen. 
Ook is het uitvoeren van een dierproef eigenlijk niet mogelijk om helemaal in je eentje te doen. 
Mienke, wat was ik blij te zien hoe jij in een week met de ratjes kon omgaan alsof je niet anders 
gewend was. Wat een precisie, geduld en nauwkeurigheid had jij in een razend tempo ontwikkeld 
op het dierenlab. Met een gerust hart kon ik de dierproef dan ook een maand aan jou overlaten, 
wat een super team waren we zo. Bedankt voor jouw inzet zowel in het dierenlab alsook op de 
nierfunctiekamer. Het ga je goed als huisarts! Al het labwerk dat uitgevoerd moet worden tijdens 
en na een dierproef is teveel om alleen te doen. Marinda, wat was het super om jou in het team 
te hebben. Niks was te veel, te lastig of te ingewikkeld, jij pakte al het werk met beide handen aan. 
Zelfstandig hard aan het werk en het was klaar voordat ik er erg in had. Heel erg dank voor jouw 
kunde en inzet!
Naast Mienke heb ik nog twee andere studenten met veel plezier mogen begeleiden. Rita, wat ben 
jij een harde werker en doorzetter. Je hebt je vastgeklampt in die énorme PREVEND database en 
hebt uit die jungle prachtige data gehaald. Door jou inzet en snelle handelen is daar een prachtig 
hoofdstuk uit voortgekomen. Het was fijn samenwerken met jou. Ik wens je veel succes in je verdere 
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loopbaan als dokter. Marjolein, vanuit de collegebanken werd jij meegenomen in de wereld van de 
dierproeven. Je hebt dit super opgepakt en het was fijn samenwerken. Altijd bereid mee te helpen en 
mede dankzij jou hebben we in sneltreinvaart een dierproef kunnen uitvoeren. Dank voor jou inzet 
en veel succes tijdens de rest van je opleiding.
Na de Obstetrie, de Medische Biologie en de Pathologie te hebben gehad, word ik via Titia Lely 
gekoppeld aan de Nefrologie, en wel aan Tsjitske. Tsjitske, over ons kan ik bladzijden vol schrijven, 
maar dat schijnt niet de bedoeling te zijn. Jij komt verderop aan de beurt. Bij de Nefrologie heb ik 
geweldige onderzoekscollegae ontmoet, veel van jullie allemaal geleerd qua onderzoek en werk, 
maar ook veel gezelligheid op de ASN, meetings, tijdens fietstochtjes en op de vrijdagmiddagborrels! 
Allereerst de collega’s van de ´4.045 brug rules’. Arjan, alleskenner, rommelkont, gezelligheidsdier, 
spelletjesman, paperverslinder en –produceerder, bedankt voor onze tijd samen! Ineke, jij bent 
echt hét statistiek wonder en koekjesmonster, dank voor je gezelligheid en je snelle hulp! Nicole, 
gedreven en enthousiast en gezellige borrelaar! Janneke, schaatsgek en harde werker! Ook de wat 
oudere en ex-4.045 bewoners Solmaz, Hilde, Steef, Else en Dorien, bedankt voor de leerzame en 
gezellige tijd samen! Ook de Triadebewoners van de Nefrologie, bedankt voor de mooie tijd; Wendy, 
Ferdau, Edwin, Michel, Marieke, Laura, Charlotte, Lieneke, Jelmer en Debbie! Ook wil ik dr. R.T. 
Gansevoort bedanken voor de samenwerking. Beste Ron, eerst mocht ik onder jouw hoede aan het 
werk als onderzoeksassistente bij PREVEND waarna ik zelf met deze data een prachtig onderzoek 
heb kunnen uitvoeren. Dank voor jouw snelle feedback en behulpzaamheid, kritische blik en dank 
dat ik gebruik mocht maken van jouw schat aan ervaring! Vanuit de Nefrologie belande ik op de 
Nierfunctiekamer van het UMCG. Marian, Dirkina en Roelie, hartelijk dank voor jullie hulp, inzet, 
gezelligheid en samenwerking op de nierfunctiekamer. Jullie stonden altijd klaar om te helpen tijdens 
de verschillende onderzoeksdagen. Ik heb met veel plezier samengewerkt met jullie drieën! Vanuit 
de nierfunctiekamer een kleine stap om alle vrouwen die hebben deelgenomen aan de RETAP-studie 
te bedanken voor deelname aan het onderzoek. Het was zeker niet niks wat wij van jullie vroegen, 
zonder jullie geen nieuwe kennis om in dit proefschrift te vermelden, bedankt! Via Titia leer ik ook 
Nina kennen. Nina, bedankt voor de goede samenwerking! Wat ben jij een kei; sneller dan snel had 
je weer een nieuwe versie af, was je de literatuur ingedoken en overlegden we kritisch over statistiek. 
Dank voor al je hulp en gezelligheid. Succes met jouw eigen promotieonderzoek in Utrecht!   
Oud-huisgenoot, collega en vriendin Kim, jij past niet echt in een alinea. Maar wat ben jij ruim 
2,5 jaar van mijn promotietijd belangrijk geweest. Collega’s waren we wel, maar niet op de directe 
werkvloer, maar samenwerken deden we dan weer een soort van wel. Thuis altijd ruimte om een ei 
of verhaal kwijt te kunnen, tijd om een vraag te stellen, gezelligheid tijdens het doornemen van de 
dag en jouw enorme hulp en steun op momenten dat het alleen niet lukte. Wat ben ik jou dankbaar. 
En wat kan jij hard werken, niet normaal! Die werktijden kan een Amerikaan ‘u’ tegen zegen.  Na 
een mooi avontuur in Canada nu samen met Oscar een nieuw avontuur in Amsterdam en Leiden. 
Het ga je goed en je bent een onvergetelijke huisgenoot! Na Kim was het Mariëlle als huisgenoot, 




sinds wij een jaar of 14 zijn? Samen de middelbare school afgerond in Oosterwolde en daarna 
even gescheiden gestudeerd, jij in Utrecht en ik in Groningen. Een jaar later samen gestart met 
geneeskunde waarna jij bent begonnen aan een prachtig avontuur op Curaçao samen met jouw 
Huib. Wat heb ik bewondering voor jou doorzettingsvermogen, vechtlust en gedrevenheid. Bedankt 
voor onze lange en fijne vriendschap en de steun tijdens al mijn jaren onderzoek!
Ook Nynke, bedankt voor de leuke en gezellige babbels, uitjes als ontspanning tussen het werken 
door! Lieve vrienden van Farmacie, Nicole, Judith en Jitske, na een jaar samen te hebben gestudeerd 
gingen we ieder onze eigen weg maar altijd kon ik op jullie rekenen. Bedankt voor de vriendschap en 
jullie steun en interesse tijdens alle jaren die volgden! Lieve vrienden van Geneeskunde, Coachgroep 
‘Ever Hard’, Co’s uit Drachten, Eelco, Floor, Floris, Joris, Karim, Leonie, Licette, Linda, Meike, Tessa 
en Nienke, bedankt voor alle gezelligheid in de afgelopen jaren en de goede afleiding naast het 
onderzoekswerk en bedankt dat ik altijd bij jullie mij ei kwijt kon! Lieve fietsvrienden van Tandje 
Hoger en lief top-bestuur 2013/2014 (Dedmer, Erik, Hajo, Hanna en Luuk)! Ik was een ‘oude’ 
eerstejaars wielrenster maar wat hebben jullie mij allemaal een geweldige tijd gegeven om mijn 
hoofd leeg te kunnen fietsen na een dag hard werken! Bedankt voor alle borrels, vergaderingen, 
fietstoertochten, (NCK)trainingen, wedstrijden, uitjes, Spanjereis, etentjes, activiteiten, goede 
verhalen en mooie grappen. En Sythe, dank dat ik gebruik mocht maken van jouw creatieve brein 
om dit proefschrift van een mooie cover en lay-out te kunnen voorzien! Lieve tennisvrienden van 
de TAM, Kiki, Margot, Marlot en Tessa. Heerlijk om na een dag werken een goede bal te kunnen 
slaan op de baan, een drankje te kunnen doen in de stad of een spelletje te spelen. Bedankt voor 
jullie steun en vriendschap! Lieve nicht Christien, jij in Australië en samen in Australië, een mooi 
avontuur. Bedankt voor jouw hulp en de mooie tijd. Geniet nog van jullie Zuid-Afrika avontuur! Lieve 
Pake & Beppe en lieve Opa & Oma, fantastische grootouders waar ik altijd welkom was, op terug kon 
vallen en de helpende hand boden om mijn reizen naar Australië mogelijk te maken! 
Als laatste stap op weg naar dokter, heb ik met heel veel plezier mijn keuze co-schappen gelopen 
bij de Obstetrie & Gynaecologie en de Intensive Care in het Martini Ziekenhuis. Lieve aanstaande 
collegae van de afdeling O&G, bedankt voor jullie gezelligheid, meedenken en steun bij het afronden 
van mijn proefschrift. Ik heb zin om straks met jullie aan het werk te mogen!
I would also like to thank all the co-authors that have been working with me during the past few 
years; prof. dr. R.H. Henning, dr. D.P. van der Ham, dr. F. W. Visser, dr. G. Wallukat, dr. R. Dechend, 
prof. M. Feelisch, dr. J.D. Lefrandt, and prof. dr. A. Franx. Without your critical view and opinion, the 
research papers would not have been this quality! 
Dan mijn paranimfen, Carolien en Tsjitske. Carolien, met jou samen ben ik het avontuur van het MD/
PhD-traject aangegaan. Ik vind het dan ook bijzonder dat jij op 27 januari naast mij staat. Bedankt 
voor de fijne tijd die we hebben gehad vanaf ons eerste studiejaar geneeskunde! Op de ijsbaan, in 
de collegebanken, op Schiermonnikoog, op de wielrenfiets in Limburg, België en op de Veluwe, tijd 
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in de koffiekamer van het UMCG, maar ook samen op het terras in de stad, in de kroeg met een 
drankje en een dansje en aan de eettafel tijdens een goed gesprek. Bedankt voor onze vriendschap 
en dat je altijd voor mij klaarstond! Ik wens je heel veel succes bij jouw volgende stap nu als arts 
op de spoed in Amsterdam! Tsjitske, voor het eerst overleg in de kidney alley op de Brug, twee 
Friezinnen, dat moest volgens Titia goed komen. En dat is goed gekomen! Wat hebben wij samen 
veel meegemaakt; concerten, a capella koor op Noorderzon, congres in de USA, kamperen tussen 
de beren, de Mont Ventoux en Alpe d’Huez op fietsen, vakantie samen in Frankrijk, schaatsen, 
SC Heerenveen bij -14°C, tennissen, Tsjoeke Tsjoek altijd mee en vele hapjes, borrels, drankjes en 
pasjes in de Stad. Ook stond jij altijd voor mij klaar wanneer dat nodig was, ik kan écht zeggen dat 
zonder jou onvoorwaardelijke hulp, steun en inzet dit proefschrift zeker niet geworden was hoe het 
nu is. Bedankt voor onze fijne en waardevolle vriendschap. Bedankt dat jij tijdens de dag van de 
verdediging, 27 januri, naast mij staat. Je hebt je draai inmiddels helemaal gevonden in Enschede, ik 
weet zeker dat jij een fantastische MDL-arts gaat worden!
Lieve Peter, bedankt voor al jouw steun en hulp aan het begin van mijn studie- en onderzoekstijd, 
eindeloos kon ik bij jou mijn frustraties uiten en altijd was je bereid te helpen en te relativeren. 
Bedankt voor de fijne tijd die we gehad hebben in Appelscha, Groningen en Australië. 
Lieve broer en zus, lieve Pier en Selma. Na Appelscha alle drie onze eigen weg ingegaan, maar op 
jullie kon ik altijd rekenen! Pier, ik weet dat jij wat anders denkt over ratjes, maar met jou ontspannen 
persoonlijkheid was dit gelukkig nooit een probleem! Selma, wat heb ik een bewondering voor jou 
ontzettend zware avontuur dat jij bent aangegaan na je Master in Groningen, jij hebt het managen 
in je vingers en je gaat zeker slagen op en na Nyenrode! 
Lieve paps en mams, lieve Kees en Jouk. Wat hebben jullie mij altijd onvoorwaardelijk gesteund! Alle 
kansen die ik de afgelopen jaren heb gekregen heb ik door jullie hulp, vertrouwen en ondersteuning 
met beide handen kunnen grijpen. Mijn studietijd van meer dan 10 jaar is voor jullie nooit een 
probleem geweest, nog eventjes en dan kan ik eindelijk op mijn eigen benen staan.
Lieve, lieve Marten, wat heerlijk en fijn dat jij elke dag bij mij bent! Met jou aan mijn zijde kan ik alles 
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